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Background: Group cognitive stimulation therapy programmes can benefit cognition and quality of life for
people with dementia. Evidence for home-based, carer-led cognitive stimulation interventions is limited.
Objectives: To evaluate the clinical effectiveness and cost-effectiveness of carer-delivered individual
cognitive stimulation therapy (iCST) for people with dementia and their family carers, compared with
treatment as usual (TAU).
Design: A multicentre, single-blind, randomised controlled trial assessing clinical effectiveness and
cost-effectiveness. Assessments were at baseline, 13 weeks and 26 weeks (primary end point).
Setting: Participants were recruited through Memory Clinics and Community Mental Health Teams for
older people.
DOI: 10.3310/hta19640 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 64
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Orgeta et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
vii
Participants: A total of 356 caregiving dyads were recruited and 273 completed the trial.
Intervention: iCST consisted of structured cognitive stimulation sessions for people with dementia,
completed up to three times weekly over 25 weeks. Family carers were supported to deliver the sessions
at home.
Main outcome measures: Primary outcomes for the person with dementia were cognition and quality of
life. Secondary outcomes included behavioural and psychological symptoms, activities of daily living,
depressive symptoms and relationship quality. The primary outcome for the family carers was mental/
physical health (Short Form questionnaire-12 items). Health-related quality of life (European Quality of
Life-5 Dimensions), mood symptoms, resilience and relationship quality comprised the secondary outcomes.
Costs were estimated from health and social care and societal perspectives.
Results: There were no differences in any of the primary outcomes for people with dementia between
intervention and TAU [cognition: mean difference –0.55, 95% confidence interval (CI) –2.00 to 0.90;
p-value= 0.45; self-reported quality of life: mean difference –0.02, 95% CI –1.22 to 0.82; p-value= 0.97
at the 6-month follow-up]. iCST did not improve mental/physical health for carers. People with dementia in
the iCST group experienced better relationship quality with their carer, but there was no evidence that
iCST improved their activities of daily living, depression or behavioural and psychological symptoms. iCST
seemed to improve health-related quality of life for carers but did not benefit carers’ resilience or their
relationship quality with their relative. Carers conducting more sessions had fewer depressive symptoms.
Qualitative data suggested that people with dementia and their carers experienced better communication
owing to iCST. Adjusted mean costs were not significantly different between the groups. From the societal
perspective, both health gains and cost savings were observed.
Conclusions: iCST did not improve cognition or quality of life for people with dementia, or carers’ physical
and mental health. Costs of the intervention were offset by some reductions in social care and other
services. Although there was some evidence of improvement in terms of the caregiving relationship
and carers’ health-related quality of life, iCST does not appear to deliver clinical benefits for cognition and
quality of life for people with dementia. Most people received fewer than the recommended number of iCST
sessions. Further research is needed to ascertain the clinical effectiveness of carer-led cognitive stimulation
interventions for people with dementia.
Trial registration: Current Controlled Trials ISRCTN65945963.
Funding: This project was funded by the National Institute of Health Research (NIHR) Health Technology
Assessment (HTA) programme and will be published in full in Health Technology Assessment; Vol. 19, No. 64.
See the NIHR Journals Library website for further information.
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Plain English summary
Cognitive stimulation approaches can improve cognition and quality of life for people with dementia butlittle is known about whether cognitive stimulation interventions led by carers are effective. This study
used qualitative methods, professional expert feedback and a field-testing study to develop a home-based
individual cognitive stimulation therapy (iCST) programme for people with dementia using the established
group cognitive stimulation therapy approach. The carer-led intervention was tested using a randomised
controlled trial design to evaluate whether iCST benefits cognition and quality of life for people with
dementia, and mental and physical health for carers. We followed participants for 13 weeks and 26 weeks.
People with dementia receiving iCST did not benefit in terms of cognition at either time point. There was
no evidence that iCST improved quality of life for people with dementia or carers’ mental or physical health.
People with dementia engaging in iCST reported a better relationship quality with their family carer at
26 weeks. Carers taking part in iCST with their relative experienced better health-related quality of life
at 26 weeks. Despite evidence of improvements in the caregiving relationship for people with dementia and
health-related quality of life for carers, this study provides no evidence that carer-led cognitive stimulation
interventions help cognition or quality of life for people with dementia. Further research is needed to
evaluate the impact of carer-led cognitive-based interventions for people with dementia.
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Scientific summary
Background
There is currently growing recognition and evidence that people with dementia and their family carers
can benefit from non-pharmacological interventions, especially those of a psychosocial nature. Increasing
attention has been given to cognitive-based interventions, such as cognitive stimulation approaches. A
recent Cochrane review has shown that group cognitive stimulation programmes benefit cognition for
people with mild to moderate dementia, over and above any medication effects, and may be associated with
improvements in quality of life. Cognitive stimulation therapy (CST) is an evidence-based approach,
associated with benefits in quality of life and cognition for people with dementia when used in a group
setting. This approach is recommended by several organisations such as Alzheimer’s Disease International
and the National Institute for Health and Care Excellence (NICE) as a useful psychosocial intervention, with
proven cost-effectiveness. However, as many people with dementia may be unsuitable or unwilling to
participate in groups, investigating the potential utility and effectiveness of this approach when provided at
home is likely to be useful in making the intervention more accessible to people with dementia and their
family carers.
Objectives
The main objectives of this trial were to develop a home-based individual CST programme and to investigate
whether individual cognitive stimulation therapy (iCST) benefits cognition and quality of life for people
with dementia compared with treatment as usual (TAU) and to evaluate its cost-effectiveness as a
home-based approach.
Methods
Design
This multicentre, single-blind, randomised controlled trial had two arms, an intervention group and a TAU
control group. Assessments were blind to treatment and were carried out at baseline, 13 weeks and
26 weeks, with the 26-week assessment being the primary end point. Randomisation was carried
out remotely by an accredited clinical trials unit. Researchers, who did not undertake any follow-up
assessments, arranged for dyads to receive the treatment and supported them in getting started with
the sessions. All follow-up data were collected by researchers who were blind to treatment allocation.
Assessors rated their impression of allocation of each dyad and their confidence in that judgement.
Participants
There were 356 community-dwelling participants (mean age 78.2 years) with mild to moderate dementia
[meeting Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) criteria], who had
a relative or other unpaid (informal) carer who acted as an informant and was willing and able to deliver
the intervention. Most carers were spouses (63%). A total of 273 dyads completed the study. The most
frequent diagnosis was Alzheimer’s disease (64%), followed by vascular dementia (11%).
The trial was run in London, Bangor, Hull, Manchester, Dorset, Devon, Lincolnshire, and Norfolk and Suffolk.
Recruitment to the trial took place in a variety of community settings, including NHS Memory Clinics,
Community Mental Health Teams (CMHTs) for older people and associated outpatient clinics. Most people
with dementia were recruited through Memory Clinics, referrals from consultant psychiatrists and CMHTs.
All research activities, including assessments and intervention sessions, took place in the participants’ homes.
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Inclusion criteria
All participants were people with dementia who:
l met the DSM-IV criteria for dementia of any type
l scored 10 or above on the Mini Mental State Examination
l had some ability to communicate and understand communication, indicated by scoring either 0 or 1 on
the Clifton Assessment Procedures for the Elderly Behaviour Rating Scale items
l could see/hear well enough to participate
l had no major physical illness or disability affecting participation
l lived in the community at baseline and had regular contact with a relative or other informal carer who
could act as an informant and could participate in the intervention.
Exclusion criteria
People with dementia not living in the community (i.e. in a care home) and having no available family carer
to deliver the sessions and act as an informant.
Participants who met the specified inclusion criteria enrolled in the study only after providing informed consent
in accordance with the provisions of the Mental Capacity Act 2005 [Great Britain. The National Archives. Mental
Capacity Act 2005. URL: www.legislation.gov.uk/ukpga/2005/9/contents (accessed 14 March 2011)].
Consent was viewed as a continual process, and willingness and capacity to continue participating was
continually checked through discussion with participants during the assessments. Ethical approval
was obtained through the East London 3 Research Ethics Committee (reference number 10/H0701/71).
Intervention
The intervention consisted of one-to-one, home-based, structured cognitive stimulation sessions for people
with dementia, provided by the family carer. Dyads were asked to complete up to three 30-minute sessions per
week over 25 weeks. The programme consisted of a total of 75 activity sessions, focusing on different themes,
such as being creative, word games and current affairs. Dyads were given resources including a manual, an
activity workbook, a carer’s diary and a toolkit containing items such as compact discs, dominos and maps.
Each dyad worked with an unblinded researcher who provided initial training and ongoing support to carers.
Participants in the control group received TAU, which varied within and between centres and changed over
time. In general, services offered to this group were also available to those in the treatment group.
Main outcome measures
The primary outcomes were cognition [Alzheimer’s Disease Assessment Scale – Cognitive Subscale
(ADAS-Cog)] and self-reported quality of life [Quality of Life in Alzheimer’s Disease Scale (QoL-AD)] for the
person with dementia, and mental and physical health [mental component summary-12 and physical
component summary-12 derived from the Short Form questionnaire-12 items (SF-12)] for the family carer.
Secondary outcomes for the person with dementia included proxy-rated quality of life, behavioural and
psychological symptoms, activities of daily living and self-reported depressive symptoms. Depressive
symptoms, anxiety, health-related quality of life ratings [as measured by the European Quality of Life-5
Dimensions (EQ-5D)™], and carer resilience were secondary outcomes for family carers. Perception of
relationship quality was also measured for both carers and people with dementia. Units of health and
social care service use were measured with an adapted version of the Client Service Receipt Inventory, and
their costs established using nationally applicable unit costs. Quality-adjusted life-years (QALYs) were
calculated from the European Quality of Life-5 Dimensions-3 level response.
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Sample size
The main analysis was based on intention to treat for the primary outcome ADAS-Cog. The trial was
initially powered to detect a standardised mean difference (SMD) of 0.35, using a conservative approach
and based on previous studies and the Cochrane review. Using a two-group t-test with a 0.05 (two-sided)
significance level comparing iCST and TAU with 80% power gave a sample size of 260. Assuming 15%
attrition, we originally proposed to recruit 306 people with dementia. However, the attrition rate was
observed to be closer to 25%; thus, we revised the recruitment target upwards by 50 dyads to
accommodate this and so changed the recruitment target to 356 caregiving dyads.
Economic evaluation
The economic evaluation was a cost-effectiveness analysis, conducted first from a health and social care
perspective, and then from a societal perspective. The primary outcome measures in the economic evaluation
were the ADAS-Cog and QoL-AD for the person with dementia, and the QALY for the carer (derived from
the EQ-5D with societal weights). The incremental cost-effectiveness ratio (ICER) for each outcome for the
person with dementia, and perspective was calculated as the difference in mean costs between iCST and
TAU groups over the period of follow-up, divided by the difference in the mean end point outcome measure
between groups. In contrast, for the analysis of QALYs (for the carer), we compared mean QALY over 1 year
by carrying the last value carried forward from the final assessment to 12 months post-baseline and we
likewise annualised costs by doubling the costs estimated over the full follow-up period. Cost-effectiveness
acceptability curves were produced to represent graphically the uncertainty around the point estimate of
incremental cost-effectiveness. Seemingly unrelated regressions with bootstrapped standard errors, adjusting
for baseline covariates, were estimated to calculate net monetary benefit over a range of willingness-to-pay
values for incremental primary outcome measure changes and QALY gains.
Results
The overall attrition rate was 23% at week 26, falling to 21% if deaths are excluded. The intention-to-treat
analysis indicated that there were no differences between intervention and control groups on any of the
primary outcomes at either the primary or secondary time points [at week 26: cognition mean difference
–0.55, 95% confidence interval (CI) –2.00 to 0.90; p-value= 0.45; self-reported quality of life mean
difference –0.02, 95% CI –1.22 to 0.82; p-value= 0.97]. There were no differences between the two
groups on carers’ mental and physical health (at week 26: mental health mean difference 0.13, 95% CI
–1.65 to 1.91; p-value= 0.89; physical health mean difference 0.46, 95% CI –1.21 to 2.13; p-value= 0.59).
The intervention did not improve activities of daily living, depressive symptoms or behavioural and
psychological symptoms for people with dementia. People with dementia allocated to iCST reported
better relationship quality with their family carer in comparison to those in TAU at the primary end point
(week 26: relationship quality mean difference 1.77, 95% CI 0.26 to 3.28; p-value= 0.02). There was
no impact on carers’ mood, resilience or relationship quality with the person with dementia. Carers in
the treatment group reported higher health-related quality of life (week 26: health-related quality of life
mean difference 0.06, 95% CI 0.02 to 0.10; p-value= 0.01) in comparison with those in TAU, at the
primary end point.
Compliance analyses were conducted by taking into account the total number of sessions completed.
Overall, 22% of participants did not complete any sessions, whereas 51% of dyads completed more than
30 sessions. Adherence analyses indicated that people with dementia completing more sessions showed
improved quality in the caregiving relationship at 26 weeks, whereas carers reported lower depressive
symptoms at the primary end point.
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The intervention costs were approximately £481 per person for paid staff to deliver, or £652 if the costs
of carer time were also taken into account. Adjusted mean health and social care costs looked higher, and
adjusted societal costs looked lower in the intervention than in the control group (£4740 iCST vs. £4670
TAU and £9770 iCST vs. £10,630 TAU, respectively); however, from either perspective, costs were not
significantly different between the groups (£70, 95% CI –£1050 to £1190 greater in the intervention
group for health and social care costs only; £860, 95% CI –£2750 to £1040 less in the intervention
group for societal costs). Cost-effectiveness analyses from the health and social care perspective yielded
an ICER of £300 for achieving a SMD on the ADAS-Cog and £600 for achieving a SMD on the QoL-AD.
Incremental cost-effectiveness ratios from the societal cost perspective were negative (where the
intervention was dominant, costs were lower and effectiveness greater).
The incremental health and social care cost associated with a QALY gain for carers was £3100. The
probability of iCST being cost-effective from the health and social care perspective was 72% at a
willingness to pay (WTP) per QALY of £20,000 and 81% at a WTP per QALY of £30,000; the probability
of iCST being cost-effective from the societal perspective was 90% at a WTP per QALY of £20,000 and
93% at a WTP per QALY of £30,000. A probability of cost-effectiveness greater than 97.5% was reached
at a WTP of £84,200 per QALY (health and social care costs) or £47,300 per QALY (societal costs), and
we can be confident that the intervention is cost-effective above these upper limits. The intervention can
be considered to be cost-effective in improving unpaid carers’ health-related quality of life at a societal
WTP well above the NICE threshold of £20,000 to £30,000.
Conclusions
This trial showed that iCST does not improve cognition or quality of life for people with dementia. There was
no impact on activities of daily living, behavioural and psychological symptoms, or depression for people with
dementia. There was no benefit for carers’ mental and physical health. People with dementia participating
in iCST perceived the relationship with their carer as more positive compared with those in TAU. Carers’
reported levels of utility were significantly higher at the 5% level (on the EQ-5D index); however, physical
and mental health scores (on the SF-12) did not differ. The costs of providing the intervention appeared
to be offset by some reductions in social care and other services, although the cost difference was not
significant at the 5% level. The overall compliance rates were much lower than expected. This trial suggests
that in contrast to group approaches, carer-led cognitive stimulation interventions do not improve cognition
and quality of life for people with dementia.
Implications for dementia care
The trial provides important information about the use of carer-led cognitive stimulation approaches.
Although carers and people with dementia initially expressed interest in taking part, only 65% of the
sample allocated to treatment completed more than 10 sessions, with 22% completing no sessions,
indicating that for some people with dementia and their carers this type of intervention will not be feasible
and that methods for compliance need to be improved. Despite overall negative findings, there was some
improvement in terms of the caregiving relationship and carers’ health-related quality of life. However,
our study suggests that carer-led cognitive stimulation interventions are unlikely to lead to a clinical
benefit for cognition and quality of life for people with dementia, limiting the wider implementation of
individual approaches.
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Recommendations for further research
Future research will be useful in identifying whether or not the mode of intervention provision, such as a
group-versus home-based setting, is key to the effectiveness of cognitive stimulation approaches, given
the lack of results of benefit in cognition and quality of life for people with dementia. Future studies
should investigate factors such as compliance in carer-led cognitive stimulation interventions alongside
clinical effectiveness.
Trial registration
This trial is registered as ISRCTN65945963.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction to the individual Cognitive
Stimulation Therapy trial
Background
Cognitive stimulation therapy for dementia
Developing and evaluating psychosocial interventions for people with dementia and their family carers is
becoming increasingly important both in the UK and internationally. In fact, recent evidence indicates that
psychosocial interventions are useful and may therefore be utilised either as standalone treatments or in
addition to pharmacological treatments for dementia. Although a large number of non-pharmacological
interventions are available, there is now consistent evidence of at least moderate quality that those interventions
incorporating psychosocial1,2 or psychological approaches3 can benefit people with dementia.
Given the growing development and application of cognitive-based interventions in dementia care, it
has been emphasised that each of the different approaches should be clearly defined, in order to avoid
confusion in relation to the various interventions used.4 For example, cognitive stimulation approaches
allow opportunities for general enhancement of cognitive and social functioning through a range of
activities, usually in a group setting, that differ from cognitive training and cognitive rehabilitation techniques.2
Cognitive stimulation approaches originate from reality orientation (RO),5 a theoretical tradition postulating
that provision of intellectual and social stimulation for people with dementia can positively affect their
well-being. Cognitive stimulation interventions are, in fact, those that have been researched most
frequently and have been associated with benefits for people with dementia. A recent Cochrane review,
for example, has concluded that cognitive stimulation programmes can benefit cognition in people with
mild to moderate dementia and may have a potential beneficial effect for self-reported quality of life.2
Among cognitive stimulation approaches used, cognitive stimulation therapy (CST)6 is an evidence-based
psychosocial intervention for people with mild to moderate dementia, consisting of structured sessions
of stimulating activities delivered in a group setting. Being one of the few manualised approaches and
designed to be facilitated by health and social care professionals, the original CST programme was evaluated
in a single-blind, multicentre, randomised controlled trial (RCT), which reported benefits in cognition and
quality of life for people with dementia living in residential care.6 CST compares favourably with trials of
acetylcholinesterase inhibitors, and economic analysis has demonstrated that CST is cost-effective.7
Participation in cognitive stimulation approaches for people with dementia has been recommended by the
National Institute for Health and Care Excellence (NICE)8 and the 2011 World Alzheimer’s Report,9 which
concluded that CST interventions are among the few associated with evidence of efficacy in comparison to
other psychosocial interventions currently available and should be made available to people with mild
to moderate dementia. The recent Cochrane review2 suggested that, although cognitive stimulation
interventions can benefit cognition, further randomised controlled studies are needed to evaluate effects of
modality of delivery, such as carer-led, home-based approaches. The Cochrane review also suggested that
there is currently minimal evidence in relation to in-depth qualitative studies of these approaches.
Individual cognitive stimulation approaches are likely to increase access to this intervention, specifically for
those people with dementia who are unable to participate in groups owing to local service constraints,
personal preference, or health or mobility issues. The justification of evaluating individual carer-led
programmes stems from promising findings from studies that have applied home-based cognitive
DOI: 10.3310/hta19640 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 64
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Orgeta et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
interventions. A carer-led, home-based programme of active training in memory management including
cognitive stimulation, orientation and family carer counselling10 reported long-term benefits for cognition
for people with dementia, reduced care home admissions and improved carer well-being. Home-based
cognitive stimulation has also been associated with improvements in problem solving and memory, and a
reduction in carers’ depressive symptoms,11 whereas the first RCT evaluating a home-based RO/cognitive
stimulation intervention demonstrated improvements in cognition for the person with dementia.12
Costs of dementia and use of cognitive stimulation interventions
Dementia is a health and social care priority for many countries worldwide. It is currently estimated that
population ageing is likely to exert an enormous impact on the dementia epidemic, with rapid increases in
the number of people affected in many countries.13 Over 700,000 older people currently living in the UK
have dementia, leading to high costs of treatment, care and support, with the current overall annual cost
of dementia exceeding £26B.14 Given that a high proportion of this overall economic impact is the value of
unpaid care and support by family and other carers,14 it is important to find interventions that make good
use of society’s limited resources, including the substantial inputs from carers. Cognitive stimulation
approaches have been shown to be promising in this regard, being among the few post-diagnostic
support interventions demonstrated to be cost-effective.7 Moreover, given the high proportion of cost
carried by unpaid carers, it is important that interventions targeting well-being in people with dementia
also accommodate any associated effects on family carers and support them in their caring roles.
Aims and objectives
This report presents data on the development and evaluation of a home-based individual cognitive
stimulation therapy (iCST) programme for people with dementia and their family carers. The intervention
was evaluated using a pragmatic, single-blind, RCT design comparing the effectiveness of iCST to
treatment as usual (TAU). The objectives of the study were the following:
l to develop an individual, home-based programme of CST for people with dementia and their
family carers
l to assess the effectiveness of iCST in improving cognition and quality of life for people with dementia,
mental and physical health in carers, and other outcomes in conjunction with TAU
l to assess the cost-effectiveness of iCST in comparison with TAU.
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Chapter 2 Intervention development
Development of individual cognitive stimulation therapy:
overview and framework of development studies
The development of the iCST programme involved three separate components that informed the key
characteristics of the intervention and its delivery in the main trial. We followed guidelines of the Medical
Research Council15 for the development and evaluation of complex interventions characterised by multiple
interacting components.16 Following these guidelines, we used the best available evidence on group CST,2,6
appropriate theories5,17 and a series of development studies in order to develop the individual CST
programme. The key objectives of the development phase were: (1) to ensure that the therapeutic materials
were easy to use, clear and appropriately tailored to the needs of people with dementia and their carers;
(2) to collect professional expertise data on the development of iCST; and (3) to gather data in relation to
feasibility, appropriateness of materials and factors influencing fidelity.18
Development study 1: service users’ views about
the intervention
This component of the development phase involved assessing the appropriateness and acceptability of the
intervention, by consulting people with dementia and their family carers using individual interviews and focus
groups. During initial consultations of manual development, two family carers and two health and social care
professionals were consulted. Carers’ and professionals’ feedback was sought in relation to the adaptation of
group CST approaches6,19 and the key characteristics of previous individual cognitive-based interventions
involving carers.10,12 These consultations concluded that a carer-led manual should adapt similar layouts to
those used in previous literature (i.e. group CST) but overall length should be reduced, academic terms should
be simplified and simple instructions should be incorporated. At this stage, carers and professionals also
identified the need to emphasise the dyadic nature of the intervention and to ensure that the manual is
engaging. Data gathered from these first consultations resulted in the first draft of the iCST manual (and
associated workbook). People with dementia and family carers taking part in the individual interviews and
focus groups were recruited from local NHS and voluntary organisations in the North East London Foundation
Trust. First drafts of the iCST manual and activity workbook were presented to service users for appraisal in a
series of 10 individual interviews and six focus groups. Demographic characteristics of the sample taking part in
Development study 1 can be seen in Appendix 1.
Ten caregiving dyads were recruited to participate in the individual interviews. People with dementia and
their carers were interviewed separately, using a discussion guide that was applied to direct the content
of the interviews, with each interview typically lasting 30–45 minutes. The interview with the person with
dementia started with an appreciation of the concept of mental stimulation and involved completing a
sample of iCST activities and collecting feedback about participants’ enjoyment and the level of difficulty.
A general discussion about perceptions of, and needs for, a home-based programme of mentally stimulating
activities followed. The aims of the carer interviews were similar, focusing primarily on collecting data about
the quality and appropriateness of iCST, and identifying any practical issues that might affect the delivery
of the programme and areas of support for carers.
Six focus groups were conducted with people with dementia and family carers. Thirty-two people participated
in the groups, which aimed to identify key characteristics of mentally stimulating activities, to assess the
feasibility of a home-based activity programme and to obtain feedback about the quality of materials
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presented. Two groups were held with carers, three groups were held with people with dementia and one
group was held with both carers and people with dementia. Group discussions were conducted in a
semistructured style guided by a series of pre-determined focus points. Details of the discussion points of
the individual interviews and focus groups are presented in Appendix 1.
All individual interviews and focus groups were transcribed. Inductive thematic analysis techniques were
employed in the coding and analysis of data,20 with meaningful excerpts of text extracted and used
for categories emerging (i.e. ‘perceived barriers’). Two researchers independently reviewed all excerpts
and additionally examined whether or not any could be coded to more than one category, reaching
consensus over their category placement. Data from all focus groups were collated, then examined
further by source (carers and people with dementia) to identify any variations in views. Individual
interview data were also grouped by source and compared with data gathered from the focus groups.
The response to the first draft of the iCST manual and activity workbook was positive overall, with carers
commenting that materials were clearly laid out and written in a way that was easy for people with
dementia and carers to understand. Recommended changes to the manual included editorial changes to
improve the clarity of instructions provided and alterations to the size of text and images. ‘Monitoring
progress’ forms of overall enjoyment of activities underwent significant adjustments at this stage in
response to feedback from carers that appraisal sessions should be informal in order to avoid the person
with dementia feeling that their performance on the activities is being scrutinised. Appendix 1 provides
a summary of the qualitative results of both the individual interview and focus group data.
Development study 2: expert feedback
The main purpose of Development study 2 was to gather ‘expert data’ on the suitability of the iCST
manual and associated workbook. We used consensus methods guidelines to collect ‘expert data’ from
dementia care professionals.21 Additional objectives were to address and identify key components of the
intervention in order to inform its final development. This study comprised an online survey evaluating
the draft of the iCST manual and associated workbook, followed by a consensus conference. Health-care
professionals, academics, service users, and private and voluntary sector professionals were invited to
participate in an online survey and were asked to provide their opinions on the suitability of the iCST
manual and workbook. We also sought input from European experts in dementia care.
Experts evaluated the iCST manual and activity workbook on the following domains: overall quality
and layout; language used; font size; amount of information presented; clarity and variety of activities;
and level of engagement. Statements were evaluated on a 5-point scale as follows: ‘strongly disagree’
(1); ‘disagree’ (2); ‘neutral’ (3); ‘agree’ (4); and ‘strongly agree’ (5). Very high agreement was defined as a
median of 5, an interquartile range of 0 and ≥ 80% of participants scoring 4 or 5. High agreement was
defined by a median of 5, an interquartile range of ≤ 1 and ≥ 80% scoring a 4 or 5. Moderate agreement
was defined by a median value of 4–5, an interquartile range of ≤ 2 and ≥ 60% of participants scoring a
4 or 5.22 For overall quality a 4-point scale was used: ‘poor’ (1); ‘fair’ (2); ‘good’ (3); ‘excellent’ (4).
A total of 25 dementia experts took part in the online consensus survey, of which two were family carers
(8%), 11 (44%) were working in the NHS or social services, three (12%) were working in the private sector,
seven (28%) were academics in dementia care and two (8%) were professionals working in the voluntary
sector. Of these experts, 16 (64%) attended the consensus conference and additional workshops. Results of
the online survey for the iCST manual and associated workbook appear in Appendix 2.
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Additional qualitative comments from the online survey data were subjected to a thematic analysis.
Analyses of these data emerged in the following key domains:
l Person-centred focus: the activities and key principles of iCST should be more person-centred; there
should be an emphasis on positive emotions and pleasurable experiences for both the person with
dementia and family carer, and the manual should emphasise the dyadic nature of the intervention.
l iCST activities: for each activity the level of difficulty of the session should be clearly separated and
additional activities for people with mobility issues or compromised hearing should be accommodated.
It was emphasised that activities should be accessible to all demographics and that all iCST sessions
should be ‘collaborative’, highlighting that people with dementia and carers ‘work together’.
l Layout and clarity of intervention: the manual should provide key information about the intervention
only; it should incorporate a smaller and more manageable number of key principles and should
emphasise that discussion is one of the key purposes of iCST by including open-ended questions.
Consensus workshops
An additional component of Development study 2 was consensus workshops inviting experts to comment
on specific components of the development of the intervention, with a total of 16 experts taking part.
Themes discussed were: Getting started with iCST, iCST toolkit of resources, Overview of iCST manual and
associated workbook, Support for carers and Home-based training in iCST. A thematic analysis was used to
analyse data in each of the four workshops. In the Getting started with iCST theme, results indicated that
this aspect of the intervention would need to be tailored to individual needs and that carers should be
encouraged to identify their own style, with the use of warm-up activities that incorporate person-centred
interests. In relation to the iCST toolkit of resources theme, experts commented that physical games should
be adapted for indoors use and have an increased cognitive component, and that maps of counties will
be a useful relevant resource. In the workshop discussing the Overview of iCST manual and associated
workbook theme, it was discussed that principles of iCST should avoid replication and should be shortened
to a more manageable key list.
In the remaining two consensus expert workshops, issues of support for carers and set-up of home-based
training for iCST were discussed. Analyses indicated emphasis by experts on the importance of
empowering carers by providing extra information and help if requested, encouraging the involvement
of other family members and inclusion of a Carers Diary providing easy access and navigation to sessions
completed. Experts advised that a digital versatile disc (DVD) could be used for problem solving but that
it should not become a barrier for carers adopting their own style.
Development study 3: field testing for final refinement prior to
the main trial
The main aim of the third development study was to assess further key elements and components of
adaptation of the intervention through field testing. Twenty-six people with dementia and their carers took
part in this study. The majority of carers were family members of the person with dementia and were
recruited either from the voluntary sector or from memory services in the North East London Foundation
Trust. A small proportion of carers taking part were paid carers (n= 6), who were recruited from a private
home care agency. People with dementia were screened for eligibility using the inclusion criteria of
the main trial. Family carers were usually approached about the research study first by dementia care
professionals (consultant old age psychiatrist) and then by the research team. A senior member of staff at
the home care agency contacted potential carers working with people with mild to moderate dementia.
If the dyad consented to participate, a set-up visit was arranged by local researchers. Written consent was
provided by both the carer and the person with dementia at the beginning of the set-up visit. Demographic
characteristics of the sample can be seen in Appendix 3.
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For the purposes of the field testing, the 75-session programme was divided into six draft manuals and
accompanying workbooks. Manuals 1–5 comprised a total of 60 sessions and manual 6 contained the
remaining 15 sessions. Carers were asked to deliver up to 3 sessions per week. Participants were asked to
complete a total of 24 sessions on average.
Training and support
Family carers were trained by a member of the research team in their own home. Paid carers were trained
as a group, with training sessions lasting 1–1.5 hours. Carers were provided with materials including the
iCST manual and associated workbook and additional toolkit items (such as dominoes and playing cards).
The first part of the session focused on describing the programme, familiarising carers with the iCST
materials and explaining key principles of the intervention. A clip of a DVD developed in the recent
maintenance group CST trial19 was shown in order to demonstrate principles and examples of activities.
The second part of the session focused on practising an iCST session with support from the researcher.
In all set-up visits, carers were invited to participate in a session with their relative with dementia. At the
group training session for paid carers, staff were divided into pairs in order to practise iCST. The guided
session aimed to help carers understand the key principles of iCST and how these can be implemented in
the delivery of the sessions.
Carers completed a short evaluation questionnaire at the end of the training session rating knowledge
and confidence in delivering iCST, alongside information about the anticipated amount of support
needed. An evaluation questionnaire was also completed by the researcher in order to assess the success
of the carer’s training session and to measure additional fidelity-related components. Researchers
contacted carers weekly to provide support and to gather feedback about the dyads’ experiences with
the iCST programme. Carers provided additional feedback about each activity on ‘monitoring progress’
forms, rating the person with dementia’s interest, communication, enjoyment and level of difficulty
of each session using a 5-point Likert scale.
Final visit
Debriefing visits were arranged with dyads who completed their allocated sessions. The purpose of the
visit was to collect written feedback about the sessions and to interview the dyad about their experience
in using iCST. Carers completed a modified version of the training visit evaluation questionnaire, assessing
knowledge and confidence in delivering iCST, the quality of support received and their perceived success in
engaging with the person with dementia. Similar data were also completed by the researcher at the end
of the visit.
Appendix 3 shows number of sessions completed for dyads taking part in the field-testing phase.
The average number of sessions completed was 12 out of 24, indicating that most dyads were able
to complete approximately half of the sessions, as opposed to 3 sessions per week. For a total of
nine dyads, additional information for each of the sessions was collected in the areas of enjoyment,
communication and interest by the person with dementia. Information related to the difficulty level for
each of the sessions was also collected, as well as fidelity parameters (see Appendix 3). Pre–post
evaluations of the field-testing phase showed that carers’ knowledge of [before: mean = 2.78, standard
deviation (SD) = 0.97; after: mean = 3.11, SD = 0.93] and confidence in iCST (before: mean = 3.78,
SD = 0.83; after: mean = 4.11, SD = 0.78) increased.
Information from the field-testing phase was incorporated into the main trial, by revising sessions that
were rated either low on items of interest, communication and enjoyment for the person with dementia,
or rated high in levels of difficulty. Qualitative data were also collected during Development study 3 via
standard telephone interviews. Carers delivering iCST were asked to comment on parameters such as
barriers to being able to complete the sessions, and on the content of the manual and activity workbook.
An overview of these findings appears in Appendix 3. The most common barrier in iCST was lack of
time and availability for delivering the sessions followed by issues around the health of the person with
dementia or the carer. An additional barrier noted by both family and paid carers was experiencing
INTERVENTION DEVELOPMENT
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difficulties in motivating and engaging people with dementia in the sessions. When discussing potential
gains, a high percentage of carers mentioned that iCST provided opportunities to spend more time
with their relative and assisted in improving the caregiving relationship.
Patient and public involvement
We held initial meetings with two members of the public as part of our public and patient involvement for
the iCST study. Both were family carers of people with dementia and were asked to read all previous
group CST manuals and comment on their content and suitability for carer use. During the development
phase of iCST and the main trial, we invited two additional family carers to be consultants on the project
to comment on carer training issues and support around iCST. They both took part in meetings held to
provide peer supervision to unblinded researchers supporting carers and people with dementia with iCST.
Their feedback emphasised the need for paying attention to the needs of both people with dementia
and family carers as well as the importance of focusing on positive aspects of the intervention during
carer support.
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Chapter 3 Final intervention tested in the
main trial
The iCST intervention was developed primarily as a home-based programme of structured iCST forpeople with dementia to be delivered by carers. Dyads completed up to 3 30-minute sessions per week
over 25 weeks. The programme consisted of a total of 75 themed activity sessions, including being
creative, number games and art discussion (Box 1), which were intended to provide opportunities for
general cognitive stimulation via a choice of specific activities. In order to accommodate personal interests,
dyads were encouraged to adapt the materials provided and to take a flexible approach in relation to
choosing sessions, such as omitting any activities not suited to their interests, or revisiting activities that
were particularly enjoyable. Each iCST session followed a consistent structure, where the first few minutes
involved engaging in discussions of orientation information prompted by family carers (i.e. day, date,
weather, time, location), followed by discussion of current events (i.e. a news story, a community event
or family occasion) and the main iCST activity (15–20 minutes).
We used recent guidelines23 aimed at improving the description of interventions evaluated in RCTs
consistent with the Consolidated Standards of Reporting Trials (CONSORT) 2010 and Standard Protocol
Items: Recommendations for Interventional Trials statements, which enables replication of the specific
intervention tested. An overview of the iCST intervention using the Template for Intervention Description
and Replication checklist and guide is presented in Table 1.
Contents of individual cognitive stimulation therapy
Dyads were provided with the iCST manual, the iCST activity workbook, two carer diaries and the iCST toolkit.
The iCST manual provides guidance on how to run the iCST sessions, the key principles of iCST (Box 2) and
BOX 1 Themes of iCST sessions
l My life.
l Current affairs.
l Food.
l Being creative.
l Number games.
l Quizzes.
l Sounds.
l Physical games.
l Categorising objects.
l Household treasures.
l Useful tips.
l Thinking cards.
l Visual clips discussion.
l Art discussion.
l Faces/scenes.
l Word games.
l Slogans.
l Associated words.
l Orientation.
l Childhood.
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TABLE 1 Template for Intervention Description and Replication checklist describing the iCST intervention
Item Description
Name iCST for people with dementia
Why iCST is based on theoretical principles of RO and uses the same structure and principles of the
group CST approach. Carer-led iCST adapts a person-centred approach, in which the person
is engaging in home-based cognitive stimulation activities. iCST activities focus more on
opportunities to express opinions and less on discussing factual information, and place an
emphasis on the person with dementia and their family carer spending enjoyable time together,
using a specific framework of discussion
What Materials
iCST manual (guidance for carers)
iCST activity workbook (activities materials)
iCST carer diary (reporting and evaluating activities)
iCST toolkit (boules, playing cards, dominoes, magnifying card, sound activity compact discs,
coloured pencils, and world and UK map)
iCST training pack (iCST role-play exercises)
Procedure
Carers trained at their home, using a standardised training package aimed at demonstrating key
principles of iCST. Additional support provided over the phone and additional home support visits
Provider iCST was provided by family carers. Carer training and support was provided by the research
team of unblinded researchers who were either mental health nurses, clinical psychologists,
occupational therapists or research assistants. All unblinded researchers received standardised
training in supporting family carers in iCST
How iCST was delivered by carers. iCST carer training was delivered by unblinded researchers.
Unblinded researchers received training in a group. Support on iCST was provided as an
additional home visit and over the phone by unblinded researchers
Where iCST was delivered at the dyad’s home
When and how much iCST consisted of 75 sessions delivered by the family carer for 30 minutes, three times a week,
over 25 weeks
Tailoring Tailoring included additional home visits or telephone support, or provision of additional resources
related to the intervention (i.e. books, DVD player)
Modifications No modifications occurred during the intervention
How well Planned: intervention compliance was assessed by self-reported questionnaires completed by
carers and researchers
Actual: mean compliance was 31.6 (SD= 26.8) sessions, where 22% completed 0 sessions,
13% completed 1–10 sessions and 51% completed more than 30 sessions
BOX 2 Individual cognitive stimulation therapy key principles
iCST should:
l be ‘person-centred’
l offer people with dementia choice in a range of home-based CST activities
l focus on opinions rather than facts
l use reminiscence
l always use a focus such as senses, stimuli or objects
l aim at maximising potential
l recognise that enjoyment and fun are key for both the person with dementia and their family carer
l provide opportunities to stimulate language
l provide opportunities to strengthen the caregiving relationship.
FINAL INTERVENTION TESTED IN THE MAIN TRIAL
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guidance on activities. This manual was disseminated at the ninth UK Dementia Congress and has been
published.24 The iCST activity workbook contains paper-based resources for activities suggested in the manual,
such as word puzzles and images to stimulate discussion.
Carer training
Carers were trained in their home by an unblinded researcher. A standardised training package was
developed with interactive features, including a role-play exercise and the opportunity to see clips of group
CST activities. The first part of the training session introduces the dyad to the iCST materials (manual,
activity workbook, toolkit and carer diaries) and explains the session structure and key principles. Carers
were encouraged to take part in a role-play exercise with the researcher, developed to demonstrate ‘good’
and ‘bad’ practice in iCST. In the final part of iCST training, family carers were invited to deliver their first
iCST session with support from the unblinded researcher, who provided feedback afterwards. Where
multiple family carers were involved in delivering the programme, the researcher invited them to be trained
with the main carer.
Individual cognitive stimulation therapy support for carers
An unblinded researcher provided dyads with telephone support throughout their participation, providing
weekly, fortnightly or monthly telephone support depending on carer needs and preference. Additional
monitoring visits took place at 12 weeks and 25 weeks, which were aimed at collecting the iCST carer
diaries, providing further support if necessary and completing measures of compliance. There were a total
of 21 unblinded researchers supporting carers, of whom 81% were qualified professionals working in the
local NHS trusts. Among qualified professionals, the majority were nurses (n= 13) or clinical psychologists
(n= 3), with one member of staff being a qualified occupational therapist. The remaining staff were clinical
studies officers (n= 2) or research assistants (n= 2). All unblinded researchers supporting carers received
training in iCST.
Individual cognitive stimulation therapy fidelity
To ensure that psychosocial interventions can be replicated, and to ensure that the treatment delivered was
indeed the treatment intended (known as ‘treatment integrity’),25 iCST components were described in detail
in a treatment protocol. This protocol formed the basis of training of all unblinded researchers supporting
and training family carers in delivering iCST. iCST diaries provided a method of tracking compliance to
the programme, whereby in each theme, carers were required to record whether or not the session had
been completed, the date of completion and their relative’s interest, enjoyment and communication. Space
was provided for dyads to provide any additional comments related to the sessions. The progress of dyads
and compliance to the programme was also measured during support activities via treatment questionnaires
during both the telephone support and visits. A telephone support questionnaire was used to gather data
on the average number of sessions completed per week, average duration of sessions, average time spent
preparing and any difficulties encountered. Carers completed a self-report measure of confidence and
knowledge in the delivery of iCST, level of engagement of the person with dementia, use of iCST principles
and satisfaction with the support provided in treatment visits.
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Chapter 4 Trial phase methods
Design
A multicentre, pragmatic, single-blind, two-treatment arm (iCST vs. TAU), randomised, controlled, clinical
trial was conducted over 26 weeks. Participants were randomised to the two groups using a dynamic
adaptive randomisation stratified for site and whether or not the person with dementia was taking
acetylcholinesterase inhibitors at baseline. Data collection was at baseline, 13 weeks and 26 weeks after
completion of the intervention. The primary outcomes were assessed at both time points, with the primary
hypothesis examining outcomes at 26 weeks.
Ethics approval
A protocol was submitted for ethical review to the East London 3 Research Ethics Committee (REC)
(reference number 10/H0701/71) in January 2010, with provisional approval being granted in July 2010.
The following information was identified by the Committee as needing further clarification
and amendment:
l Participant Information Sheet to be modified to cover video-recordings and information about the
control/usual care group and minor editing changes (i.e. language use)
l consideration of a cross-over or add-on scheme and whether or not participants will be given a copy of
a DVD and manual
l provision of additional information about the interviews in both consent and participant forms and
further clarification over whether or not recruitment posters and leaflets would be used.
Final approval was granted in September 2010. Participating centres obtained approval from the
appropriate local REC and relevant NHS research and development departments.
Intervention and control conditions
Participants randomised to the intervention group received iCST at their own home. The control condition
was TAU, with participants in this group receiving no additional intervention. The services and interventions
available to people with dementia and family carers randomised to receive TAU varied between and within
the iCST centres and may have changed over time. We recorded the use of drugs and services across the
two groups and any changes that occurred. In general, services offered to the TAU group were also available
to those in the active treatment group condition.
It is very unlikely that any comparable (or even any other) individual cognitive stimulation intervention
for the person with dementia would have been available, as these types of therapies are generally
unavailable in the UK. We followed standard best-practice methods around pragmatic trials involving
an intervention group compared with usual care. Outside the iCST intervention, both groups, in general,
would have access to the same kinds of mentally stimulating activities. It is possible that some participants
in the TAU group may have engaged in some form of mentally stimulating activities in day-centres;
however, this is unlikely to have been as structured as iCST. We asked sites to note instances in which the
person with dementia may have been engaged in cognitive stimulation groups by their local services.
Those participants who have engaged in such activities during the 3 months prior to recruitment were
considered to be ineligible.
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Study population
Eight centres in England and Wales were involved in the study: London, Bangor, Hull, Manchester, Norfolk
and Suffolk, Dorset, Lincolnshire and Devon (covering Devon North and Devon South), which comprised
12 recruitment sites in total. Researchers in three centres (London, Bangor and Manchester) were based in
universities, whereas those in Hull, Norfolk and Suffolk, Dorset, Lincolnshire and Devon were based in NHS
mental health services (Table 2). Recruitment commenced in April 2012 and was completed in July 2013.
Eligibility criteria
Inclusion
All participants were people with dementia who:
l met the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition criteria for dementia of
any type (Alzheimer’s, vascular, Lewy body type and mixed)
l scored 10 or above on the Mini Mental State Examination (MMSE)
l had some ability to communicate and understand communication, indicated by a score of 1 or 0 on
the relevant items of the Clifton Assessment Procedures for the Elderly – Behaviour Rating Scale
l could see/hear well enough to participate in the programme activities
l had no major physical illness or disability affecting their participation
l lived in the community at baseline, had regular contact with a relative or other unpaid carer who could
act as an informant and could participate in the intervention.
Exclusion
People with dementia were excluded if:
l they were not living in the community (i.e. living in a care home)
l they had no available family carer to deliver the sessions and act as an informant.
TABLE 2 Centres in the iCST trial
iCST centre iCST recruitment site
London North East London NHS Foundation Trust
Barnet Enfield and Haringey Mental Health NHS Trust
Bangor Betsi Cadwaladr University Health Board
Hull Hull Humber NHS Foundation Trust
Manchester Manchester Mental Health and Social Care Trust
Lancashire Care NHS Foundation Trust Site A
Lancashire Care NHS Foundation Trust Site B
Dorset Dorset Healthcare University NHS Foundation Trust
Lincolnshire Lincolnshire Partnership NHS Foundation Trust
Norfolk and Suffolk Norfolk and Suffolk NHS Foundation Trust
Devon Devon Partnership NHS Trust
Northern Devon Healthcare NHS Trust
TRIAL PHASE METHODS
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Sample size
The main analysis was based on intention to treat for the primary outcome of cognition [Alzheimer’s
Disease Assessment Scale – Cognitive Subscale (ADAS-Cog)]. Our group CST study6 had an effect size
of 0.32. Our Cochrane review of RO26 found a standardised mean difference (SMD) of 0.58, whereas the
individual RO/CST study12 found a SMD of 0.41. Taking a conservative approach, we estimated the SMD
relative to TAU to be 0.35. A sample size of 260 will have to yield 80% power to detect a SMD of 0.35
using a two-group t-test with a 0.05 (two-sided) significance level comparing the iCST and the TAU
groups. Assuming 15% attrition, we originally proposed to recruit 306 people with dementia. During
the course of the trial the observed attrition rate was nearer to 25% than the 15% accounted for in the
sample size calculation and, therefore, the target recruitment was revised to account for this. The final
recruited sample size was 356.
Recruitment procedures
In each iCST centre, people with dementia and their family carers were recruited through mental health
services for older people, such as Memory Clinics and Community Mental Health Teams, through
dementia care professionals, including psychiatrists, and through local voluntary sector organisations, such
as the Alzheimer’s Society (see www.alzheimers.org.uk). The centres in London, Bangor and Manchester
were supported by clinical studies officers accessed through the National Institute for Social Care and
Health Research Clinical Research Centre in Wales and the Dementias and Neurodegenerative Disease
Research Network (DeNDRoN) in England. In Hull and the East Riding of Yorkshire, all patients and carers
referred with dementia (and their general practitioners who currently have additional DeNDRoN support to
assist with recruitment to dementia trials) were automatically provided with ‘opt-in information’ on current
NHS portfolio studies in dementia care, via a centralised clinical academic unit, The Hull Memory Clinical
Resource Centre.
The aim of the project was briefly described to potential participants by members of the research and
clinical team, and permission for them to be contacted by local researchers was obtained prior to further
contact. Research assistants discussed the project and provided full details to participants, answered any
questions related to the project and, if participants agreed, undertook informed consent.
Informed consent
Participants enrolled to the study only after providing informed consent in line with guidelines set by
the Mental Capacity Act 2005.27 Participants were in the mild to moderate stages of dementia and were
therefore expected to be competent to give informed consent for participation, provided that appropriate
care was taken in explaining the research and sufficient time was allowed for them to reach a decision.
It was helpful for a family member to be involved, and we aimed to ensure that this was done wherever
possible. Both people with dementia and family carers were informed that no disadvantage would accrue
if they chose not to participate, and all participants were provided with at least 24 hours to review
information about the study prior to making a decision. In seeking consent, we followed current guidance
from the British Psychological Society28 on the evaluation of capacity. In this context, consent is regarded
as a continual process rather than a one-off decision, and willingness to continue participating was
continually checked through discussion with participants during the assessments. If, at any point, the person
with dementia or family carer became uncomfortable with the assessments, these were discontinued.
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Ethical arrangements
The study was approved through the appropriate REC. All researchers received training in Good Clinical
Practice guidelines.29 There appear to be no documented harmful side effects from participating in CST
interventions or other types of cognitive-based interventions. Regular monitoring by, and support from,
the key local unblinded researchers in each centre was undertaken during the intervention to ensure that
people with dementia participating in the iCST sessions did not feel deskilled or undervalued.
Prospective participants were fully informed of the potential risks and benefits of the project. A reporting
procedure was put in place to ensure that serious adverse events (SAEs) were reported to the Chief
Investigator (see Appendix 8). On becoming aware of an adverse event involving people with dementia
or their carers, a member of the research team assessed whether or not it was ‘serious’. A SAE was
defined as any untoward occurrence experienced by either a person with dementia or carer that:
l resulted in death
l was life-threatening
l required hospitalisation or prolongation of existing hospitalisation
l resulted in persistent or significant disability or incapacity
l was otherwise considered medically significant by the investigator
l came within the scope of the Protection of Vulnerable Adults protocol,30 which was in place to ensure
that suspected cases of abuse or neglect were followed up in an appropriate manner.
A reporting form was submitted to the Chief Investigator who assessed whether or not the SAE reported was:
l related to the conduct of the trial
l unexpected.
Serious adverse events that were judged to be related and unexpected were to be reported to the REC
and the trial Data Monitoring and Ethics Committee (DMEC) within 15 days of occurrence.
Randomisation
Remote randomisation of participant allocation treatment was undertaken via a web-based
randomisation service managed by the North Wales Organisation for Randomised Trials in Health
(NWORTH) clinical trials unit, after baseline assessment and informed consent. Randomisation was
completed using a dynamic adapative allocation method,31 with an overall allocation ratio of 1 : 1.
Random allocation was stratified by site and receipt of acetylcholinesterase inhibitors (AChEIs). For
each participant randomised, the likelihood of their allocation to each treatment group is recalculated
based on the participants already recruited and allocated. This recalculation is done at the overall
allocation level, within stratification variables and within stratum level (the relevant combination
of stratification levels). By undertaking this recalculation, the algorithm ensures that balance is
maintained within acceptable limits of the assigned allocation ratio while maintaining unpredictability.
Allocation concealment
The randomisation database was held at NWORTH, and the analysts involved in the trial did not have
access to the database. The dynamic adaptive algorithm is tuned using weighting parameters. These
parameters are chosen by simulation modelling to ensure that the balance is maintained at an acceptable
level, while ensuring that the sequence of allocations does not become predictable. Strong parameters
would make the randomisation algorithm behave in a deterministic way, thus making allocation
concealment difficult. Unblinded researchers were the only staff who were informed at each of the
iCST centres of participants’ allocation.
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Implementation
A web-based randomisation system was set up at NWORTH. Unblinded researchers could log into the
system, enter participants’ details and receive randomisation results on screen and by confirmation e-mail.
The system ensured that each entry had a unique trial identification number.
Blinding
As with all psychosocial interventions, participants cannot be blind to the allocation they receive. Within
each iCST centre, there were nominated blinded and unblinded researchers; both were able to conduct
baseline assessments and request randomisation. However, once participants were randomised, follow-up
data were collected by the team of blinded researchers only, whereas the training and carer support in
delivering iCST was run by unblinded researchers. Given that participants may occasionally and inadvertently
inform researchers of the treatment they are receiving, we aimed to reduce this bias by use of self-report
measures wherever feasible and brief reminders to participants. We asked all blinded researchers to record
their impression of the group to which each participant was allocated and their confidence in that prediction.
Statisticians remained blind to allocation for the main analysis, whereas compliance analysis incorporating
compliance to the intervention was conducted after the main analyses only.
Data collection
Primary and secondary measures were completed at baseline, 13 weeks after baseline (week 13) and
26 weeks after baseline (week 26). Researchers were instructed to conduct all week-13 assessments within
the 13-week period, but no later than 2 months from the scheduled first follow-up appointment (starting
at date of baseline assessment), and to conduct all week-26 assessments by 26 weeks, but no later than
2 months from the scheduled second follow-up (starting at date of baseline assessment).
Most interviews were conducted in dyads’ homes. All questionnaire instruments were arranged in the form
of booklets, with additional show cards of responses supporting the person with dementia during the
assessment. If, at any point, the person with dementia felt uncomfortable with the assessment this was
discontinued and was only rescheduled to take place during a second visit where appropriate.
Measures
Primary outcome measures for person with dementia
(a) Cognition for the person with dementia, assessed by ADAS-Cog,32 measuring the severity of the most
important cognitive symptoms of Alzheimer’s disease (AD). ADAS-Cog is the most popular cognitive
testing instrument used in clinical trials of drug treatments for dementia consisting of 11 tasks
assessing disturbances of memory, language, praxis, attention and other cognitive abilities, often
referred to as the core symptoms of AD. This widely used test has good reliability and validity,33 and
is scored from 0 to 70, with higher scores indicative of greater cognitive impairment.
(b) Quality of life of the person with dementia, measured using the Quality of Life in Alzheimer’s Disease
Scale (QoL-AD).34 QoL-AD is a widely used, brief, self-report questionnaire, covering 13 domains of
quality of life. The QoL-AD has good validity and reliability.35 Both self and carer ratings were collected,
in which higher scores indicate better quality of life.
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Secondary outcome measures
(a) Quality of life, assessed using the Dementia Quality of Life (DEMQOL) measure,36 covering five domains
of quality of life, including daily activities, health and well-being, cognitive functioning, social
relationships and self-concept. The scale uses self-rated reports of quality of life administered to the
person with dementia. The measure was also administered to the family carer in order to collect
DEMQOL-proxy ratings.
(b) Neuropsychiatric symptoms, measured by the Neuropsychiatric Inventory.37 The Neuropsychiatric
Inventory assesses 10 behavioural disturbances occurring in people with dementia, using a screening
strategy to minimise administration time by examining and scoring only those behavioural domains
with positive responses to screening questions. Both frequency and severity of each behaviour are
determined, with both validity and reliability for the measure established.37
(c) Functional ability for the person with dementia, measured by the Bristol Activities of Daily Living Scale
(BADLS),38 a carer-rated instrument consisting of 20 daily-living abilities. The BADLS shows sensitivity to
change in people with AD receiving anticholinesterase medication and significantly correlates with
changes in the MMSE and the ADAS-Cog.39
(d) Depression, measured using the Geriatric Depression Scale (GDS)-15,40 one of the most commonly
used self-rating depression scales in geriatric populations. The shorter version of the scale comprises
easy-to-use items, designed to exclude somatic symptoms of depression that are also seen in
non-depressed elderly people. The GDS-15 has acceptable sensitivity and specificity when used
with people with mild to moderate dementia.41
(e) Quality of the relationship, measured by the Quality of Caregiver–Patient Relationship (QCPR),42
applicable to both spousal and adult child carers, completed by both the person with dementia and
family carer. The QCPR has good internal consistency and concurrent validity with other measures
of relationship quality and carer distress.42
(f) Use of health and social care services provided by public or non-public bodies, as measured on the
Client Service Receipt Inventory (CSRI),43 adapted for use in this study. The CSRI was used to collect
information on the identified carer’s costs and the participant’s use of health and social care services.
Additional data collected included medications for mental health, the carer’s provision of unpaid
care and employment status, and out-of-pocket costs to both participant and carer (travel expenses
to health and social care appointments, payment for equipment and adaptations).
Primary outcome measures for carers
(a) Mental and physical health, measured by the Short Form questionnaire-12 items (SF-12).44 The SF-12
measures health by scoring standardised responses, which are expressed in terms of two meta-scores:
the physical component summary (PCS) and the mental component summary (MCS).
Secondary outcome measures
(a) Depression, measured by the Hospital Anxiety and Depression Scale (HADS),45 a self-completed measure,
generating scores for generalised anxiety and depression, used widely to identify caseness for clinically
significant depression and anxiety.46
(b) Health-related quality of life, measured using the three-level response version of the European Quality
of Life-5 Dimensions (EQ-5D™) (hereafter EQ-5D-3L),47 a standardised instrument for use as a measure
of health outcome. Applicable to a wide range of health conditions, the EQ-5D-3L provides a simple
descriptive profile and a single index value for health status.
(c) Resilience, measured by the Resilience Scale-14 items,48 in which responses are summed and higher
scores indicate stronger resilience. The measure demonstrates high construct validity.49
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Data checking
A full data-management plan was written, encompassing data storage and processing, data filing, data
sharing, data freezing and data archiving. Data were collected in questionnaire packs and entered into
a data-management system (MACRO version 4.1.2.3750, InferMed, London), which was audited for data
entry accuracy, before being exported to Statistical Package for the Social Sciences (SPSS) files. SPSS
Predicative Analytics SoftWare version 20 (IBM Corporation, Armonk, NY, USA) was used for all further
data manipulations and analysis. In all SPSS files, cleaning processes were undertaken, including checks for
consistency and out-of-range data. If applicable, questionnaire data were cross-checked with the SPSS data
to explore any issues of inconsistency. CSRI data were cleaned and analysed in Stata 13 (StataCorp LP,
College Station, TX, USA), again checking for consistency. Adherence data were entered by unblinded
researchers into the MACRO system and used in both outcomes and economic analyses.
Data analysis
Missing data for clinical effectiveness
Data were not imputed for participants who did not provide any information at a particular time point.
However, standard statistical tests were employed to ensure that there were no significant differences in
demographics or baseline outcome scores between those who completed at a time point and those who
did not. There were two types of missing data: missing items within measures and missing measures
at time points.
Missing items within measures: pro-rating
For items missing within measures, the rules for completing missing data for the relevant measure were
applied. The missing data rules implemented for each measure are considered to be part of the validated
tool and were therefore used as designed in line with the original validation.
Pro-rating within participant measures were undertaken at the 20% missing level (i.e. if there was one
item missing for a 5-item score, this was completed with the mean of the other items).
Missing measures at time points: regression model using multiple imputation
A regression within the treatment group was applied to impute total scores in line with the trend seen
in the group, as multiple imputations, allowing an assessment of the sensitivity of the data. The multiple
imputation model included demographic variables such as sex, age, ethnicity, type of relationship and
site. It also included the completed scores for the other outcome measures at each time point. At both
follow-up time points, the model included the allocated treatment group. Scores at baseline were used
to predict scores at week 13. Scores at baseline and week 13 were used to predict scores at week 26.
Baseline characteristics
No statistical tests were conducted for significant differences in baseline characteristics between the two
treatment arms.50
Interim analyses
No interim analyses were planned for the data. No additional analyses were requested or identified by
the DMEC.
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Primary effectiveness analyses
We used an analysis of covariance (ANCOVA) model to assess the differences between the two groups in the
ADAS-Cog and the QoL-AD as the primary outcome measures for people with dementia. The dependent
variable in the model was the outcome at week 26, with covariates being the baseline measurement, age of
participants with dementia and relationship with the carer. The fitted fixed factors considered were sex, marital
status and receipt of acetylcholinesterase inhibitors. Site was added as a random factor. Both stratification
variables were included in the model (site and acetylcholinesterase inhibitors).
A similar ANCOVA model was fitted for the carer primary outcome. The dependent variable in the model
was the outcome at week 26, with the covariates being the baseline measurement, age of carer and
relationship with the person with dementia. The fitted fixed factors considered were sex and marital status.
Site was fitted as a random factor.
Secondary effectiveness analyses
The ANCOVA model described above was used to assess the differences between the two groups on all
secondary outcomes for people with dementia. A similar ANCOVA model was fitted for all carer secondary
outcomes.
Additional analyses
A basic adherence analysis was undertaken. The number of iCST sessions completed was held as a
continuous variable and added to the model of the main analysis. This would allow an insight into whether
or not the number of sessions completed was important to the outcome.
Economic analyses
The economic evaluation was a cost-effectiveness analysis, conducted first from a health and social care
perspective and, second, from a societal perspective. The primary outcome measures for the person
with dementia were the incremental cost of achieving:
(a) one SMD (taken to be 2.4 points on the scale) in the ADAS-Cog
(b) one SMD (taken to be 1.7 points on the scale) in the QoL-AD.
The primary outcome measure for the carer was the incremental cost per quality-adjusted life-year (QALY)
(derived using the EQ-5D-3L with societal weights).
In the analysis plan, the secondary economic measures for the person with dementia were set out as:
QALYs derived from the DEMQOL-U and DEMQOL-Proxy-U, the MMSE, BADLS, GDS-15 and QCPR.
Secondary economic measures for the carer were the HADS, MCS-12, PCS-12 and QCPR.
Valuation strategy for outcomes
Carers’ utility scores were calculated from the EQ-5D-3L, applying published societal weights.51
We also derived utility scores for people with dementia based on self-ratings and carer proxy-ratings
(the DEMQOL-U and DEMQOL-Proxy-U indexes, respectively) from the DEMQOL and DEMQOL-Proxy
instruments, using published societal weights.52 All QALYs were calculated using the area-under-the-curve
method with linear interpolation between the three assessment points and the last value carried forward
from the final assessment to 12 months post-baseline.
The ADAS-Cog scores were reversed so that an increased score can be interpreted as a positive change
for the purposes of deriving net benefit in order to plot cost-effectiveness acceptability curves (CEACs).
For the QCPR, an estimate of the points equivalent of the SMD was obtained by taking the baseline SD for
the QCPR and multiplying by the effect size53 of 0.35 set for the study. This gave a difference of 3.1.
TRIAL PHASE METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
20
Costs
Perspective
Costs from the health and social care perspective covered services used by the person with dementia,
including care/nursing home care, hospital care (inpatient, day, outpatient and accident and emergency
services), primary and community health and social care. Costs from a societal perspective covered the
aforesaid services, plus the costs of care and support provided by unpaid carers.
Time horizon
The economic analysis used the mean end point (week 26) outcome measure (as the primary outcome for
people with dementia and secondary outcomes) and costs over the 26-week period. In the case of the ICER
for the primary outcome for caregivers (cost per QALY), we calculated QALYs over the year from the baseline
assessment; we likewise assumed that mean costs remained unchanged since the end of the intervention
period and calculated annual equivalent costs by doubling the costs estimated for the 26-week period.
Cost data collections
Costs were calculated based on several collections:
1. data on services used by the person with dementia, as observed and reported by carers using the
CSRI.43 Service use items were collected and aggregated into cost categories
2. data on time spent by professionals (unblinded researchers) in supporting carers to deliver the training
package, using one of a suite of ‘treatment adherence’ forms
3. data on professionals’ labour costs, using a pro-forma distributed to the unblinded researchers
4. data on time spent by carers to deliver the training package:
i. average time spent in preparing and in delivering the session: these data were collected by
unblinded researchers during their telephone contacts, using one of a suite of ‘treatment
adherence’ forms
ii. number of sessions completed: this information was collected from carers who were asked to
complete a workbook feedback form after every session. A manual count of sessions completed was
conducted by unblinded researchers at each follow-up monitoring visit (one per follow-up period)
5. data on carer time spent on care and support activities, and lost employment and out-of-pocket costs,
using the CSRI
6. costs of training materials (excluding costs of the initial development and testing of the package),
supplied by the project management team.
Unit costs/valuation of health and social services and unpaid care
Unit costs were applied to units of resources in the estimation of per-participant costs. The base year
for unit costs was 2012–13. Unit costs employed are summarised in Table 3 (unit costs and sources are
given in further detail in Appendix 4). Costs of health and social care were calculated from service-use
data by applying relevant, nationally generalisable unit costs [e.g. NHS reference costs54 and the Personal
Social Services Research Unit (PSSRU) costs compendium55]. Costs of carers’ inputs were calculated using
two methods: replacement costs and opportunity costs.56–58 The primary analysis used opportunity
costs, attaching a value equal to the national minimum wage to each hour of unpaid carer time spent
on care and the cost of lost production; a replacement costs approach was employed in the sensitivity
analyses (valuing time spent on care at the unit cost of a home care worker) (see Table 3). Certain
out-of-pocket payments were also considered to be a cost to the dyad rather than to health and social
care: the travel costs of accompanying the person with dementia to dementia-related appointments by
car, public transport or taxi, and the private purchasing of equipment and adaptations.
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Valuation strategy for intervention costs
The iCST intervention was produced from both professional and carer inputs. Unblinded researchers from
the nursing and psychology disciplines worked to set up and train carers to deliver the sessions and
then provided ongoing face-to-face and telephone support to carers throughout the study period.
In order to value the costs of professional time taken to deliver the intervention, we collated information
on each researcher’s Agenda for Change band,59 on costs and full-time equivalents on the project.
We estimated workers’ indirect and direct overheads using PSSRU unit costing methods;56 in estimating
capital costs we assumed that workers were based in premises with a shared treatment space. A weighted
hourly cost of professional support was then calculated based on the full-time equivalent contribution per
Agenda for Change band. In addition, we calculated site-level average travel costs per visit, including
professionals’ travel time and costs of mileage (unblinded researchers were asked to estimate their average
travel time and miles driven in visiting participants on their iCST case load in each site). The costs of iCST
training, including professional time and travel expenses and venue costs, were provided by the University
College London project team. The project team also provided an estimate of the cost of the iCST training
manual and materials (excluding the costs of developing the manual). We calculated an average training
cost per participant and the average cost of manual materials per participant. The unit costs of professional
support time and travel, training and materials costs of the intervention are summarised in Table 4. These
unit costs were used to calculate a total cost of the package of materials and professional support in the
cost-effectiveness analysis. We attached the weighted hourly cost of professional time to the reported telephone
and face-to-face contact time for each participant, and a site average cost of mileage and travel time to reported
face-to-face visits. We spread the per-participant manual and training costs, and the costs of professionals’ time
spent in providing the set-up visit, across the two follow-up periods, allocating half the cost to each period.
TABLE 3 Unit costs summary
Service use item Unit cost (£), 2012–13
Inpatient bed-day, per specialty (range) 344–1495
Inpatient bed-day, weighted average across adult specialties 577
Day attendances, per specialty (range) 540–817
Day case, weighted average across specialties 693
Outpatient attendances (range) 27–468
A&E attendances, admitted and non-admitted (range) 115–160
Outpatient, weighted average of follow-up attendances across adult specialties 98
Primary, community and community mental health services, per contact (range) 36–115
Primary and community health services, per minute (range) 0.5–3.6
Residential care, per day (range) 76–143
Nursing home care, per day 107
Community-based social care, per minute (range) 0.4–2.7
Day services, per session/day (range) 5–38
Medications, standard quantity units (range) 0.1–6.0
Equipment and adaptations, cost over 3 months (range) 0.1–104.0
Carer hour, valued at replacement cost: home care worker, per hour 19
Carer hour, valued at opportunity cost: minimum wage, per hour 6
A&E, accident and emergency.
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Carers provided data on the number of iCST sessions completed over each follow-up period (see also Cost
data collections); they were asked by the unblinded researchers to estimate the time spent in preparing for
and delivering the sessions during scheduled telephone support calls. The average time spent in preparing
and delivering sessions in each follow-up period was calculated and this estimate was used in turn to
calculate the total hours spent in these activities in each period. This time was valued at the national
minimum wage in the primary analysis and at the unit cost of a home care worker in the sensitivity analysis.
Missing data for cost-effectiveness
For missing service-use data (collected from the CSRI), the following rules were applied: when service use was
indicated but frequency was missing, a suitable nationally applicable unit cost was used if available (e.g. cost per
visit). If no suitable unit cost was available, the cost was calculated as follows: (1) establish the mean duration
of use of those with frequency information; (2) assign that mean value to cases with missing duration data;
(3) estimate the average cost by multiplying frequency by duration by unit cost and estimate the mean cost of
those where any use of the service has been indicated; (4) assign the mean cost to cases where both frequency
and duration of use information are missing. For each case, items in each cost category (see Trial results) were
summed to give a total cost per category. Category-level costs were summed to give a total overall cost per
case. If all costs in the category were missing, the category total (per case) was also calculated as missing; if
some items were missing, these were treated as zeros and the case was assigned the cost of the sum of
available costs in the category. Missing outcomes and costs data were multiply imputed separately for the
person with dementia and the carer. We used theMI impute chained command in Stata 1360 to build a
regression model, including demographic variables (site, whether or not acetylcholinesterase inhibitors were
being taken, sex, relationship with the other member of the dyad, ethnicity, who the carer/person lived with,
level of education), treatment allocation, cost categories and scale-level non-missing primary and secondary
outcome measure variables as predictors. For the adherence data entered by unblinded researchers, the same
procedure was followed; professional support costs were imputed within the model for imputing carers’ costs.
The cost of carers’ time in delivering the intervention was imputed in cases where unblinded researchers had not
recorded the time taken to prepare and deliver sessions within the adherence forms (so that the cost of the
session time could not be estimated). Again, these costs were imputed within the model for imputing carers’
costs. The multiple imputation procedure was used to generate five complete data sets, to be combined
according to Rubin’s rules.60,61 Service use and intervention contact counts were not multiply imputed, only the
costs. If the CSRI had not been completed (e.g. no questions or just one or two initial questions had been
answered), these cases were considered wholly missing and were not included in the cost-effectiveness analyses.
Cost-effectiveness analyses
The iCST intervention was to be defined as cost-effective compared with TAU if it was:
1. less costly and more effective
2. more costly and more effective, and society is willing to pay the additional cost in order to achieve the
gain in outcome
3. less costly and less effective, and society is willing to sacrifice some of the outcome difference in order
to make a saving.
TABLE 4 Individual cognitive stimulation therapy intervention unit costs: summary of components of professional
support to carer
Costs of professional support (intervention) Unit cost (£), 2012–13
Total iCST training costs 17,288
Per participant (total divided by 180 intervention participants) 96
iCST manual and materials, per participant 94
Professional time, per hour 49
Mileage costs per one-way journey (per site) (range) 4–32
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The iCST intervention was to be defined as not cost-effective if it was both significantly more costly and
less effective compared with TAU.
The criteria for this decision was based on the following rule:
ΔC=ΔE < λ, (1)
where ΔC represents the additional cost, ΔE represents the gain in outcome associated with the treatment
and λ represents the willingness to pay (WTP) for that outcome gain.62 The incremental cost-effectiveness
ratio (ICER) (ΔC :ΔE) must be below λ to be considered cost-effective.
The ICER was defined as the difference in the mean costs of the iCST and TAU groups over the period of
follow-up, divided by the difference in the mean end point outcome measure (primary outcome for people
with dementia and secondary outcomes) between groups. In the case of the ratio of incremental costs and
QALY, the denominator was the difference in the mean QALY over the year from the baseline assessment.
The numerator was the difference between annualised costs, calculated by doubling the costs estimated
over the full follow-up period. The decision rule can be rearranged to be expressed in terms of the net
monetary benefit as λ ×ΔE –ΔC > 0,62 the monetary value of gains in outcome associated with the
treatment at a given WTP, net of the additional cost of the treatment.62 CEACs were produced to
represent graphically the uncertainty around the point estimate of the ICER.
Health economic modelling methods
Incremental costs and outcomes and their ratio (ΔC :ΔE) were estimated by seemingly unrelated
regressions (SURs), with bootstrapped standard errors (SEs). This system of equations was used to obtain
the cost/outcome difference between groups by estimating the coefficients on the intervention term in
each (cost/outcome) equation. The SUR approach is useful for obtaining an estimator for the ICER and for
net benefit for a given WTP, while also allowing for adjustment for a set of baseline covariates (which
can differ between cost and outcome equations).63 The analyses were performed on 300 bootstrapped
replications from each complete data set (generated by the multiple imputation process), using the Stata
command gsem, and the results combined. The estimates of costs and outcomes for the person with
dementia were adjusted for the covariates: site, whether or not the person with dementia was taking
AChEIs, who the person lived with, and baseline costs (cost equation only) or baseline outcome (outcome
equation only). The estimates of costs and outcomes for the carer were adjusted for the covariates: site,
whether or not the person with dementia was taking AChEls, baseline costs and who the person with
dementia lived with (cost equation only), who the carer lived with, carer sex, carer age (outcome equation
only) and baseline outcome (outcome equation only). This approach was used to calculate the net
monetary benefit over a range of WTP values for incremental benefits (SMDs in the primary and secondary
outcome measures, QALY gains), including the £20,000–30,000 NICE threshold range.64
Summary of changes to the protocol
Approval was obtained from the REC for one substantial amendment to the protocol during the trial.
This was related to the inclusion of additional questionnaires for both the person with dementia and their
family carer. There was one non-substantial amendment notified to the study’s sponsor (University College
London) representative, which was related to minor changes to the study protocol and inclusion of new
sites and investigators. There was one protocol violation (this is described in detail in Appendix 9).
TRIAL PHASE METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Chapter 5 Trial results
F igure 1 presents the details of the flow of participants through the trial. In total, 1340 people wereconsidered for recruitment to the study. From these, 356 were randomised and together constituted
the final sample for the study. The most common reason for loss between referral and randomisation was
participants not wishing to take part in the study. Losses in 22% of cases were attributable to people with
dementia not meeting the clinical criteria, indicating that this factor was, to some extent, a barrier to study
recruitment (Table 5). Table 6 shows sources of referrals to the project, of which 45% came from Memory
Clinics. Conversion of referrals to randomisation for each of the centres can be seen in Table 7. Variation
between centres may be attributable to, in part, differences in recruitment methods (e.g. note screening
vs. personal invitation by clinician).
Randomised allocation
The 356 dyads gave informed consent to the study and were randomised after completion of the baseline
assessment between April 2012 and July 2013. A total of 180 dyads were randomised to iCST and 176
to TAU. Table 7 provides rates of randomisation for each of the iCST centres.
Follow-up retention rates
Retention rates at week 13
Between randomisation and week 13 there were a total of 68 losses (Table 8), of which four were deaths.
Sixteen of the dyads were not available to complete the week-13 assessment but indicated availability
to complete the week-26 assessment. There were no differential rates of retention between sites at
week 13 [χ2= 11.9; degrees of freedom = 11; p-value= 0.37].
Retention rates at week 26
At week 26 (see Table 8), a further 31 dyads were lost to follow-up, which included a further four deaths,
equating to a total of 83 losses (including eight deaths) and a retention rate of approximately 77%, which
was the predicted rate used in the updated sample size calculations. There were no differential retention
rates between sites at week 26 (χ2= 12.5; degrees of freedom = 11; p-value= 0.33). In terms of losses
to follow-up from the study (i.e. excluding deaths), the attrition rate was 21%.
Retention rates by allocated group
Table 8 indicates that there was a total of 83 losses to follow-up. There were 46 (25%) losses in the
intervention group and 37 (21%) in the TAU group. Analyses comparing the baseline characteristics of
those who dropped out in the intervention group versus those in the TAU group did not indicate any
significant differences. Baseline characteristics for the test included sex, ethnicity, marital status,
relationship with the person with dementia, living with the person with dementia or not, living with other,
living alone, highest level of education and age.
DOI: 10.3310/hta19640 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 64
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Orgeta et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
25
Referred/screened
(n = 1340)
(a)
Excluded (n = 984)
Loss to follow-up (n = 52)
• Dyad not satisfied with
   treatment/carer struggling to
   engage with participant, n = 11
• Participant does not want
   to take part, n = 6
• Dyad disappointed with
   randomisation result, n = 6
• Participant ill health, n = 5
• Carer ill health, n = 4
• Time commitments for carer, n = 4
• Participant in residential care, n = 3
• Death of patient, n = 3
• Carer unwell, n = 2
• Participant depressed/stressed, n = 2
• Carer diagnosed with dementia, n = 1
• Carer depressed, n = 1
• Carer is no longer caring for
   participant, n = 1
• Cross-recruitment with 
   other study, n = 1
• Death of carer, n = 1
• Breakdown of caregiving 
   relationship, n = 1
Loss to follow-up (n = 31)
• Unable to contact (dyad), n = 5
• Participant death, n = 4
• Residential care, n = 3
• Participant ill health, n = 3
• Carer unwell, n = 3
• Time commitments for carer, n = 2
• Participant condition has
   deteriorated, n = 2
• Participant and carer do not
   wish to continue, n = 2
• Moving out of area, n = 1
• Lack of mental capacity 
   for participant, n = 1
• Family crisis, n = 1
• Diagnosis of cancer (participant), n = 1
• Carer too busy, n = 1
• Carer stress, n = 1
• Carer and participant abroad, n = 1
Did not complete week-13
 follow-up 1 (n = 16)
• Family crisis, n = 3
• Participant ill health, n = 3
• Lost contact with participant 
   and carer, n = 2
• Participant hospitalised, n = 2
• Participant refusing to do 
   assessement, n = 1
• Carer unwell, n = 1
• Dyad on holiday, n = 1
• Diagnosis of cancer (participant), n = 1
• Participant depressed, n = 1
• Participants moved house, n = 1
Baseline assessment
(n = 356)
Randomisation
(n = 356)
First follow-up
week-13 assessment
(n = 288)
Available for
 week-26 assessment
(n = 304)
Second follow-up
week-26 assessment
(n = 273)
FIGURE 1 (a) Participant flow through trial; and (b) participant flow through trial indicating treatment allocation.
DNC, did not complete. (continued )
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Referred/screened
(n = 1340)
Excluded (n = 984)
Allocation TAU
(n = 176)
Allocation iCST 
(n = 180)
Baseline assessment
(n = 356)
Randomisation
(n = 356)
First follow-up
week-13 assessment
Second follow-up
week-26 assessment
DNC
(n = 8)
Completed
(n = 142)
Completed
(n = 134)
Loss to
follow-up
(n = 30)
Loss to
follow-up
(n = 16)
DNC
(n = 8)
Completed
(n = 146)
Completed
(n = 139)
Loss to
follow-up
(n = 22)
Loss to
follow-up
(n = 15)
(b)
FIGURE 1 (a) Participant flow through trial; and (b) participant flow through trial indicating treatment allocation.
DNC, did not complete.
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TABLE 5 Losses between referrals and randomisation
Reason Total, n (%)
Does not wish to take part 320 (24)
iCST exclusion criteria apply 295 (22)
Dyad has not responded 215 (16)
Could not make contact/reason not known 53 (4)
Not available owing to holiday/family/work commitments 33 (2)
Health problems for dyad 21 (2)
Subtotals 937 (70)
Other
Prefers group activities/does activities at home/considers intervention not suitable 18 (1)
Already participating in similar study 16 (1)
Distressed during interview 4 (< 1)
Family not discussing diagnosis 3 (< 1)
Moved out the area 3 (< 1)
Person with dementia has died 3 (< 1)
Subtotals 47 (3)
Total lost between referral/screening and randomisation 984 (73)
Total number randomised 356 (27)
Total referred or screened 1340
TABLE 6 Sources of referrals
Source Total, n (%)
Memory Clinic 602 (45)
Consultant psychiatrist referral 315 (23)
CMHT 119 (9)
DeNDRoN clinical studies officer 67 (5)
Consultant psychologist referral 57 (4)
Alzheimer’s Society 52 (4)
Primary care dementia practitioner 41 (3)
Previous studies 25 (2)
Local Voluntary Organisation 20 (1)
Carers Support Services/Association 19 (1)
Age Concern 10 (< 1)
Newspaper article/media release 7 (< 1)
Local day centre 4 (< 1)
Admiral nurse 2 (< 1)
Total 1340
CMHT, Community Mental Health Team.
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Ratings of perception of allocation of dyads by blinded researchers
A total of 264 perception ratings were completed during week 13. These perception ratings asked the
blinded researcher to assess, after a follow-up visit, which treatment the dyad had been allocated to using
a 5-point Likert-type scale (‘definitely in iCST group’, ‘more likely to be in iCST group’, ‘equally likely to be
in iCST or TAU’, ‘more likely to be in TAU group’, ‘definitely in TAU group’). Table 9 provides the results of
these perception ratings in terms of the proportion that were correct, neutral and incorrect for treatment
allocation at week 13. A total of 60% of blinded researchers rated dyads as being equally likely to receive
iCST or TAU, with 23% making a correct judgement, of which 7% of these ratings were a definite
judgement, and 17% making an incorrect judgement, of which only 5% were definite.
A total of 255 perception ratings were completed during week 26. Table 10 provides the results of these
perception ratings in terms of the proportion that were correct, neutral and incorrect for treatment
allocation at week 26. In a similar manner to the judgements for week 13, 57% of researchers rated
treatment allocation equally to iCST and TAU, with a total of 23% making a correct judgement, of which
10% were definite judgements. A similar percentage to week 13 (20%) also made an incorrect judgement
about dyad allocation.
TABLE 7 Breakdown of referrals and randomisations by centre
Centre Total referrals, n Total randomisations, n (%)
London 255 127 (50)
Bangor 296 35 (12)
Hull 111 45 (40)
Manchester 482 53 (11)
Dorset 29 20 (69)
Lincolnshire 36 20 (55)
Norfolk and Suffolk 83 28 (34)
Devon 48 28 (58)
Total 1340 356
TABLE 8 Follow-up retention rates for each of the centres
Centre Baseline
Completed week 13
(retention rate), n (%)
Completed week 26
(retention rate), n (%)
London 127 101 (79) 96 (76)
Bangor 35 30 (86) 31 (89)
Hull 45 34 (75) 32 (71)
Manchester 53 39 (74) 37 (70)
Dorset 20 18 (90) 18 (90)
Lincolnshire 20 16 (80) 14 (70)
Norfolk and Suffolk 28 26 (93) 23 (82)
Devon 28 24 (86) 22 (79)
Total 356 288 (81) 273 (77)
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Analysis
Baseline characteristics by treatment allocation
Demographic information
Demographics information for people with dementia and their family carers appears in Tables 11 and 12,
respectively. Table 13 provides the means and SDs for age for people with dementia and their carers.
There were 226 spousal and 130 non-spousal caregiving dyads. For the 130 non-spousal dyads there were
113 carers (113/356, 31.7%) who were the son or daughter, son-in-law or daughter-in-law, or brother
or sister of the person with dementia. The remaining carers were described as having other relationships
with the person with dementia (9/356, 2.5%) or as being another relative (8/356, 2.2%). At baseline,
270 people with dementia were taking AChEIs. In practice, it would be expected that a relatively small
proportion would be stopping/starting AChEIs and randomisation should mean that this would be
consistent across groups.
Table 14 details the sex of carers/participants in the caregiving dyads. Details of dementia diagnosis for the
sample are provided in Table 15. A total of 68% of participants had a diagnosis of AD alone, 13% had a
diagnosis of vascular dementia and 8% had a diagnosis of AD in combination with vascular dementia.
Severity of dementia was measured by the Clinical Dementia Rating Scale (CDR),65 and general cognition
by the MMSE.66 A total of 70% of the sample had a CDR score of 1, 18% had a CDR score of 0.5, 12%
had a CDR score of 2, and one person with dementia received a score of 0. The total mean MMSE score
for the sample was 21.23 (SD= 4.30), with those allocated to iCST scoring a mean of 21.12 (SD= 4.48)
and those allocated to TAU scoring a total of 21.33 (SD= 4.11).
TABLE 9 Researchers’ perceptions of allocation at week 13
Researcher rating
Actual treatment allocation (N= 264)
iCST, n (%) TAU, n (%) Total, n (%)
Correct ‘definite’ judgement 13 (12) 6 (4) 19 (7)
Correct ‘more likely’ judgement 14 (13) 28 (18) 42 (16)
Equally likely to be in iCST or TAU 68 (65) 92 (58) 160 (60)
Incorrect ‘more likely’ judgement 11 (10) 20 (13) 31 (12)
Incorrect ‘definite’ judgement 0 12 (7) 12 (5)
Total 106 158 264
TABLE 10 Researchers’ perceptions of allocation at week 26
Researcher rating
Actual treatment allocation (N= 255)
iCST, n (%) TAU, n (%) Total, n (%)
Correct ‘definite’ judgement 22 (19) 4 (3) 26 (10)
Correct ‘more likely’ judgement 17 (15) 17 (12) 34 (13)
Equally likely to be in iCST or TAU 65 (57) 80 (57) 145 (57)
Incorrect ‘more likely’ judgement 10 (9) 31 (22) 41 (16)
Incorrect ‘definite’ judgement 0 9 (6) 9 (4)
Total 114 141 255
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TABLE 11 Demographics of person with dementia
Characteristic Total, n/N (%) iCST, n/N (%) TAU, n/N (%)
Sex
Female 165/356 (46) 83/180 (50) 82/176 (50)
Ethnicity
White 331/356 (93) 164/180 (50) 167/176 (50)
Marital status
Married/cohabiting/civil partnership 252/356 (71) 125/180 (50) 127/176 (50)
Living situation
Living with spouse/partner 225/356 (63) 113/180 (50) 112/176 (50)
Highest level of education
School leaver (14–16 years) 213/356 (60) 113/180 (53) 100/179 (47)
Taking acetylcholinesterase inhibitors
Yes 270/356 (76) 136/180 (76) 134/176 (76)
TABLE 12 Demographics of carer
Characteristic Total, n/N (%) iCST, n/N (%) TAU, n/N (%)
Sex
Female 261/356 (73) 135/180 (52) 126/176 (48)
Ethnicity
White 329/356 (92) 164/180 (50) 166/176 (50)
Marital status
Married/cohabiting/civil partnership 297/356 (84) 149/180 (50) 148/176 (50)
Living situation
Living with spouse/partner 236/356 (66) 119/180 (50) 117/176 (50)
Highest level of education
School leaver (14–16 years) 156/356 (45) 79/180 (50) 80/179 (50)
TABLE 13 Summary statistics of age (years) for people with dementia and carers
Dyad participant
iCST TAU Total
n Mean SD n Mean SD n Mean SD
Person with dementia 180 78.40 7.30 176 78.00 7.70 356 78.20 7.49
Carer 179a 66.01 12.76 174 65.49 13.11 353a 65.73 12.92
Spousal carer 112 73.11 7.57 111 72.50 8.22 223a 72.80 7.89
Non-spousal carer 67 54.13 10.67 63 53.16 11.00 130 53.66 10.80
a There were missing data for age for three carers.
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Primary analyses of outcomes
The mean values for the iCST group and TAU group at each of the time points are given in Table 16.
ANCOVA models were fitted for each of the measures. The primary model fitted was ANCOVA using the
week-26 time point as the dependent variable and site as the random factor. Fixed factors were marital
status, living status, sex of participant, whether or not the person with dementia was currently on AChEIs
and treatment allocation. Fitted covariates were age, baseline outcome score and relationship with the
carer. Models have also been fitted using the shorter-term week-13 follow-up as an outcome.
The number of cases with missing data, ANCOVA group means, mean differences, 95% confidence
intervals (CIs) of mean differences and p-values for the original data to compare the iCST and TAU groups
for the dementia patient outcome measures at week 26 and week 13, after adjusting for the baseline
outcome measures and covariates, are given in Tables 17 and 18. There was little difference between the
imputed value data and complete data; therefore, for ease of reading, complete case data have been
presented. The carer outcome measures at week 26 and week 13 after adjusting for the baseline outcome
measures are given in Tables 19 and 20.
A further analysis, in which imputation of the entire data set (356 participants) using the regression model
is detailed, can be found in Appendix 6. The tables presented there indicate the results for the data if the
multiple imputation model had been used to impute the data for all 356 participants at each time point.
Various methodologies for different types of missing data (e.g. death vs. ill health) have not been taken
into account as the number of each of these circumstances was minimal and would have limited impact on
the results of any imputation method. Ten imputation sets were created to establish a robust adjustment
to the data missing from each time point. There was no substantial difference between any of the
results presented.
TABLE 14 Details of the sex of participant/carer in caregiving dyads
Sex of carer and participant in caregiving dyads
Sex of person with dementia
Female Male
Sex of carer 165 191
Female 82 179
Male 83 12
Total 165 191
TABLE 15 Details of dementia diagnosis
Diagnosis Total, n/N (%) iCST, n/N (%) TAU, n/N (%)
AD 227/355 (64) 108/179 (60) 119/176 (68)
Vascular dementia 40/355 (11) 18/179 (10) 22/176 (13)
Lewy body dementia 11/355 (3) 5/179 (3) 6/176 (3)
Mixed AD and vascular dementia 36/355 (10) 22/179 (12) 14/176 (8)
Not known 41/355 (12) 26/179 (15) 15/176 (8)
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TABLE 17 Comparison of the iCST and TAU groups for person with dementia outcomes at week 26 after adjusting
for the baseline outcome measures (complete case data are presented owing to little difference between this
and imputed data results)
Outcome measure Missing iCST (n= 134) TAU (n= 139) MD 95% CI of MD p-value
ADAS-Cog 11 20.03 20.58 –0.55 –2.00 to 0.90 0.45
QoL-AD 6 37.90 37.92 –0.02 –1.04 to 1.00 0.97
DEMQOL 9 94.45 94.14 0.31 –1.62 to 2.22 0.79
NPI [P] 2 8.10 8.42 –0.32 –2.78 to 2.12 0.79
GDS-15 11 3.29 3.31 –0.02 –0.51 to 0.47 0.94
QCPR (total)a 4 57.42 55.65 1.77 0.26 to 3.28 0.02
QCPR (warmth) 1 33.74 32.93 0.81 –0.11 to 1.73 0.09
QCPR (criticism and conflict) 23.51 22.65 0.86 –1.74 to 0.02 0.06
MMSE 5 19.63 20.10 –0.47 –1.26 to 0.30 0.23
BADLS [P] 4 11.91 12.57 –0.66 –2.07 to 0.75 0.36
QoL-AD [P] 1 32.45 32.00 0.45 –0.71 to 1.60 0.45
DEMQOL [P] 2 99.67 97.94 1.73 –0.61 to 4.07 0.15
MD, mean difference; Missing, number of cases with missing data; NPI, Nueropsychiatric Inventory; [P], proxy
rated measure.
a Significant difference at 5% level.
TABLE 18 Comparison of the iCST and TAU groups for person with dementia outcomes at week 13 after adjusting
for the baseline outcome measures (complete case data are presented owing to little difference between this and
imputed data results)
Outcome measure Missing iCST (n= 142) TAU (n= 146) MD 95% CI of MD p-value
ADAS-Cog 10 22.00 21.71 0.29 –1.10 to 1.68 0.68
QoL-AD 4 38.40 38.54 –0.14 –1.12 to 0.84 0.78
DEMQOL 11 91.72 92.05 –0.33 –2.31 to 1.65 0.74
NPI [P] 2 12.27 13.72 –1.46 –3.68 to 0.76 0.20
GDS-15 12 3.27 3.36 –0.09 –0.56 to 0.38 0.71
QCPR (total) 7 56.62 55.52 1.10 –0.15 to 2.35 0.09
QCPR (warmth) 1 34.04 33.65 0.39 –0.43 to 1.21 0.36
QCPR (criticism and conflict) 1 22.49 21.85 0.63 –0.10 to 1.36 0.09
MMSE 3 20.32 20.16 0.16 –0.60 to 0.92 0.69
BADLS [P] 1 12.73 12.93 –0.20 –1.44 to 1.04 0.75
QoL-AD [P] 3 32.66 31.91 0.75 –0.27 to 1.77 0.15
DEMQOL [P] 3 99.28 98.73 0.55 –1.70 to 2.80 0.64
MD, mean difference; Missing, number of cases with missing data; NPI, Neuropsychiatric Inventory; [P], Proxy
rated measure.
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TABLE 19 Comparison of the iCST and TAU groups for carer outcomes at week 26 after adjusting for the baseline
outcome measures (complete case data are presented owing to little difference between this and imputed
data results)
Outcome measure Missing iCST (n= 134) TAU (n= 139) MD 95% CI of MD p-value
SF-12 PCS 1 49.57 49.11 0.46 –1.21 to 2.13 0.59
SF-12 MCS 0 48.44 48.31 0.13 –1.65 to 1.91 0.89
HADS total 1 10.27 10.96 –0.70 –1.85 to 0.46 0.24
HADS (anxiety) 1 6.09 6.30 –0.21 –0.94 to 0.52 0.57
HADS (depression) 1 4.16 4.67 –0.51 –1.09 to 0.08 0.09
EQ-5D-3L health state today 0 78.20 76.99 1.21 –2.14 to 4.57 0.48
EQ-5D-3L calculated utility valuea 2 0.82 0.76 0.06 0.01 to 0.10 0.01
RS-14 1 83.42 81.85 1.58 –0.37 to 3.52 0.11
NPI (carer distress) 2 3.13 3.22 –0.09 –0.55 to 0.37 0.70
QCPR total 13 59.65 60.21 –0.56 –1.93 to 0.82 0.43
QCPR (warmth) 12 35.05 35.13 –0.08 –0.84 to 0.68 0.83
QCPR (criticism and conflict) 13 24.65 25.05 –0.40 –1.19 to 0.39 0.32
MD, mean difference; Missing, number of cases with missing data; NPI, Neuropsychiatric Inventory; RS-14, Resilience
Scale-14 items.
a Significant difference at 5% level.
TABLE 20 Comparison of the iCST and TAU groups for carer outcomes at week 13 after adjusting for the baseline
outcome measures (complete case data are presented owing to little difference between this and imputed
data results)
Outcome measure Missing iCST (n= 134) TAU (n= 139) MD 95% CI of MD p-value
SF-12 PCS 0 50.51 50.57 –0.06 –1.45 to 1.33 0.93
SF-12 MCS 0 47.59 48.30 –0.71 –2.34 to 0.92 0.39
HADS total 1 10.47 10.31 0.16 –0.81 to 1.15 0.74
HADS (anxiety) 1 6.34 6.05 0.29 –0.35 to 0.91 0.37
HADS (depression) 1 4.13 4.27 –0.14 –0.67 to 0.39 0.60
EQ-5D health state today 1 77.55 77.00 0.55 –2.59 to 3.69 0.73
EQ-5D calculated utility value 1 0.81 0.79 0.02 –0.02 to 0.06 0.19
RS-14 0 83.35 83.41 –0.06 –1.63 to 1.51 0.94
NPI (carer distress) 2 3.16 3.15 0.01 –0.43 to 0.43 0.99
QCPR total 12 59.90 59.94 –0.04 –1.45 to 1.37 0.95
QCPR (warmth) 12 35.10 35.78 –0.68 –1.44 to 0.08 0.09
QCPR (criticism and conflict) 12 24.80 24.16 0.64 –0.23 to 1.53 0.15
MD, mean difference; Missing, number of cases with missing data; NPI, Neuropsychiatric Inventory; RS-14, Resilience
Scale-14 items.
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Person with dementia outcomes
The ADAS-Cog primary outcome for people with dementia was not statistically significant between the
iCST and TAU groups either at week 13 or at the primary time point of week 26. However, between
week 13 and week 26, the estimated adjusted marginal means decreased more in the iCST group than in
the TAU group, with a lower ADAS-Cog score being an improvement. For QoL-AD, there was no significant
difference between the groups. Similarly, there were no differences between the groups for most
secondary outcomes. There was a significant improvement for the iCST group relative to the TAU group
for QCPR total score with a mean difference of 1.77 (95% CI 0.26 to 3.28; p-value= 0.02) at week 26.
There was no evidence of significant differences for primary outcomes or secondary outcomes at week 13.
Carer outcome measures
There was no statistically significant difference in the primary outcome of SF-12 for carers between iCST
and TAU at either week 26 or week 13. At week 26, the EQ-5D calculated utility value for the carer was
significantly better for the iCST group with a mean difference of 0.06 (95% CI 0.01 to 0.10; p-value= 0.014).
At week 26 there was an indication that the HADS depression subscale was lower in the iCST than in the TAU
group, with decreases in depressive symptoms of –0.51 (95% CI –1.09 to 0.08; p-value= 0.090), but this
did not reach significance.
At week 13 there were no significant differences between the two groups for any of the secondary
outcome measures. The QCPR warmth subscale was close to significance between the iCST and TAU
groups, with a mean difference of –0.68 (95% CI –1.44 to 0.08; p-value= 0.09) (see Table 19). In view of
these results, and the fact that the QCPR measure for carers had the most missing data, we have also
presented the results for the imputed analysis. Table 21 shows the imputation analyses, with the final two
columns showing the range of F-values for the five imputed data sets. The suggestion from the observed
data that the QCPR warmth subscale may have an effect was not substantiated by the imputed data sets
with a pooled mean difference of –0.65 (F-range 2.35–3.66; p-range 0.06–0.13).
Adherence analysis
The number of sessions completed by people with dementia and their carers ranged from 0 to 75 over the
26 weeks. Table 22 shows the number of sessions completed by the 180 participants randomised to
receive iCST available for analysis. Overall, 22% of participants did not complete any sessions, whereas
51% completed more than 30 sessions.
TABLE 21 Results of the imputation analyses for the QCPR scores where there are more than five missing values
QCPR
outcome
and
subscales
iCST,
n= 142;
TAU,
n= 146 Mis., n
Pooled
mean
Pooled
SE
Pooled mean
difference
(iCST–TAU)
Pooled
SE
Median
F-value Low F-value High F-value
F p-value F p-value F p-value
Carer
QCPR
total
iCST 8 59.73 0.51 –0.087 0.708 0.017 0.897 0.005 0.944 0.097 0.756
TAU 4 59.81 0.50
QCPR
(warmth)
iCST 8 35.05 0.28 –0.650 0.392 2.900 0.090 2.353 0.126 3.660 0.057
TAU 4 35.70 0.27
QCPR
(criticism
and
conflict)
iCST 8 24.68 0.32 0.565 0.441 1.681 0.196 1.257 0.263 2.115 0.147
TAU 4 24.11 0.31
Mis., missing number of participants with missing data.
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A number of options were explored in terms of the best way to consider analyses for adherence. The
analysis methods for beginning to understand the ‘dose’ relationship were considered exploratory in
nature. These options included whether or not an average of 1.5 or 2 sessions per week had been
completed up to week 13 and week 26. The most efficient approach was considered to be to model the
total number of sessions attended at each time point. Linear regression was used to assess the relationship
between the follow-up outcome measures and the number of iCST sessions attended after adjusting for
baseline outcome measures. Appendix 7 reports observed data with values of coefficients, SEs, F-values
and p-values, and pooled data showing pooled coefficients, SEs, median F-values, with F-values and
p-values for both the person with dementia and carer, respectively, at each time point.
Outcomes for person with dementia
There was no statistical relationship between the number of sessions completed by the person with
dementia and the ADAS-Cog primary outcome at any time point (see Appendix 7). However, the total
number of sessions completed from baseline to week 26 was significant, with an improvement for both
the QCPR total (p-value= 0.003) and QCPR criticism subscale (p-value= 0.001) for the iCST group. This
result was consistent for the QCPR total after regression analysis with imputed data. The imputation was
not conducted for QCPR (criticism) at week 26 as no data were missing. At week 13, only QCPR (criticism)
had a significant association with the number of sessions (p-value= 0.004). However, several measures
were close to significance, suggesting a potential pattern of improvement for people with dementia
undertaking iCST. This included the QCPR total (p-value= 0.06; imputed values: p-range 0.06–0.06), the
MMSE (p-value= 0.10; imputed values: p-range 0.09–0.12) and the QoL-AD (p-value= 0.08: imputed
values; p-range 0.08–0.10).
Outcomes for carer
There were no significant associations between the SF-12 primary outcome and the number of sessions
completed by carers at either week 13 and week 26. At week 26, HADS (depression) showed a significant
reduction in the iCST group (p-value= 0.02), suggesting that a higher number of iCST sessions was
associated with a decrease in depression scores (see Appendix 7). This was supported by the imputation
analysis (p-range 0.01–0.02). Imputation suggested that the HADS total (p-range 0.03–0.05) was also
associated with numbers of sessions completed. The EQ-5D utility showed a trend in favour of iCST
(p-value= 0.09; imputed values: p-range 0.08–0.10). At week 13, there were no significant associations
between the secondary outcomes and the number of sessions completed; however, there was borderline
significance for carer EQ-5D health state being associated with higher adherence (p-value 0.06; imputed
values: p-range 0.05–0.06).
Adverse events
Individual cognitive stimulation therapy was not a Clinical Trial of an Investigational Medicinal Product, so
there were no associated risks to participants by taking part. However, qualitative interviews indicated that
for some people with dementia, taking part in iCST was a difficult process, which for a small number of
participants resulted in feelings of frustration, especially when the activities were judged by the person
with dementia to be very easy or not challenging enough.
TABLE 22 Number of sessions completed by those randomised to receive iCST
Number of
sessions completed 0 1–10 11–20 21–30 31–40 41–50 51–60 61–70 71–75
n (%) 39 (22) 23 (13) 10 (5) 17 (9) 19 (11) 20 (11) 14 (8) 18 (10) 20 (11)
Number of sessions
completed, mean (SD)
31.68 (26.81)
TRIAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
Economic evaluation
Data on service use and unpaid care were collected using the CSRI at each assessment point. The rates of
completion of the CSRI were high at each point. At baseline, one iCST participant/carer dyad did not
complete the CSRI. At week 13, of 142 iCST dyads completing outcome assessments, 141 completed a
CSRI; of 146 TAU dyads completing outcome assessments, 145 completed a CSRI. At week 26, of 134
iCST dyads completing outcome assessments, 133 completed a CSRI; of 139 TAU dyads completing
outcome assessments, 138 completed a CSRI. Thirteen dyads in the TAU group and 16 dyads in the iCST
group completed only one follow-up CSRI. Information was available at all three time points for 129
iCST dyads and for 135 TAU dyads. There was a difference of nine dyads in the complete case information
available for the costs analyses relative to the 26-week outcomes analyses (264 vs. 273). Owing to a
protocol violation (see Appendix 9), one participant who should have been assigned to the control group
received the intervention. For the cost-effectiveness analyses, costs of all participants have been retained
and the analysis carried out according to the intended allocation.
Care and support services and costs
Professional time spent in supporting the carers of participants receiving iCST is presented in Table 23. The
amount of time (including travel) spent in delivering the set-up visit was about 2 hours. The time spent in
monitoring visits and telephone calls was similar between week 13 and week 26. Carers spent 16.8 hours,
on average, delivering the intervention at week 13, and 13.1 hours at week 26 (Table 24). Resources used
by both groups are given in Tables 25–27. Use of health and social care services was very similar between
groups during the period prior to baseline, and during the two follow-up periods (Tables 28–30).
TABLE 23 Professionals’ time (hours) spent in supporting carers to deliver the intervention, per participant, at
week 13 and week 26
Type of contact Intervention, mean (SE)a Valid, n
Week 13
Set-up visitb 2 (0) 126
Monitoring visitsb 1.3 (0) 124
Telephone calls 0.6 (0) 118
Week 26
Monitoring visitsb 1.2 (0) 121
Telephone callsb 0.4 (0) 97
a Data from treatment adherence collection.
b Includes travel time.
TABLE 24 Carers’ time (hours) spent in delivering the intervention, per participant, at week 13 and week 26
Hours of carers’ time Intervention, mean (SE)a Valid, n
Week 13, hours 16.8 (0.8) 118
Week 26, hours 13.1 (1.2) 91
a Data from treatment adherence collection.
b Includes preparation time.
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TABLE 25 Resource use over the prior 3 months, at baseline assessment
Baseline Unit
iCST (SE)
(n= 129)
TAU (SE)
(n= 135)
Mean difference
(95% CI)a
A&E department Attendances 0.0 (0.0) 0.1 (0.0) –0.1 (–0.2 to 0.0)
Inpatient services Admissions 0.0 (0.0) 0.0 (0.0) 0.0 (0.0 to 0.1)
Inpatient services Days 0.2 (0.1) 0.1 (0.1) 0.1 (–0.1 to 0.3)
Day services Days 0.0 (0.0) 0.0 (0.0) 0.0 (0.0 to 0.1)
Days in inpatient and day services Days 0.2 (0.1) 0.1 (0.1) 0.1 (–0.1 to 0.4)
Outpatient services Visits 0.7 (0.1) 1.0 (0.1) –0.3 (–0.7 to 0.1)
GP Visits 1.7 (0.2) 1.6 (0.1) 0.1 (–0.3 to 0.5)
Practice nurse Visits 0.9 (0.2) 0.7 (0.1) 0.2 (–0.3 to 0.7)
Community/district nurse Visits 0.3 (0.1) 0.5 (0.3) –0.2 (–0.8 to 0.5)
Physiotherapist Visits 0.2 (0.1) 0.2 (0.1) 0.0 (–0.2 to 0.2)
Occupational therapist Visits 0.1 (0.0) 0.1 (0.0) 0.0 (–0.1 to 0.1)
Dietician Visits 0.0 (0.0) 0.0 (0.0) 0.0 (0.0 to 0.0)
Specialist nurse Visits 0.1 (0.0) 0.1 (0.0) –0.1 (–0.2 to 0.1)
Optician Contacts 0.2 (0.0) 0.3 (0.0) 0.0 (–0.1 to 0.1)
Chiropodist Contacts 0.4 (0.1) 0.4 (0.1) 0.0 (–0.2 to 0.2)
Dentist Contacts 0.5 (0.1) 0.5 (0.1) 0.0 (–0.2 to 0.2)
Mental health nurse Contacts 0.5 (0.2) 0.5 (0.1) –0.1 (–0.5 to 0.4)
Psychiatrist Visits 0.3 (0.1) 0.4 (0.1) –0.1 (–0.3 to 0.1)
Psychologist Visits 0.1 (0.0) 0.1 (0.0) 0.0 (–0.1 to 0.1)
Counsellor Visits 0.0 (0.0) 0.1 (0.1) –0.1 (–0.3 to 0.1)
Mental health team worker Visits 0.1 (0.0) 0.3 (0.1) –0.1 (–0.3 to 0.1)
Social worker/care manager Visits 0.1 (0.0) 0.4 (0.2) –0.3 (–0.7 to 0.1)
Home care/home help Visits 12.2 (4.3) 9.3 (2.9) 2.9 (–7.3 to 13.1)
Cleaner Visits 3.9 (0.9) 2.8 (0.5) 1.1 (–0.9 to 3.0)
Meals on wheels Meals 0.0 (0.0) 0.0 (0.0) 0.0 (0.0 to 0.0)
Laundry service Contacts 0.8 (0.7) 0.3 (0.2) 0.5 (–0.8 to 1.8)
Sitting service (e.g. Crossroads) Visits 0.5 (0.3) 0.9 (0.3) –0.3 (–1.2 to 0.5)
Carer support worker Visits 0.1 (0.0) 0.3 (0.3) –0.3 (–1.0 to 0.4)
Daycentre Attendances 2.0 (0.6) 4.5 (1.9) –2.5 (–6.6 to 1.5)
Lunch club Attendances 1.0 (0.5) 0.6 (0.3) 0.5 (–0.6 to 1.6)
Patient education classes Attendances 0.2 (0.1) 0.5 (0.2) –0.2 (–0.7 to 0.2)
Items of equipment Items 1.1 (0.2) 0.9 (0.2) 0.2 (–0.3 to 0.8)
Medicationsb Units 0.9 (0.1) 0.9 (0.1) 0.0 (–0.2 to 0.2)
Unpaid care by primary carer Hours 646.3 (75.0) 652.5 (68.1) –6.2 (–205.3 to 192.9)
Unpaid care by other friends/relatives Hours 84.6 (23.0) 40.3 (7.4) 44.3 (–2.7 to 91.3)
A&E, accident and emergency; GP, general practitioner.
a Difference in group means, iCST–TAU.
b Drugs for dementia, antipsychotics and antidepressants.
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TABLE 26 Resource use over the prior 3 months, at week 13
Week 13 Unit
iCST (SE)
(n= 129)
TAU (SE)
(n= 135)
Mean difference
(95% CI)a
A&E department Attendances 0.1 (0.0) 0.1 (0.0) 0.0 (–0.1 to 0.1)
Inpatient services Admissions 0.0 (0.0) 0.0 (0.0) 0.0 (–0.1 to 0.0)
Inpatient services Days 0.1 (0.1) 0.2 (0.1) –0.1 (–0.4 to 0.2)
Day services Days 0.0 (0.0) 0.0 (0.0) 0.0 (–0.1 to 0.0)
Days in inpatient and day services Days 0.1 (0.1) 0.3 (0.1) –0.1 (–0.4 to 0.2)
Outpatient services Visits 0.8 (0.1) 0.7 (0.1) 0.1 (–0.2 to 0.4)
GP Visits 1.4 (0.2) 1.6 (0.2) –0.2 (–0.6 to 0.3)
Practice nurse Visits 0.8 (0.1) 0.7 (0.1) 0.2 (–0.1 to 0.5)
Community/district nurse Visits 0.2 (0.1) 1.2 (0.9) –1.0 (–2.8 to 0.8)
Physiotherapist Visits 0.1 (0.0) 0.3 (0.1) –0.2 (–0.4 to 0.1)
Occupational therapist Visits 0.1 (0.0) 0.1 (0.0) 0.0 (–0.1 to 0.1)
Dietician Visits 0.0 (0.0) 0.0 (0.0) 0.0 (–0.1 to 0.0)
Specialist nurse Visits 0.1 (0.1) 0.1 (0.1) –0.1 (–0.2 to 0.1)
Optician Contacts 0.2 (0.0) 0.2 (0.0) 0.0 (–0.2 to 0.1)
Chiropodist Contacts 0.4 (0.1) 0.5 (0.1) –0.2 (–0.3 to 0.0)
Dentist Contacts 0.4 (0.1) 0.4 (0.1) –0.1 (–0.2 to 0.1)
Mental health nurse Contacts 0.2 (0.1) 0.3 (0.1) –0.1 (–0.3 to 0.1)
Psychiatrist Visits 0.2 (0.0) 0.3 (0.0) –0.1 (–0.2 to 0.0)
Psychologist Visits 0.0 (0.0) 0.0 (0.0) 0.0 (0.0 to 0.0)
Counsellor Visits 0.0 (0.0) 0.2 (0.1) –0.2 (–0.5 to 0.1)
Mental health team worker Visits 0.1 (0.1) 0.3 (0.1) –0.1 (–0.4 to 0.1)
Social worker/care manager Visits 0.2 (0.1) 0.3 (0.2) –0.1 (–0.6 to 0.3)
Home care/home help Visits 10.3 (3.8) 11.6 (3.4) –1.4 (–11.4 to 8.7)
Cleaner Visits 3.4 (0.6) 2.8 (0.6) 0.6 (–1.0 to 2.3)
Meals on wheels Meals 1.2 (0.8) 0.0 (0.0) 1.2 (–0.3 to 2.8)
Laundry service Contacts 0.3 (0.1) 0.5 (0.3) –0.2 (–0.9 to 0.5)
Sitting service (e.g. Crossroads) Visits 0.4 (0.2) 0.3 (0.2) 0.0 (–0.4 to 0.5)
Carer support worker Visits 0.1 (0.0) 0.4 (0.2) –0.3 (–0.8 to 0.1)
Daycentre Attendances 2.7 (0.7) 3.1 (0.8) –0.5 (–2.5 to 1.5)
Lunch club Attendances 1.2 (0.5) 0.2 (0.1) 1.0 (–0.1 to 2.0)
Patient education classes Attendances 0.4 (0.1) 0.9 (0.3) –0.4 (–1.0 to 0.2)
Items of equipment Items 1.1 (0.2) 0.9 (0.2) 0.3 (–0.2 to 0.8)
Medicationsb Units 0.8 (0.1) 0.9 (0.1) –0.1 (–0.2 to 0.1)
Unpaid care by primary carer Hours 705.6 (71.9) 732.7 (71.8) –27.1 (–227.3 to 173.0)
Unpaid care by other friends/relatives Hours 87.7 (22.9) 40.9 (8.6) 46.8 (–0.7 to 94.4)
Intervention: professional supportc Contacts 4.9 (0.2) 0.04 (0.0) 4.9 (4.5 to 52)
A&E, accident and emergency; GP, general practitioner.
a Difference in group means, iCST–TAU.
b Drugs for dementia, antipsychotics and antidepressants.
c contacts of unblinded researchers providing iCST support to dyads (telephone and face-to-face visits) – contacts for
set-up, monitoring and telephone support are summed and any missing values here treated as zero; TAU includes the
mean contacts with TAU carer delivering the intervention (protocol violation)
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TABLE 27 Resource use over the prior 3 months, at week 26
Week 26 Unit
iCST (SE)
(n= 129)
TAU (SE)
(n= 135)
Mean difference
(95% CI)a
A&E department Attendances 0.2 (0.1) 0.1 (0.0) 0.1 (–0.1 to 0.3)
Inpatient services Admissions 0.1 (0.0) 0.1 (0.0) 0.0 (–0.1 to 0.0)
Inpatient services Days 0.4 (0.2) 0.6 (0.3) –0.3 (–0.9 to 0.4)
Day services Days 0.0 (0.0) 0.0 (0.0) 0.0 (0.0 to 0.0)
Days in inpatient and day services Days 0.4 (0.2) 0.6 (0.3) –0.3 (–0.9 to 0.4)
Outpatient services Visits 0.8 (0.2) 0.5 (0.1) 0.3 (–0.1 to 0.6)
GP Visits 1.2 (0.1) 1.4 (0.1) –0.2 (–0.5 to 0.2)
Practice nurse Visits 0.7 (0.1) 0.6 (0.1) 0.1 (–0.2 to 0.4)
Community/district nurse Visits 0.6 (0.3) 0.4 (0.2) 0.2 (–0.5 to 0.8)
Physiotherapist Visits 0.2 (0.1) 0.2 (0.1) 0.0 (–0.4 to 0.3)
Occupational therapist Visits 0.1 (0.0) 0.3 (0.2) –0.2 (–0.6 to 0.2)
Dietician Visits 0.0 (0.0) 0.0 (0.0) 0.0 (–0.1 to 0.0)
Specialist nurse Visits 0.1 (0.0) 0.2 (0.1) –0.1 (–0.2 to 0.1)
Optician Contacts 0.2 (0.0) 0.2 (0.0) 0.0 (–0.1 to 0.1)
Chiropodist Contacts 0.4 (0.1) 0.5 (0.1) –0.1 (–0.3 to 0.1)
Dentist Contacts 0.4 (0.1) 0.4 (0.1) 0.0 (–0.1 to 0.2)
Mental health nurse Contacts 0.2 (0.0) 0.1 (0.0) 0.1 (0.0 to 0.2)
Psychiatrist Visits 0.1 (0.0) 0.2 (0.0) 0.0 (–0.1 to 0.1)
Psychologist Visits 0.0 (0.0) 0.0 (0.0) 0.0 (–0.1 to 0.1)
Counsellor Visits 0.0 (0.0) 0.1 (0.1) –0.1 (–0.3 to 0.1)
Mental health team worker Visits 0.2 (0.0) 0.2 (0.1) 0.0 (–0.3 to 0.2)
Social worker/care manager Visits 0.1 (0.0) 0.2 (0.1) –0.1 (–0.3 to 0.0)
Home care/home help Visits 14.0 (4.9) 14.5 (4.0) –0.5 (–12.9 to 11.9)
Cleaner Visits 3.2 (0.6) 4.3 (0.8) –1.1 (–3.1 to 0.9)
Meals on wheels Meals 1.2 (0.8) 0.0 (0.0) 1.2 (–0.3 to 2.7)
Laundry service Contacts 0.1 (0.1) 0.2 (0.1) –0.1 (–0.4 to 0.2)
Sitting service (e.g. Crossroads) Visits 1.0 (0.4) 0.9 (0.3) 0.1 (–0.8 to 1.1)
Carer support worker Visits 0.6 (0.5) 0.2 (0.2) 0.4 (–0.6 to 1.4)
Daycentre Attendances 2.0 (0.6) 3.4 (0.8) –1.4 (–3.3 to 0.5)
Lunch club Attendances 1.4 (0.5) 0.7 (0.3) 0.7 (–0.5 to 1.9)
Patient education classes Attendances 0.7 (0.3) 1.2 (0.4) –0.5 (–1.4 to 0.3)
Items of equipment Items 1.0 (0.2) 0.5 (0.1) 0.5 (–0.0 to 0.9)
Medicationsb Units 0.8 (0.1) 0.9 (0.1) 0.0 (–0.2 to 0.1)
Unpaid care by primary carer Hours 720.5 (72.5) 912.8 (79.0) –192.4 (–403.9 to 19.1)
Unpaid care by other friends/relatives Hours 69.0 (15.4) 51.9 (12.2) 17.2 (–21.3 to 55.7)
Intervention: professional supportc Contact 2.6 (0.14) 0.0 (0.0) 2.5 (2.3 to 2.8)
A&E, accident and emergency; GP, general practitioner.
a Difference in group means, iCST–TAU.
b Drugs for dementia, antipsychotics and antidepressants.
c Contacts of unblinded researchers providing iCST support to dyads (telephone and face-to-face visits): contacts for
set-up, monitoring and telephone support are summed and any missing values here treated as zero; TAU includes the
mean contacts with TAU carer delivering the intervention (protocol violation).
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TABLE 28 Mean (raw) costs of dyad: person with dementia’s health and social care, unpaid carer costs, intervention
costs, and total health and social care and societal costs over prior 3 months, at baseline assessment (£), 2012–13
Baseline
iCST, mean
(SE) (n= 129)
TAU, mean
(SE) (n= 135)
Mean difference
(95% CI)a
Hospital 233 (62) 297 (69) –64 (–248 to 121)
Primary and community health 150 (13) 144 (10) 6 (–26 to 38)
Respite in residential/nursing home 0 (0) 13 (9) –13 (–32 to 6)
Community-based social care 901 (243) 817 (175) 84 (–502 to 670)
Community mental health 126 (31) 118 (18) 8 (–62 to 78)
Daycare (any provider) 685 (176) 1012 (227) –327 (–897 to 243)
Equipment and adaptations 4 (1) 3 (1) 1 (–3 to 5)
Medicationsb 172 (15) 176 (14) –4 (–45 to 36)
Health and social carec 2271 (312) 2581 (317) –309 (–1186 to 567)
Unpaid care and supportd 4535 (477) 4282 (414) 253 (–988 to 1493)
a Difference in group means, iCST–TAU.
b Drugs for dementia, antipsychotics and antidepressants.
c Person with dementia’s health and social care costs.
d Costs of unpaid carers’ time in providing care and support to participant with dementia, lost production and out-of-pocket
expenditure, time valued at minimum wage.
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TABLE 29 Mean (raw) costs of dyad: person with dementia’s health and social care, unpaid carer costs, intervention
costs, and total health and social care and societal costs over prior 3 months, week 13 (£), 2012–13
Week 13
iCST, mean (SE)
(n= 129)
TAU, mean (SE)
(n= 135)
Mean difference
(95% CI)a
Hospital 253 (57) 198 (46) 55 (–89 to 199)
Primary and community health 125 (13) 142 (12) –17 (–51 to 17)
Respite in residential/nursing home 31 (22) 0 (0) 31 (–11 to 73)
Community-based social care 845 (245) 1072 (235) –227 (–895 to 441)
Community mental health 36 (7) 76 (12) –40 (–68 to –12)
Daycare (any provider) 327 (69) 439 (75) –112 (–314 to 89)
Equipment and adaptations 4 (2) 2 (1) 2 (–2 to 6)
Medicationsb 188 (17) 217 (15) –29 (–72 to 15)
Health and social care excluding interventionc 1809 (268) 2146 (279) –337 (–1099 to 426)
Intervention: professional supportd 249 (4) 1 (1) 249 (240 to 257)
Health and social care including intervention
(professional)e
2058 (267) 2147 (278) –88 (–849 to 673)
Unpaid care and supportf 4930 (448) 4770 (444) 159 (–1083 to 1401)
Intervention: carer delivered
g
101 (5) 1 (1) 100 (90 to 110)
Intervention: professional support and carer
deliveredh
350 (8) 2 (2) 348 (333 to 363)
Societal excluding interventioni 6739 (540) 6916 (587) –177 (–1751 to 1396)
Societal including intervention (professional
and carer)j
7089 (539) 6918 (586) 171 (–1402 to 1744)
a Difference in group means, iCST–TAU.
b Drugs for dementia, antipsychotics and antidepressants.
c Person with dementia’s health and social care costs.
d Paid/professional support to carers delivering the intervention (includes costs of training and toolkit).
e Person with dementia’s health and social care costs and paid/professional support to carers delivering the intervention
(includes costs of training and toolkit).
f Costs of unpaid carers’ time in providing care and support to participant with dementia, lost production and out-of-pocket
expenditure, time valued at minimum wage.
g Time spent by carers in delivering the intervention valued at minimum wage.
h Paid/professional support to carers delivering the intervention (includes costs of training and toolkit) and time spent by
carers in delivering the intervention, valued at minimum wage.
i Person with dementia’s health and social care costs and costs of unpaid carers’ time in care and support, lost production
and out-of-pocket expenditure, time valued at minimum wage.
j Person with dementia’s health and social care costs and costs of unpaid carers’ time in care and support, lost production
and out-of-pocket expenditure, time valued at minimum wage. Paid/professional support to carers delivering the
intervention (includes costs of training and toolkit) and time spent by carers in delivering the intervention, valued at
minimum wage.
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TABLE 30 Mean (raw) costs of dyad: person with dementia’s health and social care, unpaid carer costs, intervention
costs, and total health and social care and societal costs over prior 3 months, week 26 (£), 2012–13
Week 26
iCST, mean (SE)
(n= 129)
TAU, mean (SE)
(n= 135)
Mean difference
(95% CI)a
Hospital 364 (106) 377 (111) –12 (–316 to 291)
Primary and community health 122 (12) 138 (14) –16 (–53 to 21)
Respite in residential/nursing home 34 (24) 0 (0) 34 (–12 to 81)
Community-based social care 1010 (281) 1142 (227) –131 (–840 to 577)
Community mental health 37 (8) 40 (8) –3 (–25 to 19)
Daycare (any provider) 505 (109) 783 (130) –278 (–613 to 58)
Equipment and adaptations 5 (2) 1 (1) 4 (0 to 8)
Medicationsb 200 (16) 207 (14) –7 (–49 to 35)
Health and social care excluding interventionc 2279 (360) 2688 (344) –409 (–1389 to 571)
Intervention: professional supportd 231 (4) 1 (1) 231 (223 to 239)
Health and social care including intervention
(professional)e
2510 (360) 2688 (344) –178 (–1158 to 801)
Unpaid care and supportf 4902 (448) 5941 (481) –1039 (–2336 to 258)
Intervention: carer delivered
g
71 (6) 1 (1) 70 (58 to 82)
Intervention: professional support and carer
deliveredh
302 (8) 1 (1) 301 (285 to 317)
Societal excluding interventioni 7181 (605) 8629 (630) –1448 (–3171 to 274)
Societal including intervention (professional
and carer)j
7483 (604) 8630 (630) –1147 (–2869 to 574)
a Difference in group means, iCST–TAU.
b Drugs for dementia, antipsychotics and antidepressants.
c Person with dementia’s health and social care costs.
d Paid/professional support to carers delivering the intervention (includes costs of training and toolkit).
e Person with dementia’s health and social care costs and paid/professional support to carers delivering the intervention
(includes costs of training and toolkit)
f Costs of unpaid carers’ time in providing care and support to participant with dementia, lost production and out-of-pocket
expenditure, time valued at minimum wage.
g Time spent by carers in delivering the intervention, valued at minimum wage.
h Paid/professional support to carers delivering the intervention (includes costs of training and toolkit) and time spent by
carers in delivering the intervention, valued at minimum wage.
i Person with dementia’s health and social care costs and costs of unpaid carers’ time in care and support, lost production
and out-of-pocket expenditure, time valued at minimum wage.
j Person with dementia’s health and social care costs and costs of unpaid carers’ time in care and support, lost production
and out-of-pocket expenditure, time valued at minimum wage. Paid/professional support to carers delivering the
intervention (includes costs of training and toolkit) and time spent by carers in delivering the intervention, valued at
minimum wage.
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Carers were asked to report which types of care and support activities they typically engaged in
(see Appendix 4). The proportions of carers reporting each type of activity did not vary significantly
between groups. The majority reported assisting with supervision, helping the person with dementia with
finances and medication, and taking them to appointments. At week 26, approximately 40% of carers
across the groups were assisting the person with dementia with personal care.
The (imputed) costs of health and social care and unpaid carer inputs, including the costs of delivering the
intervention, are given in Tables 28–30. The costs of delivering the intervention were estimated from
the health and social care perspective, including the costs of paid/professional staff, training and materials,
and also from the broader perspective of the time costs to carers (see Tables 29–30). The paid staff costs
of delivering the intervention were slightly higher and the unpaid carer costs were approximately 40%
higher at the week-13 follow-up compared with the week-26 follow-up period. The mean cost of the
intervention, taking paid staff time into account, was £481 over the period of the study; the mean cost of
delivering the intervention, if carer time was valued at the minimum wage, was £171. It cost £652 to
deliver the intervention, considering both paid staff and unpaid carer inputs. Costs of other health and
social care and carer costs were similar between the groups at baseline and, for the most part, did not
significantly differ (at the 5% level) between the groups during the follow-up period. The total raw mean
costs of health and social care and costs to carers at week 26 were somewhat, but not significantly, less
for the intervention than the control group (7483 iCST vs. 8631 TAU; t= 1.312; p-value= 0.191).
Cost-effectiveness analyses
The primary outcomes and costs for the person with dementia and their carers are presented in Tables 31–34.
Only primary outcomes (ADAS-Cog, QoL-AD, QALY) and secondary outcomes (QCPR, person with dementia)
with significant between-group differences at the 5% level are presented here.
TABLE 31 Person with dementia: outcome scores at 6 months
Outcomes iCST (n= 129) (95% CI) TAU (n= 135) (95% CI) Difference (n= 264) (95% CI)a
ADAS-Cog 20.53 (19.19 to 21.87) 21.19 (19.78 to 22.61) –0.66 (–2.25 to 0.92)
QoL-AD 37.96 (37.09 to 38.84) 37.71 (36.86 to 38.57) 0.25 (–0.81 to 1.3)
QCPR 56.95 (55.63 to 58.27) 55.24 (53.74 to 56.75) 1.71 (0.15 to 3.27)
a Estimates from outcome equation: adjusted for site, whether or not person with dementia is taking anticholinesterase,
categories of coresidents (spouse/partner and other family and/or others; other family/other; no-one), treatment
allocation, baseline outcome.
TABLE 32 Person with dementia: mean costs at 6 months
Costs iCST (n= 129) (95% CI) TAU (n= 135) (95% CI) Difference (n= 264) (95% CI)
Health and social care (£)a,b 4740 (3790 to 5700) 4670 (3680 to 5660) 70 (–1050 to 1190)
Societal (£)a,c 9770 (8410 to 11140) 10630 (9140 to 12120) –860 (–2750 to 1040)
a Estimates from costs equation: adjusted for site, whether or not person with dementia is taking anticholinesterase,
categories of coresidents (spouse/partner and other family and/or others; other family/other; no-one), treatment
allocation, costs in 3 months pre-baseline. Results rounded to nearest £10.
b Person with dementia’s health and social care costs and paid/professional support to carers delivering the intervention
(includes costs of training and toolkit).
c Person with dementia’s health and social care costs and costs of unpaid carers’ time in care and support, lost production
and out-of-pocket expenditure, time valued at minimum wage. Paid/professional support to carers delivering the
intervention (includes costs of training and toolkit) and time spent by carers in delivering the intervention, valued at
minimum wage.
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Outcomes and costs for the person with dementia
The SUR analyses produced very similar estimates of between-group differences on these outcomes at
week 26 to the ANCOVA approach used in the main analysis (see Primary analyses of outcomes). On the
primary outcomes for the person with dementia (see Table 31), the groups’ mean outcome scores did not
differ significantly. The mean (adjusted) difference in ADAS-Cog scores was –0.66 (95% CI –2.25 to 0.92).
On the QoL-AD, the intervention group scores were marginally, but not significantly, higher than those
of the intervention (difference of 0.25, 95% CI –0.81 to 1.3). On the secondary outcomes, the mean
between-group difference in the QCPR was 1.71 (95% CI 0.15 to 3.27).
For the costs for the person with dementia (see Table 32), the groups’ (adjusted) mean health and social
care costs did not differ significantly. The (adjusted) mean week-26 health and social care costs were
slightly, but not significantly, higher in the intervention group, giving a between-group difference of £70
(95% CI –£1050 to £1190). In terms of societal costs, however, the control group’s (adjusted) mean
week-26 costs were £860 (95% CI –£2750 to £1040) higher than those in the intervention group (but not
significantly so).
Outcomes and costs for carers
Mean QALYs (see Table 33) for the carers in the intervention group were significantly higher than for
carers in the control group [0.82 (95% CI 0.78 to 0.85) vs. 0.77 (95% CI 0.74 to 0.8), respectively, a
difference of 0.05, 95% CI 0.01 to 0.09]. The annual-equivalent health and social costs in the intervention
group were slightly higher than in the control group (see Table 34). From the broader societal perspective,
the annual equivalent costs in the intervention group were somewhat lower than in the control, by £1710
(95% CI –£5570 to £2150).
TABLE 34 Carers: mean costs
Costs iCST (n= 129) (95% CI) TAU (n= 135) (95% CI)
Difference (n= 264)
(95% CI)
Annual equivalent: health
and social care (£)a,b
9480 (7370 to 11,600) 9340 (7300 to 11,390) 140 (–2360 to 2640)
Annual equivalent: societal (£)a,c 19,550 (16,730 to 22,370) 21270 (18,170 to 24,350) –1710 (–5570 to 2150)
a Estimates from costs equation: adjusted for site, whether or not person with dementia is taking anticholinesterase,
categories of coresidents (spouse/partner and other family and/or others; other family/other; no-one), treatment
allocation, costs in 3 months pre-baseline. Results rounded to nearest £10.
b Person with dementia’s health and social care costs and paid/professional support to carers delivering the intervention
(includes costs of training and toolkit).
c Person with dementia’s health and social care costs and costs of unpaid carers’ time in care and support, lost production
and out-of-pocket expenditure, time valued at minimum wage. Paid/professional support to carers delivering the
intervention (includes costs of training and toolkit) and time spent by carers in delivering the intervention, valued at
minimum wage.
TABLE 33 Carers: QALY
Outcomes iCST (n= 129) (95% CI) TAU (n= 135) (95% CI)
Difference (n= 264)
(95% CI)
QALYa,b 0.82 (0.78 to 0.85) 0.77 (0.74 to 0.80) 0.05 (0.01 to 0.09)
a Estimates from outcome equation: adjusted for site, whether or not person with dementia is taking anticholinesterase,
categories of carer coresidents (spouse/partner and other family and/or others; other family/other; no-one), treatment
allocation, baseline outcome, carer sex, carer age.
b QALY calculated using the area-under-the-curve method with linear interpolation between assessment points, and the
last value carried forward from the final assessment to 12 months post-baseline.
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Incremental cost-effectiveness ratios
The ICERs for people with dementia and for carers are presented in Table 35.
Person with dementia
The incremental health and social care cost of a difference of 2.4 points in the ADAS-Cog score at week
26 was £300. The probability of cost-effectiveness on the ADAS-Cog from the health and social care
perspective rises from 45% at a WTP of £0 to approximately 80% at a WTP of £20,000 (see Figure 2).
As the control group’s mean (adjusted) 6-month societal costs were greater than those in the intervention
group, which constitutes a cost-saving (not significant at the 5% level), the ICER produced is negative.
The probability of cost-effectiveness by reference to ADAS-Cog (see Figure 2) from the broader societal
perspective rises from 80% at a WTP of £0 and then falls to approximately the same level as given by the
health and social care perspective. This is a pattern that can occur when the joint density of incremental
outcomes and costs crosses all quadrants of the cost-effectiveness plane.67
The incremental health and social care cost of a difference of 1.7 points in QoL-AD score at week 26 was
£600. The ICER from the societal perspective was negative (–£7100). The probabilities of cost-effectiveness
follow a fairly similar pattern as in the case of the ADAS-Cog measure (see Figure 3).
Going beyond the ICER point estimates and taking sampling uncertainty into account, on both ADAS-Cog
and QoL-AD measures, and from either the health and social care or the societal perspective, the CEACs
and the (absence of) confidence limits of the ICERs indicate that there is no positive WTP where we can be
95% confident that the two interventions differ in terms of cost-effectiveness.68
On the secondary outcomes, the incremental cost to achieve a difference of 3.1 points in the QCPR was £100
from the health and social care perspective, whereas the ICER from the societal perspective was negative.
Taking sampling uncertainty into account, we can be confident that the intervention is cost-saving at a WTP of
TABLE 35 Person with dementia and carer: ICER for intervention over control, from health and social care and
societal perspectives
Cost perspectivea ADAS-Cog (95% CI)b QoL-AD (95% CI)c QCPR (95% CI)d QALY (95% CI)e
Person with dementia, 6 months
Health and social
caref
300 (unbounded to
unbounded)
600 (unbounded to
unbounded)
100
(–3200 to 5400)
NA
Societalg –3300 (unbounded to
unbounded)
–7100 (unbounded to
unbounded)
–1600
(–13,300 to 2400)
NA
Carer, annual equivalent costs and outcomes
Health and social
caref
NA NA NA 3100
(–71,000 to 84,200)
Societal
g
NA NA NA –38,400
(–236,000 to 47,300)
NA, not applicable.
a Results rounded to nearest £100.
b Cost of achieving a 2.4-point difference between groups at week 26.
c Cost of achieving a 1.7-point difference between groups at week 26.
d Cost of achieving a 3.1-point difference between groups at week 26.
e Cost of achieving a QALY gain.
f Person with dementia’s health and social care costs and paid/professional support to carers delivering the intervention
(includes costs of training and toolkit).
g Person with dementia’s health and social care costs and costs of unpaid carers’ time in care and support, lost production
and out-of-pocket expenditure, time valued at minimum wage. Paid/professional support to carers delivering the
intervention (includes costs of training and toolkit) and time spent by carers in delivering the intervention, valued at
minimum wage.
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over £5400 considering health and social care costs, or at a lower WTP of over £2400 considering societal
costs. The CEAC (see Figure 4) indicates that the probability of cost-effectiveness exceeds 97.5% over these
WTP thresholds.
Carers
The incremental cost per QALY gained was £3100 (95% CI –£71,000 to £84,200). Given the 95% CIs of the
ICER, we cannot be certain that the iCST and TAU alternatives are different in terms of cost-effectiveness at
a WTP below the upper limit of about £84,200, but we can be confident that the intervention is cost-effective
above this upper limit.68 The probability of iCST being cost-effective from this perspective was 72% at a WTP
per QALY of £20,000 and 81% at a WTP per QALY of £30,000.
From the broader societal perspective, as costs were lower and QALYs gained were higher in the intervention
group, the ICER point-estimate was negative. The probability of iCST being cost-effective from this perspective
was 90% at a WTP per QALY of £20,000 and 93% at a WTP per QALY of £30,000 (see Figure 5). There is a
> 97.5% probability of cost-effectiveness at WTP values over £47,300 per QALY, given the upper confidence
limit of the ICER, and we can be confident that the intervention is cost-effective above this upper limit.
Sensitivity analyses
The estimates of societal costs were tested by varying the valuation of time spent by carers in providing
assistance with care and delivering the intervention using a replacement cost approach (Tables 36 and 37).
This approximately doubled ICERs for all outcomes (Table 38). As measured by achieving a difference of
3.1 points in the QCPR and seen from this cost perspective, we can be confident that the intervention is
cost-saving at a WTP of over £11,700, in light of sampling uncertainty. The probability of achieving a
QALY gain at a WTP of £30,000 was lower than in the main analysis, at 73% (see Figure 5). The upper
confidence limit for the ICER is much higher than in the main estimates, at £244,500 (see Table 38).
TABLE 36 Sensitivity analyses: person with dementia – mean costs at 6 months
Costs iCST (n= 129) (95% CI) TAU (n= 135) (95% CI) Difference (n= 264) (95% CI)a
Societal: replacement cost (£)b 35,510 (30,900 to 40,120) 37,250 (32,470 to 42,030) –1740 (–7920 to 4430)
a Costs equation: adjusted for site, whether or not person with dementia is taking anticholinesterase, categories of
coresidents (spouse/partner and other family and/or others; other family/other; no-one), treatment allocation, costs in
3 months pre-baseline. Results rounded to nearest £10.
b Person with dementia’s health and social care costs and costs of unpaid carers’ time in care and support, lost production
and out-of-pocket expenditure, time valued at the cost per hour of a home care worker, paid/professional support to
carers delivering the intervention (includes costs of training and toolkit) and time spent by carers in delivering the
intervention, valued at the cost per hour of a home care worker.
TABLE 37 Sensitivity analyses: carers – mean costs
Costs iCST (n= 129) (95% CI) TAU (n= 135) (95% CI) Difference (n= 264) (95% CI)a
Annual equivalent (societal:
replacement cost) (£)b
71,010 (61,420 to 80,600) 74,520 (64,020 to 85,020) –3510 (–16,170 to 9140)
a Estimates from costs equation: adjusted for site, whether or not person with dementia is taking anticholinesterase,
categories of coresidents (spouse/partner and other family and/or others; other family/other; no-one), treatment
allocation, costs in 3 months pre-baseline. Results rounded to nearest £10.
b Person with dementia’s health and social care costs and costs of unpaid carers’ time in care and support, lost production
and out-of-pocket expenditure, time valued at the cost per hour of a home care worker, paid/professional support to
carers delivering the intervention (includes costs of training and toolkit) and time spent by carers in delivering the
intervention, valued at the cost per hour of a home care worker.
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TABLE 38 Sensitivity analyses: person with dementia and carer – ICER for intervention over control, from health
and social care and societal perspectives
Cost perspectivea ADAS-Cog (95% CI)b QoL-AD (95% CI)c QCPR (95% CI)d QALY (95% CI)e
Person with dementia, 6 months
Societal:
replacement costf
–6600 (unbounded to
unbounded)
–14,500 (unbounded to
unbounded)
–3200
(–35,600 to 11,700)
NA
Carer, annual equivalent costs and outcomes
Societal:
replacement costf
NA NA NA –78,300
(–595,100 to 244,500)
NA, not applicable.
a Results rounded to nearest £100.
b Cost of achieving a 2.4-point difference between groups at week 26.
c Cost of achieving a 1.7-point difference between groups at week 26.
d Cost of achieving a 3.1-point difference between groups at week 26.
e Cost of achieving a QALY gain.
f Person with dementia’s health and social care costs and costs of unpaid carers’ time in care and support, lost production
and out-of-pocket expenditure, time valued at the cost per hour of a home care worker, paid/professional support to
carers delivering the intervention (includes costs of training and toolkit) and time spent by carers in delivering the
intervention, valued at the cost per hour of a home care worker.
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Chapter 6 Qualitative study
Background
Despite the increasing number of RCTs evaluating cognitive-based interventions for people with dementia,
little is known about the experiences of people with dementia taking part. This is the first RCT to conduct
an embedded qualitative study exploring experiences of people with dementia taking part in a cognitive
stimulation intervention alongside their family carers. In this study we used qualitative methods to explore
the views of people with dementia taking part in the iCST programme. Given that qualitative data from
the development phase of the trial indicated that interpersonal aspects of the caregiving relationship may
be particularly relevant within the context of a home-based, carer-led individual cognitive stimulation
approach, we additionally explored whether or not taking part in iCST was associated with any changes in
interpersonal aspects of quality of life such as the relationship between the person with dementia and their
family carer.
Aims
To explore the experiences of people with dementia and family carers taking part in the iCST programme.
Methods
Sampling and recruitment to the qualitative study
This was a qualitative study using semistructured in-depth interviews, using a convenience sub-sample of
participants allocated in the treatment group, regardless of how many sessions they completed. During
the baseline assessments participants were informed about the iCST qualitative study and were invited
to consent to the possibility of participating in the qualitative interview if they were assigned to the
intervention group. Unblinded researchers made contact with the participants to discuss the qualitative
component of the trial after they completed the intervention (at week 25). The contact was usually at
monitoring visit 2, via telephone and, occasionally, via e-mail. The unblinded researcher asked participants if
they would be willing to take part in an individual interview about their experiences of taking part in the
iCST programme. If participants agreed to be interviewed, a confirmation letter and Participant Information
Sheet were sent to them.
A subsample of 23 dyads of the group allocated to receive iCST took part, consisting of 22 people with
dementia (one participant refused to participate) and 23 family carers. Demographic characteristics of the
sample can be seen in Table 39. The mean age was 74.73 years for participants and 65.87 for family
carers. People with dementia taking part in the qualitative study had a mean baseline MMSE score of 22.5,
indicative of mild dementia. There were 17 spousal carers, 5 adult–child carers and 1 sibling carer. The
minimum number of sessions completed was 18 and the maximum was 75, with 61% of the sample
completing more than 38 sessions.
Data collection
The researcher undertaking the individual interviews was not involved in recruiting or providing the
intervention to participants. Semistructured, in-depth interviews took place at the participants’ homes, with
each interview fully audio-recorded and transcribed. The interview questions were established by focusing
mainly on non-directive questions, with overall interview duration ranging from 30 to 45 minutes. People
with dementia and their carers were asked separately to describe their experiences in taking part in the
iCST programme using initially open-ended questions, followed by questions focusing on specific domains,
presented in Box 3. All interviews started with an informal conversation while the dyad welcomed the
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TABLE 39 Demographic characteristics of people with dementia and family carers taking part in the
qualitative study
Characteristics
People with dementia, n= 22 Carers, n= 23
Mean (%) Mean (%)
Age 74.73 (6.00) 65.87 (13.68)
Sex
Male 16 (73) 4 (17)
Female 6 (27) 19 (83)
Ethnicity
White British 15 (68) 20 (87)
Other white 4 (18) 2 (8)
Caribbean 3 (14) 1 (4)
Education
School leaver (14–16 years) 12 (54) 10 (43)
School leaver (18 years of age) 4 (18) 2 (8)
Higher education 4 (18) 6 (26)
Further education 2 (9) 4 (17)
Postgraduate 0 1 (4)
MMSE 22.5 (3.38)
Number of iCST sessions completed 49.41 (18.38)
BOX 3 Key topic areas explored during interviews with people with dementia and their carers about their
experiences of taking part in iCST
Key topic area questions
How would you describe your experiences of taking part in the iCST programme?
How did you find the iCST programme?
How would you describe taking part in iCST to someone else?
Have you experienced any changes as a result of your participation in iCST?
Have you experienced any changes in your everyday life?
Have you experienced any changes in your relationship with your relative?
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interviewer into their home, in order to build up optimal rapport and increase the reliability of the
interview.69 In the second part the interviewer went through the Participant Information Sheets with
the person with dementia and their carer and explained topic areas of the questions.
Data analysis
Interviews were analysed using Framework Analysis,70 which is considered to be a suitable and reliable
method of qualitative analysis providing a systematic model for managing and mapping the data.71
Framework Analysis consists of stages of familiarisation, identifying a thematic framework, indexing,
charting, mapping and interpretation. The interviews were transcribed verbatim, checked for accuracy and
read thoroughly by two independent researchers. After several readings of the interviews, a coding frame
was developed using Nvivo 10 software (QSR International, Warrington, UK). Initial codes were refined and
modified during the analytic process. A coding scheme was created to organise the data to interpretations.
A spreadsheet was used to generate a matrix with data ‘charted’ into the matrix. Researchers compared
and contrasted styles of summarising in the early stages of the analysis process to ensure consistency.70
Quotations were tagged automatically by using Nvivo10.
Results
A total of 22 people with dementia and 23 carers were interviewed. Ten dyads were recruited from
London, four dyads from Manchester, five dyads from Norfolk and Suffolk and four dyads from Dorset.
The analyses identified five main themes in relation to participation in iCST which were common across
transcripts for both people with dementia and their carers. These themes were the following: (1) iCST was
described as providing opportunities for both general and specific intellectual stimulation; (2) iCST was
of value and useful for both the person with dementia and carer; (3) iCST offered opportunities for
enjoyment and allowed the person to take part in pleasant activities; (4) iCST promoted being active in
everyday life; and (5) iCST brought the carer and person with dementia closer. An additional theme
identified in the carer data was that iCST provided opportunities for carers to become more aware of the
‘needs’ of the person with dementia and the experience of ‘living with dementia’ from their perspective.
Opportunities for stimulation
A total of 73% of people with dementia and 65% of carers reported that iCST provided opportunities for
general mental stimulation and non-specific memory improvement. Some participants described their
experience of mental stimulation as being alert and noted that the intervention helped in terms of both
raising general ‘awareness of what is happening’ and enabling them to ‘think better’. A number of carers
noticed changes in their relative’s alertness, orientation and likelihood of engaging, and being active, in
discussions. Non-specific memory changes were reported by both people with dementia and their carers.
It helped to try and get my memory back and look at different things.
Participant (Manchester)
The course has re-stimulated me to think.
Participant (London)
I found it interesting, looking at the different things and trying to remember some of the logos and
different things from the past . . . It keeps the mind active and it is a good thing . . . how I would
describe it . . . really it was good.
Participant (Dorset)
. . . It varied the awareness of what is happening I think, otherwise just carry on not thinking about
things but then get aware of what it is all about and start thinking a little bit more about it.
Participant (Norfolk and Suffolk)
Made my relative more alert.
Carer (London)
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He became a little more active, more willing to participate in discussions, activities that we did
together outside of the activities in the book. He tended to snooze a lot before.
Carer (London)
It does sharpen up what you are doing.
Participant (Norfolk and Suffolk)
It does obviously get your mind focused on trying to think of the past as well, very interesting.
Participant (Dorset)
The activities motivate you to think better.
Participant (Norfolk and Suffolk)
However, 20% of the people with dementia did not find iCST stimulating or not stimulating enough as
the activities were too easy. Although some participants and carers found that the activities were not
challenging enough, they were aware of, and emphasised, the fact that the intervention was probably
designed to meet the different ‘needs’ of a wide range of people. Carers commented that the
effectiveness of the activities can vary and that this possibly depends on the topics, levels of interest and
issues around level of ‘difficulty’ of cognitive impairment. Some participants were not quite sure about
iCST when they first started the programme but later found the activities to be worthwhile.
I didn’t honestly find the material all that stimulating for me.
Participant (London)
I would say there was much of it I enjoyed but I didn’t gain much from it, because a lot of it wasn’t
appropriate for my particular stage of difficulty . . . you must have so many people at different stages,
with different needs.
Participant (London)
Sometimes it is difficult, depending on the topic on the subject, the reaction is quite
different sometimes.
Carer (London)
Well I wasn’t quite sure, but now I have started to appreciate it.
Participant (Manchester)
Most of the things were mind stretching in the actual books but some of the things weren’t, but then
of course you have got a whole range of people to actually hit the book with haven’t you and I
thought it was worthwhile.
Participant (Norfolk and Suffolk)
Individual cognitive stimulation therapy was useful and of value for the
person with dementia and carer in terms of communication
Most people with dementia and their carers found that the programme was very useful and important.
Although most described iCST as a useful programme, one participant valued it as a ‘learning course’.
Both people with dementia and carers found the design and structure of the programme easy to adjust to
and remember overall, thus providing a focus. Carers mentioned that engaging their relative in
conversation can be difficult and that doing the iCST activities not only helped to stimulate thinking but
helped to frame a conversation.
It was useful for us and perhaps even for other people at some time . . . it was all worthwhile in my
opinion, I found it extremely good.
Participant (Norfolk and Suffolk)
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It is mostly about the course, about learning and recalling . . . it has re-stimulated me to think that
maybe I should talk a bit more.
Participant (London)
It does give a structure and a focus on something that you can do together and just sharpen things up
and I would guess if you are bit further along it would be even more important.
Carer (London)
I would just describe it as a pack with activities to help stimulate the mind of the person with
dementia and help the carer find new ways of communicating and talking to that person.
Carer (Manchester)
Opportunities for enjoyment and allowing the person with dementia to
increase pleasant activities
A total of 82% of people with dementia found iCST to be enjoyable. They described the activities as
pleasurable, entertaining and interesting. Carers found the activities to be enjoyable for both their relative
and for themselves. Some participants mentioned that they did not remember the activities, but they were
able to reflect on the enjoyment related to taking part. For one participant, the feelings of enjoyment
and achievement outweighed any experience of remembering the activities.
I enjoyed the whole programme . . . if I didn’t enjoy it, then there is something wrong with me and
there is something wrong all together.
Participant (London)
I think we both really enjoyed it and I think some work better than others, but it was a good way of
sitting down having some time dedicated to actually talking about our particular subject or something
specific, and I think that was helpful and it was fun as well.
Carer (London)
I don’t remember the activities, but I enjoyed what we were doing.
Participant (London)
Yeah even though like things might not stay with me . . . but it’s brilliant.
Participant (Manchester)
I have felt I have done something when it is time to pack up, and put the things away . . . I enjoy
doing them . . . feel you’ve accomplished something.
Participant (London)
Individual cognitive stimulation therapy promotes being active in
everyday life
People with dementia and their carers reported that being involved in the iCST programme added value to their
daily experience in terms of taking up new activities, feeling motivated and raising awareness of ‘things around’.
Some participants applied iCST sessions to everyday life. One couple made a journey to their home town to
compare the old town with new changes. For some participants, taking part in iCST was an ‘obligation’, which
has helped them not only to ‘think better’ but also to engage in other activities. A few people with dementia
found that some of the activities helped them to revisit activities/hobbies that they enjoyed in the past or to look
for new activities and interests. Some carers experienced changes in their everyday life, such as having ‘more of
a focus’ or looking for further information related to cognitive stimulation activities for their relative.
It makes you aware of what is going on . . . It just keeps you going otherwise you would slump away
and sleep the day away.
Participant (Norfolk and Suffolk)
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It gives you a point of reference to do something and not just sit.
Participant (London)
Makes me more inquisitive and enlightens me about things.
Participant (Norfolk and Suffolk)
We were going through the street of that town, trying to remember each shop.
Participant (Norfolk and Suffolk)
I think having the obligation as we did here, to sit down in a particular day of the week or whenever it
was, to actually do that, and it does make you think and work what’s left of my brain, and things like
that, and yes I think it did well, it did well.
Participant (Norfolk and Suffolk)
It’s made me start thinking about doing what I used to do which was painting . . . over there there’s
about two or three paintings over there, that I’ve done on that table and I think I could do more
painting and that might make me better, you know and I can get up and do things more easily.
Participant (London)
It gives you a break from everyday life because while you’re doing this, you’re concentrating on doing
that, therefore your mind relaxes from other problems . . . with this it makes him think and I’ve noticed
a difference. When he was doing that, you see, that helped him think of normal ordinary day
living things.
Carer (Norfolk and Suffolk)
Individual cognitive stimulation therapy gets the carer and person with
dementia ‘together’
Most people with dementia and carers reported that iCST activities brought them closer, kept their
‘relationship going’ and helped people with dementia to ‘build up confidence’. A carer emphasised that
spending time doing iCST together with her relative gave her the opportunity to ‘listen’.
It brings you together in a very nice way and it is good . . . we ought to continue them because it does
get you together.
Participant (Norfolk and Suffolk)
It has really brought us closer . . . through it . . . because we were doing things together instead of
things apart . . . If he’s left alone to his own devices he loses confidence, but through doing these sort
of things that helps to build them up.
Carer (Norfolk and Suffolk)
I think if it involves you in something, and particularly if you can get a laugh out of it, the barriers
come down . . . We enjoyed that time together.
Participant (Norfolk and Suffolk)
. . . Just opening topics of conversation, maybe listening to her, encouraging her to express herself and
talk about things rather than just getting on with the business of how are we going to sort out the
mess in this flat, what shopping do we need or what bills need to be dealt with. All that kind of stuff
that is quite tedious and I think it is nice to just have the time to sit down and spend half an hour just
looking through some photos or looking at a book together.
Carer (Manchester)
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Carers were made aware of the ‘needs’ of the person with dementia and
‘understanding dementia in everyday life’
The final theme emerging from the carer data only was that engaging in the iCST activities with the
person with dementia allowed carers to have a better understanding of their needs and to become more
aware of situations their relative is likely to encounter in everyday life.
On the whole the experience has been really good . . . It disciplined us . . . so I think it raised an
awareness of the need.
Carer (London)
I did not really notice any drastic changes . . . but the main changes were in how I was probably
relating to her and thinking about how she would understand things, and how that could be in
everyday situations . . . The change is probably more about me that I noticed about her.
Carer (Manchester)
My understanding of my relative’s needs that have changed a lot.
Carer (London)
Discussion
The study aimed to explore experiences of people with dementia and their carers taking part in the iCST
programme through semistructured qualitative interviews. Major themes emerging from the qualitative
data were opportunities for stimulation, changes in everyday life, interpersonal issues, such as the
caregiving relationship, and understanding dementia in everyday life. The study findings suggested that
taking part in the iCST programme provided opportunities for both general and intellectual stimulation,
helping people with dementia to ‘think better’ and increase their alertness and awareness.72 Some
participants perceived the design and structure of the iCST programme as a tool which helped them to
open up conversations and provided a frame for communication. A large number of participants and
carers found that iCST offered opportunities to be involved in enjoyable and pleasant activities, revisiting or
focusing on new interests and hobbies. In line with previous qualitative findings, although a few people
with dementia expressed that they could not remember all of the activities they have completed during the
intervention, they were able to reflect on moments of enjoyment and their feelings.73
Interestingly, reports were consistent with the observation that iCST provided opportunities for people with
dementia and their carers to ‘come closer’ and further strengthen their relationship. This is in line with
results of the secondary analyses of more positive perceptions of relationship quality by people with
dementia. As most people with dementia are cared for at home by family carers, it will be important for
future research to understand better the factors that are likely to influence the caregiving relationship
within the context of a carer-led, cognitive-based intervention. A considerable number of carers
emphasised that iCST provided a framework for gaining a better understanding of the needs of the person
with dementia, possibly by making carers more aware of the nature of the difficulties encountered by
people with dementia and the experience of dementia in everyday life from the perspective of the person
with dementia.
There are several limitations in this qualitative study, especially in relation to the fact that this was a
convenience subsample. Most participants interviewed have done well with the intervention and reported
higher than average compliance, which may have biased findings towards reporting positive changes
related to the intervention. We did not interview dyads that did not complete any sessions or reported
poor compliance (i.e. 10 sessions or fewer). In addition, data could have been affected by social desirability
bias and participants thinking that the intervention has worked. Most people with dementia and their
carers found the iCST programme to be interesting, useful and of value; however, a few reported that the
programme was too easy and did not help them in terms of stimulating their thinking, judging the
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programme overall as not suitable for them. Future research should investigate issues of suitability of
cognitive-based interventions and the importance of matching activities to personal preferences and ‘level
of stimulation’.
This study reflected the experiences of people with dementia and their carers taking part in iCST and
provided further insight into the perspectives of people with dementia and their feelings relating to
engaging in a home-based cognitive stimulation programme. Some participants did not remember details
of the activities but they were able to reflect on feelings of enjoyment and expressed the importance and
value of taking part, its impact on their everyday life and their relationship with their family carer.
The results indicate that many carers and people with dementia found iCST to be of great value in
promoting mental stimulation and communication, and enhancing their relationship. These findings
indicate that it will be important for future studies to include qualitative data in the design and evaluation
of cognitive-based interventions for people with dementia and their carers.
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Chapter 7 Discussion
Main findings
The iCST trial was a pragmatic, multicentre, RCT of a complex, individual, carer-led cognitive stimulation
intervention. The trial was designed to evaluate the effects of iCST on cognition and quality of life for
people with dementia and their family carers. We recruited a total of 356 caregiving dyads, making this
study the largest in the current literature on CST-based approaches.
Primary outcomes
For people with dementia, the primary outcomes did not indicate any specific benefit for those allocated to
receive iCST, given that there was no clinically significant improvement in cognition or quality of life
compared with people with dementia receiving usual care. Carers’ physical and mental health was not
significantly different between the intervention and control groups.
Secondary outcomes
We found no evidence that iCST reduced behavioural and psychological symptoms or depressive symptoms
for people with dementia. There was also no evidence of change in activities of daily living. Although no
effects were observed on most of the secondary outcomes, analyses indicated that people with dementia
allocated to receive the intervention reported improvements in relationship quality with their family carer.
iCST did not improve secondary outcomes such as carers’ mood, resilience or relationship quality with
the person with dementia. Despite no differences in most secondary outcomes, health-related quality of
life ratings for family carers allocated to the intervention group improved at the primary end point.
This, however, was in contrast to no evidence of improvement on carers’ SF-12 component scores. This
discrepancy in findings between the two generic instruments (SF-12 and EQ-5D-3L) may reflect intrinsic
differences between these two instruments or differences in terms of each instrument’s sensitivity
to change.
This is the first economic analysis of an iCST intervention for people with dementia and their family carers.
Although costs from either the health and social care or the societal perspective did not differ substantially
between the groups at either follow-up time point, there was a consistent pattern of lower costs in the
iCST group over the 26-week period. In terms of the primary outcomes for people with dementia, it
appears that iCST is not more cost-effective than TAU from either cost perspective, when we take
sampling uncertainty into account. There are no established societal WTP thresholds for improvements in
ADAS-Cog, QoL-AD or QCPR. In terms of QALY gain for carers, iCST was more effective than TAU. Taking
carers’ costs into account, costs in the iCST group were lower, but not significantly lower, than in the TAU
group. Taking sampling uncertainty into account, and assuming no further change in utility or costs in
either group for the following 6 months, the probability that iCST is cost-effective was 93% at a societal
WTP per QALY of £30,000. Under the same assumptions, we can be confident that iCST is cost-effective
at a societal WTP of approximately £47,300 to gain a QALY, and, excluding costs to carers from this
calculation, we can be confident that iCST is cost-effective at approximately £84,200 per QALY. The
intervention can be considered to be cost-effective in improving unpaid carers’ health-related quality of
life only at a societal WTP well above the NICE threshold of £20,000–30,000. However, societal decision-makers
may be willing to accept somewhat lower levels of certainty to achieve this outcome. Given the results of the
sensitivity analysis, this conclusion is dependent on a relatively low valuation of carer time.
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When considering the number of sessions received, as opposed to allocation, some improvements were
observed. People with dementia completing more sessions were more likely to experience gains in terms of
the caregiving relationship at 26 weeks. Reports of improvements in the caregiving relationship by people
with dementia are consistent with previous studies indicating that meaningful activities conducted
alongside family carers can preserve and enhance the caregiving relationship.74 Improvements were
observed for carers completing more sessions with their relative, expressed by a reduction in depressive
symptoms. These findings are consistent with previous research, in which a home-based cognitive
stimulation programme was associated with lower depressive affects in carers.11
Overall, however, findings are in contrast to previous studies demonstrating that group short-term CST
benefits cognition and quality of life for people with dementia,6 and maintains quality of life improvements
when provided long term.19 These results also contrast with previous RCTs reporting benefits in cognition
for people with dementia associated with home-based individual RO/cognitive stimulation.12 In relation
to effects on cognition, not replicating results of group CST approaches may be attributable to the lack of
a group setting when CST sessions are provided. In addition, although we tried to use similar activities to
those provided in group CST, it is unlikely that the activities were the same, indicating that differences may
relate to differences on group versus individual CST approaches. In relation to effects of quality of life,
this is the first study to include a measure of quality of life for a home-based approach for people with
dementia. Our results therefore indicate that the benefits in quality of life are more likely to be associated
with interventions that combine or use CST approaches within a social setting. Our findings may be of
importance in relation to updating the Cochrane review. This may indicate the need for separate analyses
of group and individual approaches to cognitive stimulation.
Treatment implementation is an important parameter when evaluating psychosocial interventions. In order
to ensure that iCST was ‘delivered as intended’, we used a treatment protocol that specified all
components of the intervention in detail, in order to ensure that the intervention was delivered as planned.
Each unblinded researcher received training in iCST, and there were frequent opportunities for researchers
supporting carers in the delivery of iCST to receive supervision and feedback. Furthermore, there were a
number of challenges associated with implementing iCST, particularly with regard to carers fitting iCST
into a busy timetable, the lack of ‘stimulation’ for some participants and difficulties reported by carers
in engaging in the intervention with their relative. Compliance will be, therefore, an important component
to consider in order to optimise similar psychosocial interventions for people with dementia and their
carers. At this stage, it is not clear if there are any specific characteristics that would identify the very low
compliance group who completed no sessions at all, but we plan to look at further analyses on this topic
in due course.
In line with our projections in relation to sample size, a total of 81% of the sample completed the 13-week
assessments and 71% completed the 26-week assessments. The most common reason for not being
available to complete follow-up appointments was reporting problems with engaging in iCST, indicating
that, although the intervention may have a high uptake, it still may be difficult or not suitable for some
carers and people with dementia. Although most carers were able to engage in iCST with their relative,
there were frequent reports by carers of struggling to engage with their relative in the sessions and, often,
this was a common reason of loss to follow-up. A total of 22% of dyads allocated to receive iCST did not
complete any sessions and 13% completed fewer than 10. A threshold of completing over 38 sessions was
set on the basis of number of sessions completed by the whole of the sample, as indicative of compliance to
the intervention. We did not find any evidence of differential attrition, and analyses exploring differences
between completers versus non-completers did not suggest any differences between the two groups in
terms of baseline characteristics.
In terms of cognition and quality of life, our findings do not provide support for the use of home-based
cognitive stimulation programmes for people with dementia, which is contrary to previous work on
home-based memory rehabilitation10 and RO for people with dementia.12 It is unclear which factors could
account for the differential efficacy. It is likely that in some studies participants are highly selected,
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resulting in different patient groups recruited and, therefore, different levels of dementia severity and
cognitive function. For example, in our study most of the sample had mild dementia in comparison to
previous studies. Other factors could reflect differences between studies in terms of power or chance
variation, given that previous studies are of varying quality with small samples overall.2 Importantly,
although treatment compliance is not reported in detail across studies, the ‘dose’ received in each of the
studies may be an important determinant of efficacy.
Despite generally negative findings, people with dementia reported better relationship quality with their carer,
indicating that individual cognitive stimulation interventions have the potential to improve inter-relationship
outcomes for people with dementia. Relationship quality, rated by the person with dementia, has been
shown to be an important contributor to quality of life for people with dementia and is the cornerstone of
relationship-centred care.75 We also found that health-related quality of life for family carers significantly
increased, indicating that carer involvement in cognitive-based interventions may increase carer well-being.
This may be related to the fact that, although iCST was developed largely as a home-based, carer-led,
individual cognitive stimulation approach, the intervention incorporated additional psychoeducational elements
such as communication, opportunities to increase pleasant events for both carers and people with dementia,
which are components less likely to be incorporated in group CST-based approaches. This is consistent with
the findings of the qualitative study where carers reported that iCST provided opportunities to understand
dementia, its impact on communication and confidence for the person with dementia, and to increase
pleasant activities both for themselves and their relative. Interventions that therefore target communication
between people with dementia and their carers may reduce the strain on the caregiving relationship and may
potentially improve general well-being outcomes for both.
A further variable of interest is unblinded researchers’ level of expertise and experience, which is an
important factor to consider in the development of psychosocial interventions. Consultation groups
with unblinded researchers indicated that they were generally well received by carers and people with
dementia, although dyads differed widely in their level of engagement with the intervention. The level of
expertise was judged as sufficient, and training and background in dementia care was considered to be
important in supporting carers in delivering the sessions.
Implications for health care
It was expected that iCST may be beneficial for people with dementia in terms of cognition; however, this was
based on smaller studies using both cognitive stimulation and RO techniques and using less well-defined
methods. However, it is notable that participants in this study had better cognition (mean baseline MMSE
score of 21) than those in the original group CST study (mean baseline MMSE score of 14), which was also
limited to people with dementia scoring between 10 and 24 on the MMSE. This suggests that in the current
study there was less scope for improvement, and some participants may have had cognitive function that was
too high to benefit from iCST.
Most of the evidence on effects on cognition for cognitive stimulation is based on group approaches, so future
research will need to focus on understanding the mechanisms that are more likely to be associated with the
reported effects and differential effects of outcomes between group versus individual approaches. There was
evidence in this trial that some people with dementia and their family carers will not be able to engage
successfully in iCST, as 34% of the sample allocated to receive the intervention completed 0 or fewer than
10 sessions. Our qualitative findings indicated that, although most people with dementia and carers enjoyed
the sessions, there were also a few comments that the iCST sessions were not challenging enough, indicating
that the type of carer-led, cognitive-based intervention may be key in terms of producing a therapeutic effect.
Despite overall negative findings, improvements on the carer–patient relationship and carers’ health-related
quality of life suggest that iCST may have a key role in improving communication for people with dementia
and their carers.
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Limitations
Participants dropping out will have introduced bias if they had a different response to the intervention or
TAU conditions compared with those that completed the trial. However, there was no evidence from
demographic variables or baseline outcome scores that those who did complete the study were different
from those who did not.
Although significant efforts were made to obtain outcome data, the trial may have been underpowered to
detect significant differences for the primary outcome measure owing to the attrition rate and low levels of
compliance in the overall number of sessions completed. Nevertheless, this is the largest RCT of a cognitive
stimulation intervention in which carers lead the sessions and which shows no effect on cognition and
quality of life for people with dementia compared with usual care.
An important limitation is that the observed differences of improvement in the caregiving relationship for
people with dementia and health-related quality of life for carers may be attributable to incidental findings,
driven by the multiple comparisons tested, and may, therefore, be attributable to chance. Despite people
with dementia and carers expressing interest in the intervention, compliance was low overall, indicating
that cognitive stimulation interventions delivered by carers may not be the ideal mode of delivery for many,
thereby limiting wider applicability and generalisability of this approach, and indicating that better methods
of monitoring and support for adherence are needed. Identifying subgroups of caregiving dyads that are
more likely to benefit from this intervention is likely to be an important aim for future research.
Recommendations for future research
The null effect reported in this study leaves unanswered the question of whether or not carer-led cognitive
stimulation interventions are effective. Despite the appeal of home-based programmes led by carers,
cognitive stimulation approaches may be better provided on a group basis unless further evidence
becomes available.
1. If carer-led interventions are to be further pursued, future research should identify which factors are
more likely to make the intervention most successful and adaptable to the needs of people with
dementia. As feedback from people with dementia in the qualitative interviews indicated that some
sessions were not stimulating enough, future studies should consider that people earlier in the disease
trajectory may have different cognitive stimulation needs from those with moderate dementia.
2. Given that less than half of the iCST group completed at least two sessions per week this reduced the
power of the study to identify potential differences with the control group and indicates limitations in
relation to the applicability of the intervention. Future work is needed to investigate the characteristics
of caregiving dyads that are most likely to adhere to and benefit from carer-led individual cognitive
stimulation interventions and methods to improve adherence. The involvement of paid domiciliary care
workers or volunteer befrienders in delivering sessions should be explored further, as this may increase
adherence by placing less responsibility on family carers.
3. Given that carer-led, cognitive-based approaches are relatively new treatments, research designs that
address their efficacy are more relevant than designs addressing mechanisms at this point. Therefore,
comparisons of group versus individual approaches are likely to be premature at this stage.
4. It is important that future research and different research groups evaluate further the effects of
individual cognitive stimulation interventions. This work will help to ensure the reliability and robustness
of the effects reported in this trial, in relation to benefits of relationship quality for people with
dementia and health-related quality of life for carers.
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Conclusions
The evidence from this trial suggests that taking part in iCST sessions does not result in improvements on
cognition or quality of life for people with dementia. There was no evidence of improvements for carers’
mental and physical health. There was no evidence that iCST improved secondary outcomes for people
with dementia, such as activities of daily living, mood or behavioural and psychological symptoms.
Analyses indicated that iCST did not confer any benefit for carers’ mood, resilience or relationship quality
with the person with dementia. Although people with dementia receiving iCST reported better relationship
quality with their carer (in itself, an important component of quality of life for people with dementia) and
carers reported improved health-related quality of life, these findings need to be interpreted with caution
given limitations owing to multiple testing. Despite efforts to minimise loss to follow-up, the study
may have still been underpowered to detect significant differences for the primary outcome. Given that
iCST did not achieve the expected change, it is unlikely to lead to clinical benefit in improving cognition
and quality of life for people with dementia.
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Appendix 1 Development study 1: service users’
views about the intervention
TABLE 40 Demographic characteristics of people with dementia and family carers: Development study 1
Characteristics Focus groups Individual interviews
People with dementia n= 18 n= 10
Sex, n (%)
Male 7 (39) 5 (50)
Female 11 (61) 5 (50)
Mean age (years), n (SD) 80.50 (5.80) 84.44 (4.10)
Ethnicity, n (%)
White 18 (100) 10 (100)
Living status, n (%)
With spouse 6 (33) 6 (60)
With adult child 2 (11) 3 (30)
Alone 4 (22) 1 (10)
In care 2 (12) –
Unknown 4 (22) –
Family carers n= 14 n= 10
Gender, n (%)
Male 6 (43) 3 (30)
Female 8 (57) 7 (70)
Mean age (years), n (SD) 65.23 (9.65) 67.67 (14.35)
Ethnicity, n (%)
White 11 (79) 10 (100)
Relationship, n (%)
Spouse 7 (50) 6 (60)
Adult child 7 (50) 4 (40)
Cohabiting, n (%)
Yes 8 (57) 9 (90)
Years caring, n (range, SD) 5.61 (1–16, 4.03) 2.89 (1.5–7, 1.78)
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TABLE 41 Discussion guide themes for focus groups and individual interviews with people with dementia and
family carers: Development study 1
Themes Discussion points
Focus group Interview
Carer Participant Combined Carer Participant
Mental stimulation Importance of mental stimulation ✗ ✗ ✗ ✗ ✗
Characteristics/types of mentally
stimulating activities
✗ ✗ ✗ ✗ ✗
iCST manual
Content Additional information required ✗ ✗ ✗
Additional information required ✗ ✗ ✗
Layout Size of text/images and quality ✗ ✗ ✗
Layout and format ✗ ✗ ✗
General Positive/negative comments ✗ ✗ ✗
Ease of use ✗ ✗ ✗
iCST activity workbook
Content Clarity of instructions ✗ ✗ ✗
Activities ✗ ✗ ✗
Layout Layout and format ✗ ✗ ✗
Quality of images ✗ ✗ ✗
Activities Level of difficulty ✗ ✗ ✗
Level of engagement/enjoyment ✗ ✗ ✗
Issues around improving activities ✗ ✗ ✗
Feasibility of iCST Acceptability/iCST schedule
(30 minutes/three times weekly)
✗ ✗ ✗ ✗ ✗
Anticipated difficulties ✗ ✗ ✗
Support needed ✗ ✗ ✗
Group- vs. home-based training ✗ ✗ ✗
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TABLE 42 Results of qualitative analyses of focus groups and individuals interviews with people with dementia and
family carers: Development study 1
Themes of qualitative analyses Person with dementia Family carer
Mental stimulation
Importance of mental stimulation ‘Keep up to date’ and improve
thoughts
Keeps from ‘going backwards’
Keeps mind and body active
Important for person with dementia
Person is dependent on carer for
stimulation
Improves mood, alertness and quality of
life
Mentally stimulating activities Newspapers, watching TV,
sports/exercise
Puzzles/quizzes, household tasks
Playing cards/quizzes, attending clubs/
social events/trips, keeping fit, well-being
activities
iCST manual/activity workbook
Content/language/terminology Awakens thoughts/ideas, ‘opens the
mind’
Include more images as ‘words are a
problem’
Provides ideas to stimulate discussion
Easy to understand, instructions clear
Layout/format/size of
text/images
Ring-bound hard-copy material
preferred
Increase size of text
Good, pleasing to the eye, bright and
happy, putting you ‘in a good mood’
Increase size of text/images
Layout should discourage feeling ‘being
tested’
Ring-bound and hard-copy material
preferred
Outstanding, great colours, nicely done
iCST activities Reduce difficulty level
Include factual information
Reduce difficulty level and avoid ‘deep’
questions
Use activities that trigger memories
Feasibility Limited time of family carers
Important for carers to assist
Household duties may be a barrier
Person with dementia has plenty of
time
Carer will not need a lot of support
Professionals delivering better suited
Sessions feel ‘formal’
Useful for winter months
Accommodate everyday events/personal
needs
Sessions in chunks would feel less like
‘therapy’
Mental/physical challenges of caring
Training would be necessary
Resources/training Resources forum/’iCST expert’ carers
Phone support preferred over visits
Group training encourages peer learning
Individual training personal/easier to ask
questions and not require arranging care
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Appendix 2 Development study 2: expert
feedback
TABLE 43 Results of the online survey for the evaluation of the iCST manual: expert knowledge in dementia –
Development study 2
Statement
Response options, n (%)
Strongly
disagree Disagree Neutral Agree
Strongly
agree Conclusion
Language is easy to
understand
0 2 (8) 2 (8) 6 (24) 15 (60) High agreement
Size of font is appropriate 0 2 (8) 1 (4) 12 (48) 10 (40) Moderate agreement
Manual is stimulating/
engaging
0 1 (4) 4 (16) 16 (64) 4 (16) Moderate agreement
Amount of information is
appropriate
1 (4) 1 (4) 4 (16) 14 (56) 5 (20) Moderate agreement
Activities are clearly
presented
0 0 2 (8) 12 (48) 11 (44) Moderate agreement
Layout is appropriate 0 0 2 (8) 11 (44) 12 (48) Moderate agreement
Adequate variety in
activities
0 0 4 (16) 15 (60) 6 (24) Moderate agreement
Participant/carer will enjoy
the activities
0 0 6 (24) 16 (64) 3 (12) Moderate agreement
TABLE 44 Results of the online survey for the evaluation of the iCST workbook: expert knowledge in dementia –
Development study 2
Statement
Response options, n (%)
Strongly
disagree Disagree Neutral Agree
Strongly
agree Conclusion
Language is easy to
understand
0 0 1 (4) 11 (44) 13 (52) High agreement
Size of font is appropriate 0 0 1 (4) 14 (56) 10 (40) Moderate agreement
Workbook is stimulating/
engaging
0 0 3 (12) 16 (64) 6 (24) Moderate agreement
Amount of information is
appropriate
0 0 1 (4) 16 (64) 8 (32) Moderate agreement
Activities are clearly
presented
0 0 1 (4) 13 (52) 11 (44) Moderate agreement
Layout is appropriate 0 0 0 14 (56) 11 (44) Moderate agreement
Adequate variety in
activities
0 0 3 (12) 15 (60) 7 (28) Moderate agreement
Participant/carer will enjoy
the activities
0 0 5 (20) 14 (56) 6 (24) Moderate agreement
DOI: 10.3310/hta19640 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 64
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Orgeta et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
79

Appendix 3 Development study 3: field testing of
the intervention for final refinement prior to the
main trial
TABLE 45 Demographic characteristics of people with dementia and carers taking part in field testing:
Development study 3
Demographic characteristics, N= 25
Family caregiving dyads, n = 19
People with dementia
Age, mean (SD) 80.60 (5.15)
Sex, %
Male 47.4
Female 52.6
Ethnicity, %
White 78.9
Black 5.3
Unknown 15.8
Living status, %
Living with spouse 42.1
Living with adult child 15.8
Living alone 26.3
Unknown 15.8
Carers
Age, mean (SD) 65.00 (10.52)
Sex, %
Male 21.1
Female 78.9
Ethnicity, %
White 84.2
Mixed 5.3
Unknown 10.5
Relationship, %
Spouse 57.9
Adult child 42.1
Years caring, mean (SD) 4.32 (1.87)
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TABLE 45 Demographic characteristics of people with dementia and carers taking part in field testing:
Development study 3 (continued )
Demographic characteristics, N= 25
Paid caregiving dyads, n = 6
People with dementia
Age, mean (SD) 83.25 (8.22)
Sex, %
Male 50.0
Female 50.0
Ethnicity, %
White 83.3
Unknown 16.7
Living status, %
Living alone 83.3
Living with paid carer 16.7
Carers
Age, mean (SD) 42.6 (16.13)
Sex, %
Male 16.7
Female 83.3
Ethnicity,%
White 33.3
Black 33.3
Mixed 33.3
Years caring, mean (SD) 1.75 (1.50)
TABLE 46 Number of sessions completed by participants during field testing: Development study 3
Sessions completed (range 4–24) (N= 9)
0–6, n (%) 1 (11)
7–11, n (%) 5 (56)
12–16, n (%) 2 (22)
17–24, n (%) 1 (11)
Mean number of sessions, n (SD) 11.56 (5.59)
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TABLE 47 Evaluation ratings of iCST sessions during the field-testing phase: Development study 3
Evaluation ratings of iCST sessions, (n= 9)
iCST theme
Frequency
Interest Communication Enjoyment Difficulty level
My life sessions (6 ratings) Not at all (1) 0 0 0 0
A little (2) 0 0 0 4
Moderately (3) 6 1 4 2
Quite a lot (4) 0 5 2 0
Extremely (5) 0 0 0 0
Mean ratings (SD) 3.00 (0.00) 3.83 (0.41) 3.33 (0.52) 2.33 (0.52)
Current affairs (4 ratings) Not at all (1) 1 0 1 1
A little (2) 0 2 1 1
Moderately (3) 1 0 2 2
Quite a lot (4) 2 2 0 0
Extremely (5) 0 0 0 0
Mean ratings (SD) 3.00 (1.41) 3.00 (1.15) 2.25 (0.95) 2.25 (0.96)
Food (6 ratings) Not at all (1) 1 0 2 1
A little (2) 3 2 2 0
Moderately (3) 0 0 0 2
Quite a lot (4) 2 4 2 1
Extremely (5) 0 0 0 2
Mean ratings (SD) 2.50 (1.22) 3.33 (1.03) 2.33 (1.37) 3.50 (1.51)
Being creative (5 ratings) Not at all (1) 2 2 2 4
A little (2) 0 1 0 1
Moderately (3) 1 0 1 0
Quite a lot (4) 2 2 2 0
Extremely (5) 0 0 0 0
Mean ratings (SD) 2.50 (1.22) 3.33 (1.03) 2.33 (1.37) 3.50 (1.51)
Number games (4 ratings) Not at all (1) 0 0 0 2
A little (2) 1 0 2 1
Moderately (3) 1 2 2 1
Quite a lot (4) 2 2 0 0
Extremely (5) 0 0 0 0
Mean ratings (SD) 3.25 (0.96) 3.50 (0.58) 2.50 (0.58) 1.75 (0.96)
Quiz games (2 ratings) Not at all (1) 0 0 0 2
A little (2) 0 0 0 0
Moderately (3) 0 0 0 0
Quite a lot (4) 2 1 1 0
Extremely (5) 0 1 1 0
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TABLE 47 Evaluation ratings of iCST sessions during the field-testing phase: Development study 3 (continued )
Evaluation ratings of iCST sessions, (n= 9)
iCST theme
Frequency
Interest Communication Enjoyment Difficulty level
Mean ratings (SD) 3.25 (0.96) 3.50 (0.58) 2.50 (0.58) 1.75 (0.96)
Sounds (3 ratings) Not at all (1) 0 0 2 0
A little (2) 0 0 0 1
Moderately (3) 0 0 1 0
Quite a lot (4) 3 3 0 2
Extremely (5) 0 0 0 0
Mean ratings (SD) 4.00 (0.00) 4.00 (0.00) 1.67 (1.15) 3.33 (1.15)
Physical games (6 ratings) Not at all (1) 0 0 0 4
A little (2) 0 0 0 0
Moderately (3) 2 2 2 2
Quite a lot (4) 2 0 2 0
Extremely (5) 2 4 2 0
Mean ratings (SD) 4.00 (0.89) 4.33 (1.03) 4.00 (0.89) 1.67 (1.03)
Categorising objects (6 ratings) Not at all (1) 0 0 0 2
A little (2) 0 0 0 4
Moderately (3) 4 4 2 0
Quite a lot (4) 2 2 4 0
Extremely (5) 0 0 0 0
Mean ratings (SD) 3.33 (0.52) 3.33 (0.52) 3.67 (0.52) 1.67 (0.52)
Household treasures (6 ratings) Not at all (1) 0 0 0 2
A little (2) 0 0 0 4
Moderately (3) 4 2 6 0
Quite a lot (4) 2 4 0 0
Extremely (5) 0 0 0 0
Mean ratings (SD) 3.33 (0.52) 3.67 (0.52) 3.00 (0.00) 1.67 (0.52)
Useful tips (5 ratings) Not at all (1) 0 0 1 2
A little (2) 0 0 0 2
Moderately (3) 3 1 2 1
Quite a lot (4) 2 4 2 0
Extremely (5) 0 0 0 0
Mean ratings (SD) 3.40 (0.55) 3.80 (0.44) 3.00 (1.22) 1.80 (0.84)
Thinking cards (2 ratings) Not at all (1) 0 0 0 0
A little (2) 0 0 0 2
Moderately (3) 0 0 0 0
Quite a lot (4) 2 2 2 0
Extremely (5) 0 0 0 0
Mean ratings (SD) 4.00 (0.00) 4.00 (0.00) 4.00 (0.00) 4.00 (0.00)
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TABLE 47 Evaluation ratings of iCST sessions during the field-testing phase: Development study 3 (continued )
Evaluation ratings of iCST sessions, (n= 9)
iCST theme
Frequency
Interest Communication Enjoyment Difficulty level
Art discussion (4 ratings) Not at all (1) 0 0 0 4
A little (2) 0 0 0 0
Moderately (3) 2 0 0 0
Quite a lot (4) 0 2 2 0
Extremely (5) 2 2 2 0
Mean ratings (SD) 4.00 (1.15) 4.50 (0.58) 4.50 (0.58) 1.00 (0.00)
Faces/scenes (4 ratings) Not at all (1) 0 0 0 2
A little (2) 0 0 0 0
Moderately (3) 0 0 2 2
Quite a lot (4) 4 4 2 0
Extremely (5) 0 0 0 0
Mean ratings (SD) 4.00 (0.00) 4.00 (0.00) 3.50 (0.58) 2.00 (1.15)
Word games (14 ratings) Not at all (1) 0 0 0 8
A little (2) 0 0 0 2
Moderately (3) 0 2 2 4
Quite a lot (4) 12 8 4 0
Extremely (5) 2 4 8 0
Mean ratings (SD) 4.14 (0.36) 4.14 (0.66) 4.43 (0.75) 1.71 (0.91)
Slogans and visual clips
(4 ratings)
Not at all (1) 0 0 2 2
A little (2) 0 0 0 0
Moderately (3) 2 2 0 0
Quite a lot (4) 2 2 2 2
Extremely (5) 0 0 0 0
Mean ratings (SD) 3.50 (0.58) 3.50 (0.58) 2.50 (1.73) 2.50 (1.73)
Orientation (7 ratings) Not at all (1) 0 0 2 2
A little (2) 2 2 2 2
Moderately (3) 5 4 1 1
Quite a lot (4) 0 1 2 0
Extremely (5) 0 0 0 2
Mean ratings (SD) 2.71 (0.48) 2.86 (0.69) 2.43 (1.27) 2.71 (1.70)
Using money (6 ratings) Not at all (1) 0 0 0 4
A little (2) 2 0 0 0
Moderately (3) 2 4 4 2
Quite a lot (4) 0 0 0 0
Extremely (5) 2 2 2 0
continued
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TABLE 47 Evaluation ratings of iCST sessions during the field-testing phase: Development study 3 (continued )
Evaluation ratings of iCST sessions, (n= 9)
iCST theme
Frequency
Interest Communication Enjoyment Difficulty level
Mean ratings (SD) 3.33 (1.37) 3.67 (1.03) 3.67 (1.03) 1.67 (1.03)
Childhood (4 ratings) Not at all (1) 0 0 0 2
A little (2) 0 0 0 0
Moderately (3) 0 0 0 2
Quite a lot (4) 4 2 2 0
Extremely (5) 0 2 2 0
Mean ratings (SD) 4.00 (0.00) 4.50 (0.58) 4.50 (0.58) 2.00 (1.54)
TABLE 48 Information collected during set-up visits to inform main trial: Development study 3 (n= 22; family
carers only)
Carer ratings Researcher ratings
% Mean (SD) % Mean (SD)
iCST knowledge 3.04 (1.00) Success of set-up visit 3.77 (0.75)
Poor (1) 0 Poor (1) 0
Fair (2) 31.8 Fair (2) 0
Good (3) 45.5 Good (3) 41.2
Very good (4) 9.1 Very good (4) 41.2
Excellent (5) 13.6 Excellent (5) 17.6
Confidence in iCST 3.95 (0.78) Successful engagement 3.70 (0.47)
Very little (1) 0
Some (2) 0 Not at all (1) 0
Fair (3) 31.8 A little (2) 0
Good (4) 40.9 Quite a bit (3) 29.4
Very confident (5) 27.3 A lot (4) 70.6
Support required 2.10 (0.55) Support required 1.52 (0.51)
Not at all (1) 5.0 Not at all (1) 47.1
A little (2) 85.0 A little (2) 52.9
Quite a lot (3) 5.0 Quite a bit (3) 0
A lot (4) 5.0 A lot (4) 0
Training arrangement
Own home 54.5
In groups 22.7
Either 22.7
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TABLE 49 Qualitative findings of the field-testing phase using standardised telephone interviews: Development
study 3 (n= 22)
Themes Family carers Paid carers
Barriers in iCST delivery Time/availability
Health of person with dementia/carer
Job/family commitments
Difficulties motivating/engaging person with
dementia
Life events
Carer on annual leave
Difficulties motivating/engaging person
with dementia
Life events
Health of the person with dementia
Visits suspended or person with dementia
on holiday
Barriers specific to iCST
activities/programme
Using opinion rather than facts
Person with dementia finds activities difficult
Locating resources to use
Person with dementia demotivated if
activity is too easy
iCST programme/structure Doing sessions in ‘chunks’
Make sessions feel ‘informal’
Separate orientation with current affairs
Skip orientation discussion
Repeating sessions out of order helpful
Make sessions feel ‘informal’
Completing sessions out of order helpful
Frequency/duration of iCST
sessions
Difficult to complete three sessions weekly
Sessions last longer than 30 minutes
Feasible to complete three sessions weekly
iCST manual Easy to use
Promotes discussion/ideas
Provides variation in difficulty of activities
Easy to use
Important to adjust ratings of difficulty
Remove reference to ‘person with
dementia’
iCST resources Feasible to use own resources when
prompted
Feasible to use own resources when
prompted
Response to the iCST
activities from the person
with dementia
Enjoying activities
Asking questions can make person nervous
Mood is lifted, sense of achievement
Improvements in conversation
Enjoying activities
Mood is lifted
Person interested/engaged in activities
Caregiving relationship Gives carer a sense of purpose
Brings dyad ‘closer together’
Activities help dyad to communicate
Opportunities to laugh together
Carer is giving person more of their time
Support in delivering iCST None needed
Friends and family help with sessions
Family is often too busy to help
None needed
Family members help with sessions
DOI: 10.3310/hta19640 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 64
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Orgeta et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
87

Appendix 4 Economic evaluation: unit costs and
types of care and support tasks carried out by carers
TABLE 50 Unit costs
Service use item Unit cost (£) Sources
Costs of professional support (intervention)
iCST training costs 17,288 Project team
Per-participant (total divided by 180 intervention
participants)
96
iCST manual and materials, per participant 94 Project team
Weighted cost of professional support, per hour 49 Project data collection; Health and
Social Care Information Centre 201276
Mileage costs per one-way journey (per site) Range: 4–32 Project data collection; NHS Employers77
Carer costs (value of time)
Replacement cost: average cost of independent sector,
local authority-purchased home worker, per hour
19 Curtis 201355
Opportunity cost: minimum wage, per hour 6 UK Government78
Hospital costs
Inpatient bed-day, per specialty Range: 344–1495 Department of Health54
Inpatient bed-day, weighted average across adult
specialties
577 Department of Health54
Day attendances Range: 540–817 Department of Health54
Day case, weighted average across specialties 693 Department of Health54
Outpatient attendances Range: 27–468 Department of Health54
Outpatient, weighted average of follow-up attendances
across adult specialties
98 Department of Health54
Average cost of memory clinic contact 465 Curtis 201355
A&E attendances, admitted and non-admitted Range: 115–160 Department of Health54
Primary and community health services
District nursing time: average cost of direct contact, per contact 38 Department of Health54
District nursing time: average cost of an hour of home visit,
per minute
1 Curtis 201355
District nursing visit: average cost of an hour of nurse time,
per minute
0.7 Curtis 201355
Practice nurse visit: average cost of an hour of direct
contact time, per minute
0.7 Curtis 201355
Practice nurse visit: per consultation, per consultation 11 Curtis 201355
Specialist nursing; adult, face to face, per contact Range: 45–90 Department of Health54
Weighted average of specialist nursing across adult
specialities, per contact
59 Department of Health54
NHS community occupational therapy, per minute 0.5 Curtis 201355
NHS community occupational therapy, per visit 73 Curtis 201355
NHS community physiotherapy, per visit 50 Department of Health54
continued
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TABLE 50 Unit costs (continued )
Service use item Unit cost (£) Sources
NHS community physiotherapy average cost of an hour of
home visit, per minute
0.5 Curtis 201355
GP time: average cost per minute of home visit, excluding
direct staff and qualification, per minute
4 Curtis 201355
GP time: per home visit lasting 23.4 minutes (including
travel), per visit
85 Curtis 201355
GP time: average cost per minute in clinic, excluding direct
staff and qualification, per minute
3 Curtis 201355
GP time: average cost of surgery visit of 11.7 minutes,
excluding direct staff and qualification, per consultation
34 Curtis 201355
Chiropodist (NHS): reference (average) cost of visit for
community podiatry, episode/contact
41 Curtis 201355
Dentist (NHS): reference (average) cost of visit for
community dentistry, per contact
115 Department of Health54
Dentist (private): average price of check-up, per contacta 26 Office of Fair Trading79
NHS sight test: paid for sight test to optometrists, per test 21 Department of Health80
Private sight test: average charge to patients for a private
sight test, excluding discounts and special offers, per test
22 Optics at a glance81
Social care
Private residential care, mean cost per day 76 Curtis 201355
Local authority residential care, mean cost per day 143 Curtis 201355
Private nursing home care, mean cost per day 107 Curtis 201355
Social work: average cost per hour of face-to-face contact,
per minute
3 Curtis 201355
Independent home carer weekday face-to-face, per minute 0.4 Curtis 201355
Meals on wheels: average cost per meal on wheels, per meal 4 Curtis 201355
Community mental health services Curtis 201355
Consultant psychiatrist: face-face contact, per minute 4 Curtis 201355
Mental health nurse: face-to-face contact, per minute 1 Curtis 201355
Counselling services in primary care: per surgery
consultation
58 Curtis 201355
Community psychologist: per hour of client contact per minute 2 Curtis 201355
Day services
Day services: per session 38 Curtis 201355
Day services: per day, weighted average over all services
(stroke, elderly, other)
155 Department of Health54
Lunch club: per session 8 Banerjee et al. 201382
Social club: per session 5 Banerjee et al. 201382
‘Other’
Medications: standard quantity units Range: 0.1–6.0 Health and Social Care Information
Centre 201383
Equipment and adaptations, cost over 3 monthsa Range: 0.1–104.0 Curtis 2012,56 Curtis 201355
A&E, accident and emergency; GP, general practitioner.
a Uprated using Hospital and community health services prices inflator.
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TABLE 51 Types of care and support tasks carried out by carers
Type of care iCST (SE) (n= 129) TAU (SE) (n= 135) Mean differencea
Baseline
Personal care 43% 36% 6%
Helping with finances 82% 76% 7%
Practical help 78% 77% 1%
Taking the person to appointments 91% 86% 6%
Medications 78% 79% –1%
Keeping the person company 89% 91% –2%
Making sure the person is safe (supervision) 68% 76% –7%
Helping person to organise scheduleb 2% 2% –1%
Helping person’s mental state: moraleb 1% 2% –1%
Week 13
Personal care 40% 30% 11%
Helping with finances 82% 81% 1%
Practical help 81% 80% 1%
Taking the person to appointments 87% 89% –2%
Medications 81% 80% 1%
Keeping the person company 91% 91% 0%
Making sure the person is safe (supervision) 75% 79% –3%
Helping person to organise scheduleb 2% 1% 0%
Helping person’s mental state: moraleb 2% 2% –1%
Week 26
Personal care 43% 40% 3%
Helping with finances 84% 82% 1%
Practical help 84% 85% –1%
Taking the person to appointments 89% 90% 0%
Medications 82% 81% 1%
Keeping the person company 92% 96% –3%
Making sure the person is safe (supervision) 79% 81% –2%
Helping person to organise scheduleb 2% 4% –3%
Helping person’s mental state: moraleb 1% 1% 0%
a iCST–TAU.
b Derived from ‘other’ tasks, free-text descriptions.
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Appendix 5 Cost-effectiveness acceptability
curves
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FIGURE 2 Cost-effectiveness acceptability curve: ADAS-Cog.
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FIGURE 3 Cost-effectiveness acceptability curve: QoL-AD.
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FIGURE 4 Cost-effectiveness acceptability curve: QCPR, person with dementia.
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FIGURE 5 Cost-effectiveness acceptability curve: QALY, carers.
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Appendix 6 Full imputation data set
The tables presented here indicate the results for the data if the multiple imputation model had beenused to impute the data for all 356 participants at each time point. Various methodologies for different
types of missing data (e.g. death vs. ill health) have not been taken into account as the number of each
of these circumstances was minimal and would have limited impact on the results of any imputation
method. Ten imputation sets were created to establish a robust adjustment to the data missing from each
time point.
TABLE 52 The pooled means (and 95% CIs) of the multiple imputations comparing the iCST and TAU for person
with dementia outcomes at week 26 after adjusting for the baseline outcome measures
Person with dementia
outcome measure iCST (N= 180) TAU (N= 176) Pooled MD
95% CI of
pooled MD p-value
ADAS-Cog 22.16 22.61 –0.45 –1.95 to 1.05 0.56
QoL-AD 37.74 37.71 0.03 –1.94 to 2.00 0.98
DEMQOL 93.23 93.57 –0.34 –2.48 to 1.80 0.76
NPI [P] 10.52 9.80 0.72 –1.85 to 3.29 0.58
GDS-15 3.45 3.33 0.12 –0.34 to 0.58 0.61
QCPR total 56.59 55.21 1.38 –0.16 to 2.92 0.08
QCPR (warmth) 33.48 32.83 0.65 –0.31 to 1.61 0.18
QCPR (criticism and conflict) 23.06 22.43 0.63 –0.26 to 1.52 0.17
MMSE 18.98 19.68 –0.7 –1.44 to 0.04 0.07
BADLS [P] 13.38 13.47 –0.09 –1.40 to 1.22 0.89
QoL-AD [P] 31.27 31.03 0.26 –0.91 to 1.38 0.69
DEMQOL [P] 99.05 97.94 1.11 –1.16 to 3.38 0.34
MD, mean difference; NPI, Neuropsychiatric Inventory; [P], Proxy rated measure.
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TABLE 53 The pooled means (and 95% CIs) of the multiple imputations comparing the iCST and TAU for person
with dementia outcomes at week 13 after adjusting for the baseline outcome measures
Carer outcome measure iCST (N= 180) TAU (N= 176)
Pooled
MD
95% CI of
pooled MD p-value
ADAS-Cog 22.24 22.00 0.24 –1.37 to 1.85 0.77
QoL-AD 38.28 38.20 0.08 –0.85 to 1.01 0.86
DEMQOL 90.99 91.41 –0.42 –2.65 to 1.81 0.71
NPI [P] 13.41 14.52 –1.11 –3.24 to 1.02 0.31
GDS-15 3.43 3.42 0.01 –0.54 to 0.57 0.96
QCPR total 56.27 55.16 1.12 –0.13 to 2.36 0.08
QCPR (warmth) 33.72 33.43 0.29 –0.59 to 1.17 0.52
QCPR (criticism and conflict) 22.49 21.86 0.63 –0.06 to 1.32 0.08
MMSE 20.06 20.01 0.05 –0.70 to 0.80 0.89
BADLS [P] 12.96 13.18 –0.22 –1.45 to 1.01 0.73
QoL-AD [P] 32.56 31.76 0.80 –0.31 to 1.92 0.16
DEMQOL [P] 101.57 100.58 0.99 –1.22 to 3.2 0.38
MD, mean difference; NPI, Neuropsychiatric Inventory; [P], Proxy rated measure.
TABLE 54 The pooled means (and 95% CIs) of the multiple imputations comparing the iCST and TAU for carer
outcomes at week 26 after adjusting for the baseline outcome measures
Carer outcome measure iCST (N= 134) TAU (N= 139) MD 95% CI of MD p-value
SF-12 PCS 47.80 46.99 0.81 –1.18 to 2.80 0.43
SF-12 MCS 46.84 47.52 –0.68 –2.82 to 1.47 0.54
HADS total 10.56 10.67 –0.12 –1.39 to 1.16 0.86
HADS (anxiety) 6.04 5.97 0.07 –0.74 to 0.88 0.87
HADS (depression) 4.63 4.83 –0.20 –0.83 to 0.43 0.53
EQ-5D health state today 75.33 74.90 0.42 –3.03 to 3.88 0.81
EQ-5D calculated utility valuea 0.79 0.74 0.05 0.01 to 0.09 0.02
RS-14 82.83 82.05 0.78 –1.23 to 2.80 0.45
NPI (carer distress) 3.79 3.78 0.01 –0.45 to 0.47 0.97
QCPR total 58.20 58.67 –0.46 –1.79 to 0.87 0.50
QCPR (warmth) 34.38 34.44 –0.06 –0.74 to 0.62 0.87
QCPR (criticism and conflict) 23.88 24.25 –0.38 –1.21 to 0.46 0.38
MD, mean difference; NPI, Neuropsychiatric Inventory; RS-14, Resilience Scale-14 items.
a Significant difference at 5% level.
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TABLE 55 The pooled means (and 95% CIs) of the multiple imputations comparing the iCST and TAU for carer
outcomes at week 13 after adjusting for the baseline outcome measures
Carer outcome measure iCST (N= 180) TAU (N= 176) MD 95% CI of MD p-value
SF-12 PCS 49.95 50.14 –0.19 –1.59 to 1.22 0.80
SF-12 MCS 46.28 47.08 –0.80 –2.48 to 0.88 0.35
HADS total 11.27 11.01 0.26 –0.74 to 1.27 0.61
HADS (anxiety) 6.84 6.58 0.26 –0.41 to 0.92 0.45
HADS (depression) 4.58 4.60 –0.02 –0.51 to 0.47 0.93
EQ-5D health state today 74.91 74.56 0.35 –3.00 to 3.70 0.84
EQ-5D calculated utility value 0.80 0.78 0.02 –0.01 to 0.06 0.21
RS-14 81.37 81.75 –0.38 –2.00 to 1.25 0.65
NPI (carer distress) 3.14 3.04 0.10 –0.32 to 0.52 0.64
QCPR total 58.05 58.21 –0.16 –1.66 to 1.34 0.84
QCPR (warmth) 34.76 35.54 –0.77 –1.61 to 0.06 0.07
QCPR (criticism and conflict) 23.30 22.67 0.64 –0.26 to 1.53 0.16
MD, mean difference; NPI, Neuropsychiatric Inventory; RS-14, Resilience Scale-14 items.
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Appendix 7 Compliance analysis
The model fitted uses linear regression to assess the relationship between outcome measure and numberof iCST sessions attended at each outcome visit after adjusting for the baseline outcome measure.
DOI: 10.3310/hta19640 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 64
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Orgeta et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
99
TA
B
LE
56
Th
e
re
g
re
ss
io
n
co
ef
fi
ci
en
t
(a
n
d
SE
)
o
f
th
e
re
la
ti
o
n
sh
ip
b
et
w
ee
n
ea
ch
p
er
so
n
w
it
h
d
em
en
ti
a
o
u
tc
o
m
e
m
ea
su
re
an
d
th
e
n
u
m
b
er
o
f
se
ss
io
n
s
o
f
iC
ST
at
te
n
d
ed
at
w
ee
k
26
af
te
r
ad
ju
st
in
g
fo
r
th
e
b
as
el
in
e
o
u
tc
o
m
e
m
ea
su
re
s
Pe
rs
o
n
w
it
h
d
em
en
ti
a
o
u
tc
o
m
e
m
ea
su
re
O
b
se
rv
ed
d
at
a
Im
p
u
te
d
d
at
a
W
ee
k
26
Po
o
le
d
co
ef
fi
ci
en
t
SE
M
ed
ia
n
F
Lo
w
F
H
ig
h
F
Pa
rt
ic
ip
an
t
w
it
h
d
em
en
ti
a
C
o
ef
fi
ci
en
t
SE
F
p
-v
al
u
e
F
p
-v
al
u
e
F
p
-v
al
u
e
F
p
-v
al
u
e
A
D
A
S-
C
og
–
0.
01
3
0.
01
4
0.
83
7
0.
36
1
–
0.
01
5
0.
01
5
1.
15
6
0.
28
3
0.
63
3
0.
42
7
1.
48
8
0.
22
4
Q
oL
-A
D
0.
00
8
0.
01
0
0.
70
3
0.
40
2
0.
00
9
0.
01
0
0.
65
9
0.
41
8
0.
60
1
0.
43
9
1.
26
0
0.
26
3
D
EM
Q
O
L
0.
00
7
0.
01
9
0.
15
8
0.
69
1
0.
00
8
0.
01
9
0.
21
0
0.
64
7
0.
06
8
0.
79
4
0.
35
2
0.
55
3
N
PI
to
ta
l
–
0.
00
2
0.
02
3
0.
00
8
0.
92
7
–
0.
00
3
0.
02
3
0.
01
8
0.
89
2
0.
00
4
0.
95
2
0.
02
9
0.
86
5
G
D
S-
15
0.
00
1
0.
00
5
0.
05
5
0.
81
5
0.
00
2
0.
00
5
0.
09
1
0.
76
3
0.
01
9
0.
88
9
0.
27
0
0.
60
4
Q
C
PR
to
ta
la
0.
04
3
0.
01
4
9.
18
4
0.
00
3
0.
04
2
0.
01
4
9.
25
6
0.
00
3
9.
01
6
0.
00
3
9.
65
9
0.
00
2
Q
C
PR
(w
ar
m
th
)
0.
01
2
0.
00
9
1.
97
3
0.
16
1
0.
01
1
0.
00
9
1.
66
1
0.
19
9
1.
55
7
0.
21
3
1.
83
9
0.
17
6
Q
C
PR
(c
rit
ic
is
m
an
d
co
nf
lic
t)
a,
b
0.
02
9
0.
00
8
12
.6
33
0.
00
1
M
M
SE
0.
00
6
0.
00
8
0.
55
9
0.
45
5
0.
00
6
0.
00
8
0.
44
7
0.
50
4
0.
38
3
0.
53
6
0.
84
6
0.
35
9
BA
D
LS
[P
]
–
0.
01
5
0.
01
3
1.
25
4
0.
26
4
–
0.
01
5
0.
01
3
1.
27
2
0.
26
0
1.
23
0
0.
26
8
1.
41
3
0.
23
6
Q
oL
-A
D
[P
]
0.
01
2
0.
01
1
1.
22
5
0.
26
9
0.
01
2
0.
01
1
1.
22
5
0.
26
9
1.
22
5
0.
26
9
1.
22
5
0.
26
9
D
EM
Q
O
L
[P
]
0.
01
3
0.
02
3
0.
34
4
0.
55
8
0.
01
3
0.
02
3
0.
32
6
0.
56
9
0.
31
2
0.
57
7
0.
42
1
0.
51
7
N
PI
,
N
eu
ro
ps
yc
hi
at
ric
In
ve
nt
or
y;
[P
],
Pr
ox
y
ra
te
d
m
ea
su
re
.
a
Si
gn
ifi
ca
nt
di
ff
er
en
ce
.
b
W
he
n
th
er
e
ar
e
no
m
is
si
ng
da
ta
th
e
im
pu
te
d
da
ta
co
lu
m
ns
ar
e
le
ft
bl
an
k.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
100
TA
B
LE
57
Th
e
re
g
re
ss
io
n
co
ef
fi
ci
en
t
(a
n
d
SE
)
o
f
th
e
re
la
ti
o
n
sh
ip
b
et
w
ee
n
ea
ch
p
er
so
n
w
it
h
d
em
en
ti
a
o
u
tc
o
m
e
m
ea
su
re
an
d
th
e
n
u
m
b
er
o
f
se
ss
io
n
s
o
f
iC
ST
at
te
n
d
ed
at
w
ee
k
13
af
te
r
ad
ju
st
in
g
fo
r
th
e
b
as
el
in
e
o
u
tc
o
m
e
m
ea
su
re
s
Pe
rs
o
n
w
it
h
d
em
en
ti
a
o
u
tc
o
m
e
m
ea
su
re
O
b
se
rv
ed
d
at
a
Im
p
u
te
d
d
at
a
W
ee
k
13
Po
o
le
d
co
ef
fi
ci
en
t
SE
M
ed
ia
n
F
Lo
w
F
H
ig
h
F
Pe
rs
o
n
w
it
h
d
em
en
ti
a
C
o
ef
fi
ci
en
t
SE
F
p
-v
al
u
e
F
p
-v
al
u
e
F
p
-v
al
u
e
F
p
-v
al
u
e
A
D
A
S-
C
og
0.
00
6
0.
03
0
0.
04
2
0.
83
8
0.
00
2
0.
03
0
0.
03
8
0.
84
6
0.
00
5
0.
94
6
0.
07
1
0.
79
0
Q
oL
-A
D
0.
01
9
0.
02
1
0.
86
6
0.
35
3
0.
01
9
0.
02
1
0.
82
4
0.
36
5
0.
68
5
0.
40
9
1.
01
5
0.
31
5
D
EM
Q
O
L
–
0.
02
1
0.
04
2
0.
24
6
0.
62
0
–
0.
02
0
0.
04
2
0.
19
0
0.
66
3
0.
12
2
0.
72
7
0.
40
8
0.
52
4
N
PI
to
ta
l
–
0.
04
5
0.
04
8
0.
88
0
0.
34
9
–
0.
04
6
0.
04
8
0.
90
3
0.
34
3
0.
87
7
0.
35
0
0.
91
6
0.
33
9
G
D
S-
15
–
0.
00
3
0.
01
0
0.
07
6
0.
78
3
–
0.
00
3
0.
01
0
0.
05
5
0.
81
5
0.
00
0
0.
98
6
0.
62
8
0.
42
9
Q
C
PR
to
ta
l
0.
04
9
0.
02
6
3.
45
8
0.
06
4
0.
04
9
0.
02
6
3.
49
5
0.
06
3
3.
46
8
0.
06
4
3.
54
6
0.
06
1
Q
C
PR
(w
ar
m
th
)
0.
00
3
0.
01
8
0.
03
6
0.
85
0
0.
00
3
0.
01
8
0.
03
3
0.
85
6
0.
03
1
0.
85
9
0.
04
3
0.
83
6
Q
C
PR
(c
rit
ic
is
m
an
d
co
nf
lic
t)
a
0.
04
3
0.
01
5
8.
26
8
0.
00
4
0.
04
3
0.
01
5
8.
38
3
0.
00
4
8.
37
7
0.
00
4
8.
38
6
0.
00
4
M
M
SE
0.
02
6
0.
01
6
2.
66
7
0.
10
4
0.
02
6
0.
01
6
2.
76
4
0.
09
8
2.
41
9
0.
12
1
2.
86
1
0.
09
2
BA
D
LS
[P
]b
0.
02
4
0.
02
9
0.
67
1
0.
41
3
Q
oL
-A
D
[P
]
0.
03
8
0.
02
2
3.
01
5
0.
08
4
0.
03
7
0.
02
2
2.
83
3
0.
09
3
2.
78
2
0.
09
6
3.
18
1
0.
07
6
D
EM
Q
O
L
[P
]
0.
01
9
0.
04
8
0.
15
5
0.
69
4
0.
01
9
0.
04
8
0.
16
0
0.
68
9
0.
13
7
0.
71
1
0.
19
5
0.
65
9
N
PI
,
N
eu
ro
ps
yc
hi
at
ric
In
ve
nt
or
y;
[P
],
Pr
ox
y
ra
te
d
m
ea
su
re
.
a
Si
gn
ifi
ca
nt
di
ff
er
en
ce
.
b
W
he
n
th
er
e
is
no
m
is
si
ng
da
ta
th
e
im
pu
te
d
da
ta
co
lu
m
ns
ar
e
le
ft
bl
an
k.
DOI: 10.3310/hta19640 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 64
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Orgeta et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
101
TA
B
LE
58
Th
e
re
g
re
ss
io
n
co
ef
fi
ci
en
t
(a
n
d
SE
)
o
f
th
e
re
la
ti
o
n
sh
ip
b
et
w
ee
n
ea
ch
ca
re
r
o
u
tc
o
m
e
m
ea
su
re
an
d
th
e
n
u
m
b
er
o
f
se
ss
io
n
s
o
f
iC
ST
at
te
n
d
ed
at
w
ee
k
26
af
te
r
ad
ju
st
in
g
fo
r
th
e
b
as
el
in
e
o
u
tc
o
m
e
m
ea
su
re
s
C
ar
er
o
u
tc
o
m
e
m
ea
su
re
O
b
se
rv
ed
d
at
a
Im
p
u
te
d
d
at
a
W
ee
k
26
Po
o
le
d
co
ef
fi
ci
en
t
SE
M
ed
ia
n
F
Lo
w
F
H
ig
h
F
C
ar
er
C
o
ef
fi
ci
en
t
SE
F
p
-v
al
u
e
F
p
-v
al
u
e
F
p
-v
al
u
e
F
p
-v
al
u
e
SF
-1
2
PC
S
0.
01
8
0.
01
6
1.
19
6
0.
27
5
0.
01
7
0.
01
6
1.
05
2
0.
30
6
1.
17
1
0.
28
0
1.
25
3
0.
26
4
SF
-1
2
M
C
Sa
0.
01
7
0.
01
7
0.
92
1
0.
33
8
0.
01
7
0.
01
7
H
A
D
S
to
ta
lb
–
0.
02
0
0.
01
1
3.
46
3
0.
06
4
–
0.
02
2
0.
01
1
4.
08
5
0.
04
4
3.
85
0
0.
05
1
4.
81
5
0.
02
9
H
A
D
S
(a
nx
ie
ty
)
–
0.
00
7
0.
00
7
1.
15
6
0.
28
3
–
0.
00
9
0.
00
7
1.
65
5
0.
19
9
1.
27
9
0.
25
9
2.
09
1
0.
14
9
H
A
D
S
(d
ep
re
ss
io
n)
b
–
0.
01
3
0.
00
6
5.
68
4
0.
01
8
–
0.
01
4
0.
00
6
6.
27
5
0.
01
3
5.
54
9
0.
01
9
6.
66
7
0.
01
0
EQ
-5
D
he
al
th
st
at
e
to
da
ya
0.
02
0
0.
03
2
0.
40
6
0.
52
5
0.
02
0
0.
03
2
EQ
-5
D
ca
lc
ul
at
ed
ut
ili
ty
va
lu
e
0.
00
07
0.
00
04
2.
88
8
0.
09
0
0.
00
07
0.
00
04
2.
99
2
0.
08
5
2.
69
1
0.
10
2
3.
00
6
0.
08
4
RS
-1
4
0.
02
3
0.
01
9
1.
43
3
0.
23
2
0.
02
3
0.
01
9
1.
47
9
0.
22
5
1.
40
7
0.
23
7
1.
50
9
0.
22
0
N
PI
(c
ar
er
di
st
re
ss
)
–
0.
00
5
0.
00
4
1.
46
1
0.
22
8
–
0.
00
5
0.
00
4
1.
55
8
0.
21
3
1.
43
8
0.
23
2
1.
66
3
0.
19
8
Q
C
PR
–
0.
00
6
0.
01
3
0.
17
9
0.
67
3
–
0.
00
4
0.
01
3
0.
06
5
0.
79
8
0.
01
0
0.
91
9
0.
18
4
0.
66
9
Q
C
PR
(w
ar
m
th
)
–
0.
00
01
0.
00
7
0.
00
02
0.
98
8
0.
00
1
0.
00
7
0.
01
9
0.
89
0
0.
00
1
0.
98
2
0.
04
4
0.
83
3
Q
C
PR
(c
rit
ic
is
m
an
d
co
nf
lic
t)
–
0.
00
4
0.
00
8
0.
27
3
0.
60
2
–
0.
00
3
0.
00
8
0.
22
9
0.
63
3
0.
06
0
0.
80
6
0.
32
6
0.
56
8
N
PI
,
N
eu
ro
ps
yc
hi
at
ry
In
ve
nt
or
y;
[P
],
Pr
ox
y
ra
te
d
m
ea
su
re
;
RS
-1
4,
Re
si
lie
nc
e
Sc
al
e-
14
ite
m
s.
a
W
he
n
th
er
e
ar
e
no
m
is
si
ng
da
ta
th
e
im
pu
te
d
da
ta
co
lu
m
ns
ar
e
le
ft
bl
an
k.
b
Si
gn
ifi
ca
nt
di
ff
er
en
ce
.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
102
TA
B
LE
59
Th
e
re
g
re
ss
io
n
co
ef
fi
ci
en
t
(a
n
d
SE
)
o
f
th
e
re
la
ti
o
n
sh
ip
b
et
w
ee
n
ea
ch
ca
re
r
o
u
tc
o
m
e
m
ea
su
re
an
d
th
e
n
u
m
b
er
o
f
se
ss
io
n
s
o
f
iC
ST
at
te
n
d
ed
at
w
ee
k
13
af
te
r
ad
ju
st
in
g
fo
r
th
e
b
as
el
in
e
o
u
tc
o
m
e
m
ea
su
re
s
C
ar
er
o
u
tc
o
m
e
m
ea
su
re
O
b
se
rv
ed
d
at
a
Im
p
u
te
d
d
at
a
W
ee
k
13
Po
o
le
d
co
ef
fi
ci
en
t
SE
M
ed
ia
n
F
Lo
w
F
H
ig
h
F
C
ar
er
C
o
ef
fi
ci
en
t
SE
F
p
-v
al
u
e
F
p
-v
al
u
e
F
p
-v
al
u
e
F
p
-v
al
u
e
SF
-1
2
PC
Sa
0.
01
5
0.
03
0
0.
27
0
0.
60
4
SF
-1
2
M
C
Sa
0.
00
7
0.
03
4
0.
04
0
0.
84
3
H
A
D
S
to
ta
l
–
0.
02
4
0.
02
1
1.
27
1
0.
26
0
–
0.
02
3
0.
02
1
1.
23
5
0.
26
7
1.
21
9
0.
27
1
1.
31
0
0.
25
3
H
A
D
S
(a
nx
ie
ty
)
–
0.
01
2
0.
01
3
0.
80
6
0.
37
0
–
0.
01
1
0.
01
3
0.
75
2
0.
38
7
0.
71
6
0.
39
8
0.
84
7
0.
35
8
H
A
D
S
(d
ep
re
ss
io
n)
–
0.
01
4
0.
01
1
1.
51
9
0.
21
9
–
0.
01
4
0.
01
1
1.
49
6
0.
22
2
1.
45
0
0.
23
0
1.
66
7
0.
19
8
EQ
-5
D
he
al
th
st
at
e
to
da
y
0.
12
6
0.
06
6
3.
68
9
0.
05
6
0.
12
7
0.
06
6
3.
77
3
0.
05
3
3.
58
2
0.
05
9
3.
79
6
0.
05
2
EQ
-5
D
ca
lc
ul
at
ed
ut
ili
ty
va
lu
e
0.
00
1
0.
00
1
2.
57
3
0.
11
0
0.
00
1
0.
00
1
2.
56
6
0.
11
0
2.
55
8
0.
11
1
2.
60
7
0.
10
8
RS
-1
4a
–
0.
03
1
0.
03
3
0.
89
1
0.
34
6
N
PI
(c
ar
er
di
st
re
ss
)
–
0.
00
7
0.
00
9
0.
65
8
0.
41
8
–
0.
00
7
0.
00
9
0.
64
6
0.
42
2
0.
59
8
0.
44
0
0.
74
6
0.
38
9
Q
C
PR
to
ta
l
–
0.
00
4
0.
03
0
0.
02
2
0.
88
3
–
0.
00
3
0.
03
0
0.
03
3
0.
85
5
0.
00
2
0.
96
8
0.
08
8
0.
76
6
Q
C
PR
(w
ar
m
th
)
–
0.
00
8
0.
01
7
0.
22
3
0.
63
7
–
0.
00
6
0.
01
7
0.
07
4
0.
78
6
0.
02
0
0.
88
8
0.
46
6
0.
49
5
Q
C
PR
(c
rit
ic
is
m
an
d
co
nf
lic
t)
0.
00
5
0.
01
9
0.
06
1
0.
80
6
0.
00
4
0.
01
9
0.
07
0
0.
79
2
0.
00
1
0.
98
0
0.
20
6
0.
65
0
N
PI
,
N
eu
ro
ps
yc
hi
at
ry
In
ve
nt
or
y;
[P
],
Pr
ox
y
ra
te
d
m
ea
su
re
;
RS
-1
4,
Re
si
lie
nc
e
Sc
al
e-
14
ite
m
s.
a
W
he
n
th
er
e
ar
e
no
m
is
si
ng
da
ta
th
e
im
pu
te
d
da
ta
co
lu
m
ns
ar
e
le
ft
bl
an
k.
DOI: 10.3310/hta19640 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 64
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Orgeta et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
103

Appendix 8 Serious adverse events
Serious adverse events
In the iCST trial a SAE was defined as an untoward occurrence, experienced by the person with dementia
or their carer, which:
(a) resulted in death
(b) was life-threatening
(c) required hospitalisation or prolongation of existing hospitalisation
(d) resulted in persistent or significant disability or incapacity
(e) is otherwise considered medically significant by the principal investigator.
In addition, any cases in which action was taken in line with the protocol with regard to alleged or
suspected abuse/neglect that required protection of vulnerable adults was considered to be a SAE.
All iCST centres were asked to report any of the above instances either for the person with dementia or
their carer by categorising them as below:
1. death
2. life-threatening
3. hospitalisation or prolongation of existing hospitalisation
4. persistent or significant disability or incapacity
5. otherwise considered medically significant by the investigator
6. alleged/suspected abuse/neglect, as detailed in protection of vulnerable adults protocol.
There were a total of 51 SAEs reported during the trial, all of which were reported directly to the Chief
Investigator. There were 25 SAEs reported in the iCST group and 26 events reported in the TAU group.
There were 10 deaths reported, of which nine were deaths of the person with dementia and one was a
carer death. There were only eight deaths noted on the CONSORT flowchart as in the remaining cases
participants were lost to follow-up prior to their death being reported. A total of 44 of the SAEs related to
the person with dementia and the remaining seven involved the carer. None of the SAEs reported was
related to the trial. Details of these events broken down by treatment allocation are provided below
(Table 60). Details of types of SAEs are presented below (Table 61). For three people with dementia there
were two SAEs reported, which included hospitalisation, followed by death.
TABLE 60 Serious adverse events reported by treatment allocation
SAE category Total iCST TAU Linked to the iCST trial
Death 10 2 8 0
Life-threatening 5 3 2 0
Hospitalisation 32 16 16 0
Disability 0 0 0 0
Medically significant 4 4 0 0
Protection of vulnerable adults 0 0 0 0
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TABLE 61 Serious adverse events reported separately for people with dementia and carers
SAE category Person with dementia Carer
Angioplasty 0 1
Car accident 0 1
Chest infection 2 0
Diagnosis of cancer 1 2
Death 9 1
Fainting incident 2 0
Fall not requiring hospitalisation 2 0
Fall requiring hospitalisation 3 0
Fracture not requiring hospitalisation 1 0
Fracture of knee/arm/femoral shaft requiring hospitalisation 3 1
Heart attack 1 0
Heart operation 0 1
Irregular heart rhythm 1 0
Kidney stones/infection 2 0
Hospitalisation reason unknown 1 0
Oedema 1 0
Chronic obstructive pulmonary disease 1 0
Person with dementia missing/wandered away 1 0
Pneumonia 3 0
Psychiatric symptoms/confusion/delusions/suicidal thoughts/lethargy/loss of appetite 5 0
Seizure 1 0
Stroke 1 0
Urinary tract infection 3 0
Total 44 7
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Appendix 9 Protocol violations
Protocol violations
There was one protocol violation in the iCST trial, which was reported to the DMEC meeting and was
attributable to an administrative error.
The protocol violation involved two dyads being accidently randomised with the wrong identification
numbers. The data entry was performed remotely under the original identification numbers and
questionnaire codes (not the ones that were actually used in randomisation). The solution proposed
in consultations with the clinical trials unit was to change the numbers for the two participants in
the database.
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